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1 Introduction 
1.1. Forward  
Signaling through the family of nuclear factor–kappaB (NF-κB) transcription 
factors is involved in the regulation of numerous genes that are activated in response 
to stressful conditions such as infection, inflammation or injury. Inflammation 
processes play pivotal roles in detrimental joint disorders including osteoarthritis (OA) 
and rheumatoid arthritis (RA), the most common degenerative conditions of the 
skeletal system. NF-κB signaling pathways have been indicated to control 
inflammation and cartilage destruction, which are participating in the in pathogenesis 
of rheumatic diseases. Consequently, the blockade of NF-κB pathways through 
pharmacological or gene therapeutic inhibition has been suggested as a potential 
strategy as treatment of OA and RA. Although blocking the components of NF-κB 
signaling cascades are attractive targets for therapy, its beneficial effects on normal 
skeletal physiology are largely unknown due to the absence of suitable animal 
models. In this research project, conditional gene targeting was applied in mouse   as 
an experimental model system in order to address the role of canonical NF-κB in the 
cartilage. Tissue-restricted inhibition of the canonical NF-κB pathway in cartilage was 
achieved by chondrocyte-specific deletion of the inhibitory κB kinase γ gene (IKKγ) 
encoding NF-κB essential modulator (NEMO), a key regulator of the NF-κB canonical 
pathway. NEMO is a regulatory subunit of the kinase responsible for deactivation of 
the inhibitor of NF-κB, therefore, NEMO deficiency leads to the lack of NF-κB 
activation. Analyzing such mouse model, we are able to broaden our understanding 
of NF-κB-mediated processes on the regulation of normal and pathological cartilage 
functions. 
1.2. Clinical relevance of cartilage disorders 
Primary disorders of cartilage such as osteochondrodysplasias and 
osteoarthritis (OA) are widely distributed clinical problems in our society. 
Osteochondrodysplasia refers to a heritable disease occurred from genetic mutations 
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that can affect the development of cartilage and/or bone. There are more than 400 
osteochondrodysplasias that are classified. Although each type of osteo-
chondrodysplasia is relatively rare, the summed prevalence of the disease group has 
raised as much as from 760 per 1 million births (Andersen and Hauge, 1989; 
Barbosa-Buck et al., 2012; Orioli et al., 1986; Rasmussen et al., 1996). 
Osteochondrodysplasia can be accompanied with various complications that affect 
auditory, cardiac, neurologic orthopedic, pulmonary and renal functions. Dwarfism is 
the most common symptom of osteochondrodysplasia. Some of them cause short-
limbed dwarfism, while the others cause short trunk dwarfism. Achondrodysplasia is 
one of the most common non-lethal osteochondro-dysplasia (frequency 1/20000) that 
causes disproportioned dwarfism	with an average adult height of 130 cm for men and 
of 125 cm for women (Krakow and Rimoin, 2010). It is resulted from a mutation of the 
fibroblast growth factor receptor-3 (FGFR-3) gene, an important regulator of bone 
growth. Due to the genetic dominance, one mutant copy of FGFR-3 gene is able to 
induce achondrodysplasia. It is either inherited from parents or arises from 
spontaneous gene mutation	(Richette et al., 2008). 
Osteoarthritis (OA), a debilitating disorder of the articular cartilage is widely 
distributed on the world. Overall, approximately 3.6 percent of the global population 
(250 million people) is suffered from knee osteoarthritis, one of the most prevalent 
forms of this disease (Vos et al., 2012). The limb OA predominantly occurs at the 
knee joint that accounts for 41% of all cases. Hands (30%) and hips (19%) are the 
secondary vulnerable joints for OA (Cushnaghan and Dieppe, 1991). Global analysis 
for the incidence has shown that OA is one of the most common musculoskeletal 
diseases (Millennium, 2003; Wieland et al., 2005). In Europe, a joint replacement is 
performed every 1.5 minutes due to OA. In Germany, osteoarthritis accounts for 
about 8 % of all orthopedic treatment (Merx et al., 2007). In the United States, the OA 
patients represented 25% of the total number of seeking medical helps and were 
responsible for half of non-steroid anti-inflammatory drugs (NSAIDs) prescriptions. It 
is estimated that approximately 500,000 joint replacements are performed per annum. 
In 2011, there were 964,000 patients hospitalized for OA treatment. The total cost of 
OA medication was approximately 1.48 billion (15400 per stay), which was the 
second-highest Medicare spending after septicemia (Pfuntner et al., 2006).  
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Generally, the articular cartilage lesions are poorly self-repaired. Partially 
healed phenomenon only appears in certain biological conditions. Articular cartilage 
lesions usually cause disability and pain symptoms, such as joint pain, locking 
phenomenon, reduce physical activity and function. In addition, articular cartilage 
lesions are usually considered to develop into a serious OA (Gilbert, 1998; Messner 
and Gillquist, 1996). According to previous studies, risk factors of OA have been 
verified (Riyazi et al., 2008; Zhang and Jordan, 2010). These factors include: (1) 
arthritis of finger joints and knee, especially in women (Gunther et al., 1998; Zhang 
and Jordan, 2008); (2) deformity of hip or femoracetabular impingements (Heliovaara 
et al., 1993); (3) race and gender (Felson et al., 2000; Zhang and Jordan, 2008); (4) 
obesity or metabolic disorders; sport injuries (Kujala et al., 1994); and (5) 
employment factors such as weighty physical work load. The incidence of lower limb 
OA reaches to the peak in 70-79-age bracket. In female population, the occurrence 
per 100000 person per years increases from 350 in 50-59 age bracket to 1700 in 70-
79 age bracket; in male population, the incidence rises from 280 in 50-59 age bracket 
to 1280 in 70-79 age bracket (Zhang and Jordan, 2008). The worldwide incidence 
and prevalence of OA are different, but in general are very high. Due to demographic 
changes and extension the human lifespan, it is estimated that the number of OA 
patients will continually increase.	 In the United States, it is predicted that additional 
19 million people will be affected by OA yearly between 1995 and 2020	(Iorio et al., 
2008). However, drug development of OA also advances side by side. Optimistically 
speaking, it is believed that effective therapeutic strategies for OA will be developed 
in the future. In general, chronic painful cartilage disorders are common invalidating 
conditions for athletes, occupational and aging population. Osteoarthritis not only 
influences patients’ life quality but also raises considerable medical expenses to the 
worldwide healthcare system. Therefore, it is pivotal to identify the key factors 
involved in the onset and progression of OA, and improve our understanding of its 
basic biology in order to develop effective therapeutical solutions for cartilage 
disorders. 
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1.3. Structure of articular cartilage 
Typically, the articular cartilage can be divided into four layers (Figure 1). Each 
layer has a different composition of the extracellular matrix (ECM). The superficial 
layer (also known as tangential layer) covers the surface of the joint. The ECM in this 
layer contains fine fibrils running parallel of the surface and only little amount of 
proteoglycans. The elongated cells within this layer are mostly inactive, but still 
contain the endoplasmic reticulum, Golgi membranes and mitochondria. Below the 
superficial zone is the transition zone. There are active chondrocytes with 
endoplasmic reticulum, Golgi membranes, mitochondria, glycogen, and intra-
cytoplasmic filaments. Besides, the collagen fibrils in transition zone are larger than 
those of the superficial zone, and they orientation is arcade-like. Chondrocytes in the 
deep zone (also known as radial layer) are similar to those in the transition zone. 
However, the cartilage cells are organized into a columns perpendicular to the 
surface. These cells still contain a large number of intermediate filaments and 
glycogen granules. This zone contains the largest collagen fibrils of articular cartilage 
running perpendicular of the surface and a huge amount of proteoglycans. The 
content of proteoglycans increases from the superficial to the deep zone, while the 
content of water decreases. The cartilage in the calcified layer is just above the 
subchondral bone and separated from the radial layer by the tidemark. Chondrocytes 
in the calcified zone have almost no cytoplasm and endoplasmic reticulum. 
 
Figure 1. Structure of the articular cartilage. The articular cartilage is organized into various vertical 
zones and represents a typical anisotropic tissue architecture. From the surface of articular cartilage to 
the subchondral bone, cartilage is composed of tangential, transitional, radial and calcified layers. 
Tidemark is located at the surface between the radial and calcified layers. Figure is adapted and 
modified from (Landínez-Parra et al., 2012). 
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1.4. Composition of articular cartilage 
1.4.1. Chondrocyte 
In cartilage tissue, chondrocyte is the only cell type which responsible for 
cartilage formation and functions. Chondrocytes originated from skeletalgenic 
mesenchymal stem cells (MSC) during embryonic development. At the site of future 
chondrogenic elements, mesenchymal stem cells proliferate and aggregate to form 
condensations in which MSCs differentiated into chondroblasts. Chondroblasts secret 
a typical cartilage ECM including collagen fibers, glycosaminoglycans and 
proteoglycans. The chondroblasts are trapped in cavities known as cartilage lacunae, 
which is enriched in interstitial fluid (Figure 2). The chondroblasts later become 
mature chondrocytes that usually stay inactive but are able to secrete and degrade 
the ECM. 
 
Figure 2. Safranin-orange stained section of the articular cartilage. The chondrocytes are trapped 
into lacuna of the cartilage matrix. 
 
1.4.2. Water 
The water content of cartilage is approximately 80% of wet weight. A small 
portion of the water is encased within the chondrocytes, but the bulk of water is 
presented in the pores of the matrix and intrafibrillar space (Maroudas et al., 1991; 
Torzilli, 1985). The content of water concentration reduces from 80% through the 
superficial and deep zones. The tissue fluid is enriched with Ca2+, Cl-, K+ and Na+ 
ions (Lai et al., 1991; Linn and Sokoloff, 1965). Water in the cartilage layers not only 
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functions as lubricating fluid but also facilitate the distribution of nutrients to 
chondrocytes. 
Principally, water within interfibrillar space is served as a gel. Through 
compression or applying a pressure gradient across the tissue, most of the water 
passes through the cartilage ECM. Owning to the high friction resistance of cartilage 
against water flow, cartilage permeability is very low. The friction resistance and the 
pressurization of water in cartilage ECM form the basic mechanisms supporting 
articular cartilage to withstand constant or repeated loads caused by body weight and 
movement of the skeleton. 
1.4.3. Collagens 
To date, there are 28 members of collagens discovered and expressed in 
various tissues. Every member in the collagen family contains triple helix structure 
from 3 polypeptide chains (α-chains). The polypeptide chains mostly consist of 
glycine and proline with occasional hydroxyproline, which stabilize the structure of 
collagen (James and Uhl, 2001). 
Collagens are the most abundant structural ECM molecules in cartilage and 
account for 60% of the dry weight	(Sophia Fox et al., 2009). Among all collagens in 
the cartilage ECM, 90% to 95% of collagens is type collagen II. Collagen II 
constitutes fibers that entrap with proteoglycan aggregates. Collagen types I, IV, V, 
VI, IX, and XI account for the remained 5%-10% in the articular cartilage. The 
cartilage fibrils besides collagen II, contain collagen IX and XI as minor components. 
In mammalian articular cartilage, proportion of collagen II, IX, and XI in cartilage 
fibrils does not alter substantially between zones. However, changes in composition 
of cartilage fibrils were observed in young versus adult articular cartilages (collagen 
IX: 10% vs. 1%, collagen XI: 10% vs. 3% and collagen II: 80% vs. 95%, respectively)	
(Eyre, 2002). The triple helix structure of fibrillar collagens accounts for the tensile 
and shear properties of articular cartilage and stabilizes the structure ECM. 
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1.4.4. Proteoglycans 
Proteoglycans are widely expressed glycosylated proteins in various types of 
tissues Proteoglycans consist of a linear core protein and coupling with multiple 
negative charged side chains glycosaminoglycan (GAG), which can be composed up 
to more than 100 monosaccharides (James and Uhl, 2001). Due to charge repulsion, 
all of the glycosaminoglycans chains in proteoglycan separate from each other. 
Articular cartilage consists of various proteoglycans such as fibromodulin, biglycan, 
decorin and aggrecan. 
The most abundant and the largest protein in cartilage ECM is aggrecan. 
Aggrecan core protein is substituted with about 100 chondroitin sulfate and multiple 
keratin sulfate GAG chains. Aggrecan molecules can bind to hyaluronan (HA) via link 
protein and subsequently form massive proteoglycan aggregates (Figure 3). 
Aggrecan is predominantly trapped between the collagen fibrils of cartilage ECM and 
it plays critical role in resisting of compressive loads due to water binding caused by 
the negative charged GAG chains. 
 
Figure 3: Cartilage extracellular matrix. According to the distance to chondrocyte, cartilage ECM 
can be divided into pericellular, territorial and interterritorial matrix. The pericellular matrix surrounds a 
chondrocyte and binds to the membrane receptors of ECM components; the territorial matrix locates 
between pericellular matrix and interterritorial matrix; the interterritorial matrix is the farthest matrix 
compartment from the chondrocytes. Each area is formed by macromolecular assemblies (e.g. 
collagen network and proteoglycan aggregates) which are modulated via numerous regulatory and 
adaptor proteins. Figure is adapted and modified from (Heinegard and Saxne, 2011). 
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The major function of non-aggregating proteoglycans is the interaction with 
collagens. Non-aggregating proteoglycans in articular cartilage such as decorin, 
biglycan and fibromodulin are much smaller than aggrecan. Although these 
proteoglycans have similar structure, they can be distinguished by the attached 
glycosaminoglycan chain. Biglycan predominantly distributes on the periphery of 
chondrocytes and contains a dermatan sulfate chain which is likely attached to 
collagen VI (Sophia Fox et al., 2009). Decorin and fibromodulin contain dermatan 
sulfate and kerain sulfate chains, respectively. They interact with collagen II fibrils 
and participate in interfibrillar stabilization and fibrillogenesis (James and Uhl, 2001). 
1.4.5. Noncollagenous glycoproteins 
In addition to proteoglycans, there are numbers of non-collagenous 
glycoproteins found within the articular cartilage	(Neame et al., 1999). Some of these 
proteins are participated in the structure organization and maintenance of cartilage 
ECM by interacting with collagens and/or proteoglycans. Thrombospondin-5/cartilage 
oligomeric matrix protein (COMP), proline- and arginine-rich end leucine-rich repeat 
protein (PRELP), matrilin-1, matrilin- 3 and fibronectin are know to stabilize the 
supermolecular assembly of the cartilage ECM (Bengtsson et al., 2000; Briggs et al., 
1995; Jenkins et al., 1990; Mann et al., 2004; Romberger, 1997; Wiberg et al., 2003). 
There are also proteins which play regulatory role in cell proliferation and 
chondrocyte metabolism such as glycoprotein-39 (gp-39), matrix gla protein (MGP), 
chondromodulins, cartilage-derived retinoic acid responsive protein (CD-RAP) and 
various growth factors (Roughley, 2001).  
By utilizing transcriptomic, proteomic and mass spectrometry techniques, 
proteins in cartilage ECM have been broadly characterized. However, the precise 
biological function of noncollagenous glycoproteins is still not completely understood.  
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1.5. Function of articular cartilage 
Articular cartilage works as shock absorber to distribute the compressive loads, 
minimize peak stresses on subchondral bone. It efficiently reduces friction resistance 
and provides weight-bearing surface. Owning to the remarkably elasticity of articular 
cartilage, it can be deformed and recover its original shape. Articular cartilage has 
been well characterized with a low level of mitotic and metabolic activities, lacks 
blood vessels, lymphatic vessels, and nerves compares to other soft tissues. 
Essentially, articular cartilage functions and stands alone.  Structure of cartilage is 
highly complexed and ordered. Unless affected by diseases or injuries, the structure 
of articular cartilage remains stable and unchanged (James and Uhl, 2001). 
1.5.1. Biomechanical function 
The biomechanical behavior of articular cartilage has been well studied. 
Articular cartilage contains solid ECM and a fluid phase with water and inorganic ions 
(e.g. sodium, calcium, chloride, and potassium), which represents 20% and 80% of 
wet weight of articular, respectively. Due to the proteoglycan aggregates and 
interstitial fluid, negative electrostatic repulsion forces is created and provides 
compressive resilience to articular cartilage (Mankin et al., 1994; Maroudas, 1979; 
Mow and Ratcliffe, 1997). 
When compressive load is applied to joint, the interstitial fluid pressure raises 
rapidly. Due to the local increase of fluid pressure, the interstitial fluid flows out of the 
ECM and generates large friction in the ECM (Frank and Grodzinsky, 1987; 
Maroudas and Bullough, 1968; Mow et al., 1984). The interstitial fluid flows back into 
ECM soon after the compressive load is removed. The low permeability efficiently 
prevents the interstitial fluid from rapidly flowing out of ECM in respond to 
compressive load. The covered cartilage layer on the both end of bones (e.g. femur 
and tibia) forms the joint with limited mechanical movements (James and Uhl, 2001). 
Articular cartilage is characterized by its viscoelasticity and demonstrates time-
dependent behavior when constant compressive loads or deformations are applied 
(Woo et al., 1987). Two mechanisms are involved in the viscoelasticity of articular 
cartilage. (1) Flow-dependent mechanism is based on the interstitial fluid and the 
friction resistance generated by this flow as mentioned above (Ateshian et al., 1997; 
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Mow et al., 1984; Mow et al., 1980; Simon et al., 1984). The dragging force from 
interstitial fluid and friction of ECM provide viscoelastic behavior of articular cartilage 
(Mow et al., 1980). (2) Flow-independent mechanism is attributed to the intrinsic 
viscoelastic property of collagen-proteoglycan supermolecular assemblies (Hayes 
and Bodine, 1978). Relying on the flow-dependent mechanism, the pressure of 
interstitial fluid counteracts the majority of total compressive load. The stress acts 
directly to solid matrix is largely reduced, viscoelastic property of solid matrix then 
covers the rest of the total load. 
Creep and stress-relaxation reaction in the articular cartilage also play 
important roles in response to compressive loads. The deformation of articular 
cartilage shows and increases with time when a constant compressive load is applied 
(Mow et al., 1984). The zonal organization of cartilage remarkably enhances the 
resistance against shear stress. Collagen fibrils within the cartilage stretch in 
response to shear stress (Hayes and Mockros, 1971; Setton et al., 1995) (Figure 4). 
The molecular composition and inter/intra-molecular interactions of collagen fibrils 
ensure the cartilage with moderate level of tensile responses (Figure 5). 
 
Figure 4: Strain curve of articular cartilage. The curve is consisted of 3 parts: toe region, linear 
region and fracture. Toe region is considered as relaxed state of collagen fibrils. The collagen fibrils 
linearly respond to the mechanical stress in toe and linear regions. With the increase of mechanical 
stress, excessive stress eventually results in cartilage fracture. Figure is adapted and modified from 
(Robi et al., 2013). 
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Figure 5: Deformation of cartilage ECM under tensile force. When mechanical stress is loaded, 
the collagen fibrils are stretched towards both ends. Figure is adapted and modified from (James and 
Uhl, 2001). 
1.6. Metabolism within the cartilage 
Articular cartilage receives nutrients from the synovial fluid due to the lack of 
penetrating blood vessels in the cartilage. Nutrients from synovial fluids diffuse into 
pores of cartilage ECM that are averagely 6 nm wide (Linn and Sokoloff, 1965; Mow 
et al., 1992). Thus, the metabolism of chondrocytes is mainly anaerobic.  
Chondrocytes play essential role in ECM deposition, maintenance and repair. 
Various chemical and biomechanical factors from peripheral microenvironment can 
mediate the metabolism of chondrocytes (James and Uhl, 2001). Cytokines (e.g. 
TNF-α and IL-1), regulator peptides (e.g. parathyroid hormone-related peptide, 
PTHrP), growth factors (e.g. IGFs, FGFs), and physiological loadings provide 
chemical and mechanical signal, respectively, which balance anabolic and catabolic 
cascades important for the homeostasis and remodeling of the articular cartilage. 
Controlled synthesis and degradation of cartilage macromolecules (like 
proteoglycans and collagens) are essential for the proper function of the cartilage. 
ECM surrounding the chondrocytes protects the potential damage from 
biomechanical forces. Cartilage ECM remains homeostatic by newly synthesized 
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macromolecules such as proteoglycans and collagens. The turnover rate of 
proteoglycan is ranged from hours to years (Masuda et al., 2003) whereas the 
turnover rate of collagens is over hundred years (Eyre et al., 2006). 
Turnover and degradation of cartilage are mainly accomplished by 
metalloproteinases includeing matrix metalloproteinases (MMPs), a disintegrin and 
metalloproteinase with thrombospondin motifs proteinases (ADAMTSs) and 
cathepsins. Metalloproteinases are synthesized as proenzymes, which need 
extracellular cleavage to be fully activated. Collagenases (MMP-1 and MMP-13) and 
gelatinases (MMP-2 and MMP-9) are responsible to disassemble fibrils of collagens 
and degradation of elastin and fibronectin, whereas stromlysin-1 (MMP-3), ADAMTS-
4 and ADAMTS-5 participate in core protein degradation of aggrecan (Poole et al., 
1987). Cathepsins are involved in aggrecan degradation (James and Uhl, 2001). 
The physiological architecture and function of articular cartilage is mainly 
maintained by joint motion and normal mechanical load. Lack of joint activity has 
been reported to cause cartilage degradation (Buckwalter and Mankin, 1998). 
Abnormal change of cartilage metabolism is often associated with inflammatory 
conditions accompanying osteoarthritis, which usually takes place when catabolism 
and anabolism of chondrocytes are imbalanced (Torzilli et al., 1999). 
1.7. The development of bone 
The development of bone is defined as bone formation and growth. 
Intramembranous ossification and endochondral ossification are responsible for the 
formation of all bone tissue from mesechymal condensation. Intramembranous 
ossification is a mechanism that predominately occurs in bones of the skull through 
the linch differentiation or bone-produced osteoblasts from skullgenic MSCs. 
Endochondral ossification is the other bone producing mechanism that transforms 
mesenchymal tissue into cartilage and sequentially into bone tissue. Endochondral 
bones grow in length at the epiphyseal growth plate mediated by a process, which is 
similar to endochondral ossification. This process continues throughout entire 
childhood and the adolescent years. When the growth of cartilage slows down and 
stops eventually, the growth plate is completely ossified and remains as an 
epiphyseal line. Even after adult stature is attained, bone development continues 
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throughout adulthood for increase of thickness or diameter, repair of fractures and 
remodeling of bone to meet change of lifestyle. 
1.7.1. Cartilage differentiation during endochondral bone formation 
Early skeletal development of endochondral bone contains two consecutive 
phases of morphogenesis and growth. In the former phase, the cartilaginous 
templates of skeletal elements are laying down from the mesenchyme, while in the 
latter phase the cartilage anlage grows into the mature skeleton. The longitudinal 
bone growth accounts for the size of organism. The skeletal development initiates 
from condensation of mesenchymal stem cells, which differentiates into 
chondroblasts (Figure 6) (Hall and Miyake, 2000; Morriss-Kay, 2001). After an 
intensive proliferation phase, chondroblasts differentiate into chondrocytes and 
secrete cartilage ECM that served as a template for the future bones. The typical 
cartilage ECM of endochondral bones contain a variety of collagens (II, IX, and XI), 
proteoglycans (aggrecan) and matrix proteins such as matrilins and cartilage 
oligomeric matrix protein (Morris, 2002). During human embryogenesis, condensation 
of mesenchymal stem cells can be observed at 6.5 weeks of the pregnancy. 
Chondrocytes differentiated from mesenchymal stem cells form the bone template 
(also known as cartilage anlagen), which can be observed from the 16th week of 
pregnancy (Uhthoff, 1988). The development of similar cartilaginous structures can 
be observed in mouse in between embryonic days E11.5 and E13.5 of the pregnancy 
(Kaufman, 1992). The transcription factors of SOX family play an important role in the 
initiation of chondrogenic differentiation (de Crombrugghe et al., 2001). SOX-9 
participates in the early stage of differentiation and induces the expression of the 
transcriptions factors SOX-5 and SOX-6, which are important for the differentiation of 
chondrocytes (Bi et al., 1999; Lefebvre et al., 2001). Moreover, SOX-9 can activate 
genes of cartilage ECM proteins including collagen II and XI (de Crombrugghe et al., 
2001). Growth factors such as bone morphogenetic proteins (BMPs), fibroblast 
growth factors (FGFs), and morphogens like Indian hedgehog (Ihh) also contribute to 
the cartilage formation, chondrocyte proliferation and differentiation (de Crombrugghe 
et al., 2001). 
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Figure 6: Endochondral bone formation. The mesenchymal stem cells condense and form the 
cartilaginous anlage surrounded by the perichondrium. Chondrocytes in the center of cartilage 
template initiate hypertrophic differentiation. The periosteal cells next to hypertrophic chondrocytes 
become osteoblasts (bone collar) followed by vascular invasion. Mature hypertrophic chondrocytes 
secrete calcified matrix and undergo apoptosis or transdifferentiate into osteoblasts. Chondroclasts 
following the invaded blood vessels degrade the calcified matrix, while osteoblasts produce the 
trabecular bone of the primary ossification center. The secondary ossification centers form at both 
ends of the long bones. The chondrocytes between primary and secondary ossification region form 
the cartilaginous growth plate, which is responsible for the longitudinal growth of bone. The groove of 
Ranvier is involved in the circumferential growth of the bone. 
1.7.2. Intramembranous ossification 
Intramembranous ossification is the other indispensable process that forms 
rudimentary bones during embryonic development. It is also known to be an 
important process in the recovery of bone fractures (Brighton and Hunt, 1991) and in 
the skull formation. Otherwise from endochondral ossification, no cartilage is created 
during intramembranous ossification. 
1.7.3. Endochondral ossification  
Endochondral ossification is an essential process to create bone tissue from 
cartilaginous templates during development of the mammalian skeletal system. It 
plays important role in longitudinal growth of the skeletal elements (Brighton and 
Hunt, 1986). In long bones, endochondral ossification begins at the middle of anlage 
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called the diaphysis (Figure 6). The perichondrium covering the cartilage templates 
differentiates into the periosteum at the level of diaphysis. A layer of undifferentiated 
cells (osteoprogenitor cells) within periosteum soon differentiate to be osteoblasts 
that are responsible for production and secretion of bone matrix. 
At the same time, diaphyseal chondrocytes enlarge and become hypertrophic in 
the center of primary ossification and secrete mineralized matrix. The remaining 
calcified ECM is taken as a scaffold and consequently turns into bone trabecula by 
osteoprogenitor cells, which enter through the periosteal bud (Horton, 2003). 
Afterwards, trabecular bones are digested by osteoclasts and release an empty 
cavity known as bone marrow. 
1.7.4. Growth plate 
The growth plate (known as epiphyseal plate or physis) is a discoidal area that 
located between the epiphysis and diaphysis of long bones. It is formed during 
endochondral ossification and mediates a process that largely transforms the 
preexisting cartilaginous template into bone. The growth plate is responsible for 
longitudinal and lateral growth of bones and composed of three anatomically distinct 
but functionally interacting areas: 1) the cartilaginous growth plate, (2) the bony 
metaphysis and (3) the peripheral ossification groove of Ranvier	 (Ballock and 
O'Keefe, 2003; Brighton, 1978).  
1.7.4.1. Structure and function of the cartilaginous growth plate 
The cartilaginous growth plate is a hierarchically structured, anisotropic tissue 
which is responsible for longitudinal growth of endochondral bones during embryonic 
and early postnatal development. Chondrocytes within the growth plate are arranged 
into horizontal zones of resting, proliferating, prehypertrophic (a transition zone 
between the proliferative and hypertrophic zones) and hypertrophic. Vertically, cells 
organized into longitudinal columns from the proliferative zone (Figure 7). The 
structure and composition of these zones and columns in the cartilaginous growth 
plate are slightly different from species to species. In avians, he cartilaginous growth 
plate is characterized as less column structure with high cellularity and less matrix 
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production. Thus, the size of proliferation zone is the primary growth rate-determining 
factor for avians	 (Farquharson and Jefferies, 2000; Howlett, 1979; Kember et al., 
1990). The columns in the cartilaginous growth plate of mammalians are more 
distinct owning to the extensive cartilage matrix synthesis. The change of 
hypertrophic chondrocyte volume, besides chondrocyte proliferation and matrix 
production, is the most critical factor regulating longitudinal growth ion vertebrates 
(Breur et al., 1991; Hunziker, 1994). Due to the balance between growth and 
resorption at the cartilage-osseous junction of the metaphysis, the thickness of 
growth plate remains almost constant during development. 
The resting (or reserve) zone consists of small and rounded chondrocytes 
within the cartilage matrix. Nucleoside analog incorporation experiments show that 
chondrocytes in resting zone have slow cell cycle and rarely proliferate (Candela et 
al., 2014; Kember, 1971; Ohlsson et al., 1992). It was suggested that resting zone is 
a pool of chondro-precursors for chondrocytes supplying in the proliferating zone. 
Supporting this hypothesis, the surgical-removed rabbit growth plate was recovered 
by re-implantation of the resting zone	 (Abad et al., 2002).  The origin of resting 
progenitors is not clear, but it is suggested that these cells are migrating from the 
bone marrow or follow penetrating blood vessels of the epiphysis (Candela et al., 
2014). 
 
Figure 7: The cartilaginous growth plate. Resting zone is considered as a reservoir of rounded, 
precursor cells for chondrocytes in the proliferation zone (Kronenberg, 2003). In the proliferating zone, 
chondrocytes flatten with right angle of the longitudinal direction of the growth, mitotically active and 
produce cartilage matrix (Ogden and Rosenberg, 1988). In the prehypertrophic zone, the cells start to 
enlarge in size, and stop to divide as a part of the chondrogenic maturation program. In the 
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hypertrophic zone, the chondrocytes eventually can be 5–12 times larger in volume compared to cells 
in the proliferative zone (Ogden and Rosenberg, 1988). Terminally differentiated hypertrophic 
chondrocytes than either die by apoptosis or transdifferentiate into osteoblasts at the chondro-osseous 
junction (Pirog and Briggs, 2010). 
The proliferating zone is consists of flattened chondrocytes which forms 
characteristic, longitudinal columns. Experiments in rodents showed that only 
chondrocytes in upper half of the proliferative zone are with mitotic activity. 
Chondrocytes in the lower half zone merging with the prehypertrophic zone stop 
proliferating and undergo the process of maturation (Vanky et al., 1998). According to 
the location of the growth plate, the average cell cycle time is from 24 to 76 hours. 
(Vanky et al., 1998; Wilsman et al., 1996). From resting zone to proliferation zone, 
chondrocytes averagely divide four times and then move into the hypertrophic zone.	
(Farnum and Wilsman, 1993). Proliferating chondrocytes divide in a specific manner 
that is different from most of cell types in the body. The general cell biological rules of 
Hertwig for the orientation of the mitotic spindle and cell division plane describe two 
prominent features of dividing proliferating chondrocytes: (1) “the axis of the mitotic 
spindle takes the direction of the greatest protoplasmic masses” and (2) “the plane of 
division always cuts the axis of the spindle perpendicularly” (Figure 8)	(Hertwig, 1893). 
While these rules explain the oriented cell division observed in the proliferative zone, 
namely that the division axis is always perpendicular with the direction of the 
longitudinal growth (e.g. the proximo-distal axis of the bone), the extension of the 
column is characterized by the classical Dodds model. The behaviors of proliferating 
chondrocytes in the columns can be summarized as the follow: (1) mitotic 
chondrocytes lie perpendicular with the proximodistal (longitudinal) and elongate 
along the mediolateral axis of the bone; (2) cell division plane is parallel to the long 
axis of the columns; (3) the newly-divided cells initially lie horizontal relative to the 
longitudinal axis of columns; and (4) by regulating the length and width ratio, the 
daughter cells eventually move backward to the original vertical axis. This model has 
a close similarity to the developmental process of convergent extension which leads 
to tissue narrowing and elongation during organogenesis (Keller et al., 2000). To 
summarize, chondrocytes in the proliferating zone (1) undergo flattening process; (2) 
are oriented perpendicularly to the direction of longitudinal growth, and (3) the 
columns extend along the longitudinal axis. 
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Figure 8: Mechanisms of chondrocyte division and column formation. Chondrocytes in the 
proliferative zone elongate along the mediolateral (ML) axis with right angle to the longitudinal, 
proximodistal axis. Following Hertwig´s rules, the mitotic spindles form in the long axis of the cell and 
division plane cut perpendicular to this axis. The horizontally oriented daughter cells than rotate back 
to the proximodistal (PD) axis by sliding movements mediated by the matrix (classical Dodds model) 
or by transient cell-cell cell-cell connections (alternative models). Figure is adapted and modified from 
(Dodds, 1930).  
Numerous growth factors, morphogens and hormones are involved in the 
regulation of chondrocyte proliferation, maturation and oriented cell division. Besides 
of the mitotic activity, chondrocytes in the proliferation zone produce the vast amount 
of typical cartilage matrix components that includes aggrecan and collagen II.  
In the prehypertrophic zone, chondrocytes initiate expression of specific 
marker genes such as Indian hedgehog (Ihh), collagen X and parathyroid 
hormone/parathyroid hormone-related protein receptor (Ppr1). Most of the 
chondrocytes in prehypertrophic zone are larger than cells in the proliferation zone 
and are mitotically inactive.  
The chondrocytes in hypertrophic zone are round to polygonal in shape and 
their cell volume is enlarged 5-10 times compared to the chondrocytes in the 
proliferating zone (Hunziker, 1994). Hypertrophic chondrocytes predominantly 
deposit collagen X instead of aggrecan and collagen II. Mature, terminally 
differentiated hypertrophic chondrocytes either undergo apoptosis or 
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transdifferentiate into osteoblasts (Park et al., 2015; Yang et al., 2014; Zhou et al., 
2014).	 The hypertrophic chondrocytes near the metaphysis produce vascular 
endothelial growth factor (VEGF), which facilitates the invasion of blood vessels into 
the hypertrophic core; and matrix metalloproteinase 13 (MMP-13) which degrade the 
cartilaginous ECM (Ortega et al., 2004). Chondroclasts and osteoblast precursors, 
which follow the invasion of the vasculature, carry out the transformation of cartilage 
into bone. 
1.7.4.2. Metaphysis 
The vascular invasion starts from the metaphysis where the primary 
ossification occurs (Ballock and O'Keefe, 2003; Brighton, 1978).  The metaphysis 
contains two regions: (1) primary spongiosa and (2) secondary spongiosa. The initial 
trabecular network at primary spongiosa is generated from partially degraded 
intercolumnar area that extends from the hypertrophic zone. Eventually, the primary 
spongiosa mineralized to form woven bones and secondary spongiosa. At secondary 
spongiosa area, the primary trabecular network becomes lamellar trabecular bone. 
Besides its role in cartilage-bone remodeling, metaphysis also support the structural 
stability of the growth plate. 
1.7.4.3. Peripheral ossification groove of Ranvier 
The growth plate cartilage laterally is surrounded by a fibro-chondro-
osseoustissue, which is composed of the groove of Ranvier and the ossification ring 
of LaCroix (Brighton, 1978; Langenskiold, 1998).	The Ranvier groove is may serve as 
a storage pool of chondrogenic progenitor cells and contributes to the circumferential 
growth of bones (Karlsson et al. 2009; Shapiro et al. 1977). The ring of LaCroix help 
to maintain the structural stability of the growth plate at the chondro-osseous 
junctions (Rodriguez et al., 1985).  
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1.8. Chronic cartilage disorders 
1.8.1. Aetiology of cartilage lesions 
The chondral injuries can be divided into two major types: degenerative and 
focal lesions. Degenerative lesions commonly result from meniscal injuries, 
displacement of the joints, osteoarthritis (OA) or joint instability due to weakening of 
the ligaments. Focal lesions are mainly induced by osteochondritis dissecans, 
osteonecrosis and trauma (Falah et al., 2010). 
Sports injury and accidents represent most prevalent trauma that causes 
osteochondral lesions or breaking the cartilage-bone interfaces. The shear force may 
cause cartilage or even subchondral bone fractures. Up to 50% of osteochondral 
lesions at the knee joint are the consequences of the dislocation of patella  (Boden et 
al., 1997). Osteochondritis dissecans (OD), first described by König in 1988, causes 
microtrauma in femoral condyles in 60% of OD patients (Bianchi et al., 1999). 
Osteonecrosis can be primary (also known as spontaneous osteonecrosis) or 
secondary, as a consequence of, for example, alcoholism, steroid therapy and 
meniscectomy (Patel et al., 1998). The cartilage lesions after age 40 are mainly 
caused by OA. In all cases, the appearance of degenerative lesion may diverge from 
each other. Such cartilage lesion progresses to subchondral bone hardness leading 
to reduced stress absorption and vulnerable cartilage ECM (Falah et al., 2010). 
Cartilage lesions and damage of subchondral bone are, in many cases, getting more 
severe because of weight bearing stress. Ligament (especially the anterior cruciate 
ligament, ACL) injury causes meniscal and knee instability, which in turn lead to 
cartilage injury (Stanitski, 1995). Previous studies have showed that about two third 
of articular cartilage lesions are linked to meniscal tears (Lewandrowski et al., 1997). 
Owning to its complex etiology, the effect of preventive treatment options of cartilage 
lesions is still controversial (Falah et al., 2010). 
1.8.2. Cartilage injuries among athletes 
There is a rising tendency of chondral injuries in professional athletes (Chow 
et al., 2004). Apart from the prominent occurrence of cartilage damage in high-end 
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competitive sports, the enhanced incidence of articular cartilage injuries is positively 
correlated with the increasing participation in leisure sports (e.g. football and 
basketball) (Arendt and Dick, 1995; Jones et al., 2001; Mithofer et al., 2005). 
Cartilage damages of the knee joints are reported as one of the most common 
reasons that accounts for sustained disability of athletes (Drawer and Fuller, 2001; 
Engstrom et al., 1990). Injuries of the articular cartilage are often associated with 
osteochondral fractures, patellar dislocations and avulsions of ligaments (Bartz and 
Laudicina, 2005; Moti and Micheli, 2003; Smith and Tao, 1995). Focal lesions in the 
femoral condyles are found in approximately 50% of the athletes who receive ACL 
reconstruction with increasing population of female athletes (Arendt and Dick, 1995; 
Piasecki et al., 2003). The cartilage injuries often strongly affect athletic performance 
and progress to early joint degeneration (Felson et al., 2000; Kujala et al., 1995). 
Since the cartilage injuries are barely self-repaired, articular cartilage lesions 
in young and physically active people have been considered as a challenge of 
treatment (Buckwalter, 1999; Jackson et al., 2001). Newly invented surgical 
techniques have attempted to address cartilage repair, joint replacement and even 
the possibility of regeneration (Alford and Cole, 2005a; Alford and Cole, 2005b; 
Brittberg et al., 1994; Moti and Micheli, 2003; Steadman et al., 2003). Because of the 
mechanical overload of the joint, articular cartilage injuries in athletes especially 
require the repair on the surface, which should bear massive impact in highly 
intensive sports (Jackson et al., 2001). The assessments of articular cartilage repair 
of athletes are mainly focused on functional scores, mobility and the chance to go 
back to sports (McAdams et al., 2010). 
In the population of athletes, the evaluation of the progression of knee 
cartilage destruction has been well documented (Drawer and Fuller, 2001; Engstrom 
et al., 1990; Felson et al., 2000; Lane et al., 2004; Roos, 1998). Healthy, normal 
articular cartilage is characterized with the best weight-bearing ability depending to 
the activity. Articular cartilage in teenagers and in people active in sports are 
thickened, and synthetize more glycosaminoglycans due to the increased weight-
bearing impacts of the joint (Roos and Dahlberg, 2005). Generally, articular function 
is positively correlated to repetitive loading in healthy athletes. However, any athletic 
activity above the threshold of this linear correlation can cause injuries of articular 
cartilage (Kiviranta et al., 1992). Massive, non-physiological mechanical stress may 
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result in chondrocyte apoptosis, activation of degradative enzymes and, 
consequently, and depletion of cartilage macromolecules such as proteoglycans 
(Arokoski et al., 1993; Jackson et al., 2001; Lohmander et al., 1994; Pearle et al., 
2005). Afterwards, the initial phase of the disease starts caused by cartilage 
breakdown, increased compressive stress and occurrence of cartilage lesions 
(McAdams et al., 2010). Meniscal injury, malalignment or ligament instability are 
known to further enhance articular cartilage degradation, which without medical 
treatments results in sustained dysfunction of articular cartilage and eventually leads 
to OA (McAdams et al., 2010). 
1.8.3. Osteoarthritis 
OA is a multifactorial and highly complex disease of the synovial joints 
affected by genetic and environmental elements (Buckwalter and Martin, 2006). OA 
is most prevalent in the joints of hip, knee and hands (Figure 11). Pain and functional 
impairment (dysfunction and joint stiffness) are the common characteristics of OA. 
Approximately 80% of the OA patients have movement limitations to certain level that 
cause imperfect performance in work, sport and everyday life. Importantly, 20% of 
OA patients aren’t able to perform most of the daily activities (Wieland et al., 2005). 
 
Figure 9: Predominant sites of OA. The common OA-occurring joints such as knee, hip, finger, 
shoulder and spine are indicated. Figure is adapted and modified from (Wieland et al., 2005). 
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OA is a slowly developing process of usually single joints that characterized by 
sustained cartilage destruction associated with occasional signs of synovitis (Figure 
12). The occurrence of OA increases with age, eventually affecting half of elderly 
people over 65 years (Badley and Wang, 1998; Millennium, 2003; Wieland et al., 
2005). Rheumatoid arthritis (RA), in contrast to OA, is fast-developing and 
generalized inflammatory disease driven by autoimmune processes that primarily 
affects younger people. Although, RA is much less common than that OA (Millennium, 
2003; Wieland et al., 2005), RA has tempted more attention than osteoarthritis in the 
past. 
 
Figure 10: Healthy versus OA-affected knee joint. Compared to healthy knee, OA-affected knee is 
characterized by cartilage breakdown, meniscal lesions and inflamed synovium. With the progression 
of OA, osteophytes and bone sclerosis may develop. Figure is adapted and modified from (Wieland et 
al., 2005). 
Multiple biological molecules are involved in cartilage breakdown at the onset 
and during the progression of OA. These molecules suppress restoration of cartilage 
and result in imbalance of cartilage metabolism (Figure 13). A shift from anabolic to 
catabolic processes in chondrocytes plays a pivotal role in the pathology of OA. In 
primary OA with no clearly identified disease-causing factors, the cartilage ECM 
production of chondrocytes is impaired due to the disproportion of catabolic and 
anabolic activities. Excessive catabolic processes in OA chondrocytes result in 
sustained and advanced damage of the articular cartilage. Secondary OA is defined 
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as the early-onset degeneration of articular cartilage due to defined factors such as 
joint malformations (dysplasias), diabetes and mechanical overload.  
Remodeling of cartilage ECM involves both proteinases like matrix 
metalloproteinases (MMPs) and caspases, and proteinase inhibitors such as tissue 
inhibitors of metalloproteinases (TIMPs). In normal articular cartilage, the activities of 
these molecules are tightly regulated at multiple levels including cytokine/growth 
factor signaling pathways, matrix-matrix and cell-matrix interactions (Figure 14). 
However, the exact nature of the pathways and the potential cross-talks among the 
different cascades are still partially understood. 
 
Figure 11: Vicious cycle of osteoarthritis. The connections between etiological factors, 
pathophysiological events and consequence are demonstrated. The pathophysiological events 
frequently affect and enhance each other. Figure is adapted and modified from (Wieland et al., 2005). 
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Figure 12: Mechanisms controlling articular cartilage function. Transmembrane receptors such 
as integrins, growth factor and cytokine receptors, discoidin domain receptor 2 (DDR-2) receive 
mechanical and chemical signal from the cartilage ECM. The following signal transduction processes 
are mediated via multiple intracellular signaling cascades involving MAPKs, PI3K, Smad, Wnt, 
GTPase, NF-κB, Hedgehog and Notch. As net effect, gene expression, cell survival, proliferation and 
actin dynamics are regulated to maintain cartilage homeostasis and differentiation. Figure is adapted 
and modified from (Legate et al., 2009). 
Cartilage resident matrix proteins interact with each other in a complex 
manner to define the physical framework for cells and to control the availability, 
activity and cell surface presentation of bioactive molecules. Almost all ECM proteins, 
directly or indirectly, bind to and activate cellular receptors such as integrins, which in 
turn stimulate intracellular signaling pathways regulating cellular behavior such as 
gene expression, proliferation, survival and cytoskeletal reorganization (Legate et al., 
2009). The pericellular matrix (PCM) – surface receptors interactions are suggested 
to play critical role in transmitting signals from cartilage ECM into chondrocytes, 
which maintain homeostasis of matrix metabolism (Knudson and Loeser, 2002). 
Alterations of cartilage ECM such as injury, proteolytic degradation and chronic 
stress, which interfere matrix-cell signaling, largely increase the risk of OA incidence 
(Roos and Dahlberg, 2005). 
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1.8.4. Current, non-surgical treatment options for cartilage injury  
According to age, daily activities, and the deterioration level of the lesion, 
current treatment options include open or arthroscopic surgery and conservative 
therapy. 
A conservative treatment aims for easing the symptoms rather than healing 
cartilage damage. Surgery is not recommended to apply for mild cartilage injuries or 
small lesions because it may do more secondary damage (Falah et al., 2010). Thus, 
clinicians may suggest several alternative treatments that are non-surgical and 
specific for patient's condition (Fritz et al., 2006). One of the most common 
treatments is medication such as hormones, analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs). Other common treatments consist of physical therapy, 
weight control and the use of bracing combined with food nutrients with possible 
chondroprotective effect (e.g. chondroitin phosphate, glucosamine, ascorbic acid). 
Acetaminophen is commonly used for pain ease and is the first-line oral 
medication for osteoarthritis even though the detail mechanism is remained unclear. 
The effect of pain relief is nearly as good as NSAIDs (Jordan et al., 2003). However, 
the following clinical studies implied that NSAIDs and COX-2 inhibitors are with better 
efficacy than acetaminophen (Lee et al., 2004a; Neame et al., 2004; Wieland et al., 
2005; Zhang et al., 2004). 
 
Figure 13: Current treatments for OA. Various therapeutic strategies, according to different level of 
OA, are used to prevent joint degradation. Figure is adapted and modified from (Wieland et al., 2005). 
NSAIDs are usually applied to the OA patients that are poorly respond to 
acetaminophen (Figure 15) (Jordan et al., 2003). NSAIDs exert its anti-inflammation 
by blocking cyclooxygenase COX-1 and COX-2. Previous study indicates that COX-2 
is induced at the inflammatory site (Vane et al., 1998). The effects of anti-
inflammatory and pain relief from NSAIDs are associated with inhibition of 
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prostaglandin and with direct influence on the nervous system (Samad et al., 2001). 
Several reviews have showed the effect of distinct NSAIDs given to knee OA patients 
is comparably similar (Warner et al., 1999; Watson et al., 2006). Application of the 
NSAIDs should always consider patient acceptance, safety and costs (Watson et al., 
2006; Wieland et al., 2005). COX-2 selective inhibitors were first described in 1999. 
Compared to non-selective COX-2 inhibitors, such selective COX-2 inhibitors have 
lower side effect, e.g. lower gastrointestinal complications (Warner et al., 1999). With 
regards to pain relief and improvement of OA patients, effect of selective COX-2 
inhibitors is similar to NSAIDs (Bensen et al., 1999; Day et al., 2000). In the cases of 
patients which barely respond to NSAIDs and selective COX-2 inhibitors, opioid 
analgesics are also considered. 
Chondroprotective nutrients such as glucosamine and chondroitin sulfate are 
common health care products that used worldwide and approved by European 
League Against Rheumatism (EULAR) (Jordan et al., 2003). However, the effects of 
such chondroprotective agents are still dubious and so far no clear indications that 
they would effectively stop or reverse the progression of OA (Chard and Dieppe, 
2001; McAlindon et al., 2000; Zerkak and Dougados, 2004). 
Administration of topical medications is noticed with lower systemic side 
effects than systemically applied drugs. Short-term, local administrated NSAIDs has 
proved to reduce knee OA (Lin et al., 2004). The effect of long-term local 
administration still remains unclear. Apart from NSAIDs, studies showed that topical 
application of capsaicin and salicylates also reduce knee OA but less effective than 
NSAIDs (Mason et al., 2004). 
Intra-articular injection is another way to apply topical administration in OA 
patients. Injection of long-lasting corticosteroids is considered as ideal treatment 
against knee pain (Jordan et al., 2003). The effect of intra-articular injection can 
reach to the peak within a week and gradually wear off until the 4th weeks (Ayral, 
2001; Gossec and Dougados, 2004). It is still unclear if multiple injections of steroids 
might accelerate progression of OA. The efficacy of steroid injection is also agonistic 
(Creamer, 1999). 
In cartilage and the synovial cavity, hyaluronic acid (HA) is one of the most 
common matrix components. HA is associated with multiple tasks such as cell-cell 
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interactions, inhibition of prostaglandin E2 (PGE2) synthesis and lubrication (Brandt 
et al., 2000; Lohmander et al., 1996). The level of HA is usually decreases in OA joint. 
To compensate the loss of HA; intra-articular injection of HA can be applied (Brandt 
et al., 2000). Compared to placebo injection, however, HA injection shows only slight 
improvement of knee OA. Thus, re-evaluation and further analysis of HA application 
are required to determine its beneficial effect (Jordan et al., 2003; Lo et al., 2003). 
1.8.5. Inhibition of NF-κB pathway by pharmacologic agents 
To date, there are more and more NF-κB inhibitors discovered. For example, 
glucocorticoids can effectively inhibit NF-κB pathway via modulating various 
intracellular signaling pathways (De Bosscher et al., 2000a; Garg and Aggarwal, 
2002; Payne and Adcock, 2001; Yamamoto and Gaynor, 2001). It is known that 
glucocorticoids increase expression of IκB, which enhances cytosolic preservation of 
NF-κB (Auphan et al., 1995; Scheinman et al., 1995). Glucocorticoids are also 
suggested to mask the DNA-binding ability of NF-κB by interacting with glucocorticoid 
receptor and NF-κB binding components (De Bosscher et al., 2000b). In some cell 
types, the activated glucocorticoid receptor can inhibit the activation of NF-κB by 
direct binding (De Bosscher et al., 1997). Some of NSAIDs (aspirin, salycilate and 
sulindac) are able to efficiently inhibit activity of IKK and IκB phosphorylation, which 
in turn results in the blockade of NF-κB activation (Tegeder et al., 2001). Likewise, 
sulfasalazine, a medication against RA, is proved to inhibit the phosphorylation of IκB 
(Wahl et al., 1998). 
Immunosuppressants such as cyclosporin A and tacrolimus can also block 
NF-κB activation. In T lymphocytes, macrophages and lymphoma cells, Cyclosporin 
A is found to inhibit degradation of IκBα via lowering proteasome activity (Frantz et al., 
1994; Meyer et al., 1997). Tacrolimus sequesters c-Rel in the cytoplasm of certain 
cell types (Jurkat cells, B- and T-lymphoctes), which consequentially blocks the 
activation of NF-κB pathway (Su and Semerjian, 1991; Venkataraman et al., 1995). 
Agents such as curcumin, flavonoids (Bremner and Heinrich, 2002), diacehrein 
(Mendes et al., 2002), glucosamine (Largo et al., 2003), lactacystin (Cuschieri et al., 
2004), leflunomide (Manna et al., 2000), pyrrolidine dithiocarbamate (Cuzzocrea et 
al., 2002), thalidomide (Meierhofer and Wiedermann, 2003), vitamin C (Carcamo et 
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al., 2002) and vitamin E (Calfee-Mason et al., 2004), are reported to suppress NF-κB 
activation. 
In recent years, new therapeutic strategies have been innovated for specific 
suppression of essential components activating NF-κB pathway (Bacher and Schmitz, 
2004; Feldmann et al., 2002; Firestein, 2004; Lewis and Manning, 1999; Smolen and 
Steiner, 2003). Decoy oligonucleotides (ODN), peptides specifically masking NLS of 
NF-κB, and proteasome inhibitors are applied to block NF-κB activation in animal 
models (Elliott et al., 2003; Epinat and Gilmore, 1999). Daily intake of bortezomib, a 
Food and Drug Administration (FDA)-approved proteasome inhibitor, can effectively 
reduce activity of NF-κB in streptococcal cell wall (SCW)-induced arthritis in a rat 
model (Roman-Blas and Jimenez, 2006). The decline of NF-κB activity is related to 
metabolism of nitric oxide (NO), and decreased levels of of IL-1 and IL-6 in the serum 
(Kawakami et al., 1999). In a collagen II induced rheumatoid arthritis rat model, intra-
articular injection of ODN can directly bind to NF-κB and therefore block its activity by 
masking the DNA-binding sequence of NF-κB. ODN significantly eases the paw-
swelling accompanied with reduced IL-1β and TNF-α in the inflammatory synovium, 
which suppressing the destruction of joint (Tomita et al., 1999). Similarly, injecting 
NF-κB decoy ODN into the knee joints of an animal OA model induced by ACL 
transection, ODN significantly ameliorated knee OA owing to the largely decreased 
IL-1β and TNF-α in cartilage and synovial (Fujihara et al., 2000). 
Novel therapeutic strategies using antisense oligonucleotides and RNA 
interference also aim for specific inhibition of NF-κB components. Lock nucleic acid 
(LNA), a type of modified nucleotides with better DNA and RNA binding affinity and 
specificity, was first introduced in 1997 (Jepsen and Wengel, 2004). Morpholino 
oligomers, which contain an ODN structure, are nucleic acid analogs that used to 
modify expression of gene (Jepsen and Wengel, 2004; Kawai et al., 2005). RNA 
interference, including micro RNA (miRNA) and small interfering RNA (siRNA), is 
defined as a post-transcriptional process of gene silencing. The target mRNA is 
specifically cleaved by siRNA-induced ribonucleoprotein complex and sent for 
degradation (Huppi et al., 2005; McManus and Sharp, 2002; Pinkenburg et al., 2004). 
It has shown a great inhibition efficacy of NF-κB by siRNA, witnessed by  the 
eliminations of downstream signaling factors such as COX-2, iNOS and MMP-9 in 
IL1β- and TNFα-treated rat chondrocytes (Lianxu et al., 2006). 
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1.8.6. Operative treatment options  
The idea of surgical intervention is to repair the damage and facilitate the 
regeneration of injured cartilage to its original state. However, regenerated tissue is 
mainly fibrocartilage with small HA level after surgery (Odenbring et al., 1992). Ideally, 
surgical treatments should orient to patients with considerations of repair associated 
problems before the operation (Falah et al., 2010; Fritz et al., 2006). Arthroscopy is 
minimally-invasive and the most common surgical procedure, which can repair 
cartilage function, relieves pain and reduces the risk and progression of OA. Under 
certain circumstances such as infection, misaligned joint and obesity, surgical 
intervention for cartilage lesions should not be performed (Falah et al., 2010). 
1.9. The NF-ĸB/Rel family of transcription factors 
The mammalian NF-ĸB family of ubiquitously expressed transcription factors 
consists of five members: NF-ĸB1 (p50 and its precursor p105, NF-ĸB2 (p52 and its 
precursor p100), RelB, c-Rel and RelA/p65 (Ghosh and Karin, 2002). NF-ĸB 
members are able to form homo- and heterodimers that in various cell types are 
cytoplasmatically-sequestered by inhibitors of NF-ĸB (IĸBs) (Figure 9). 
Phosphorylation of IĸB by IĸB kinase (IKK) complex leads to degradation of IĸB, 
which in turn can release active NF-ĸB dimers and allow them to translocate into 
nucleus for the control of gene regulation (Hayden and Ghosh, 2004; Perkins, 2007). 
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Figure 14: The members of NF-κB, IκB and IKK families. (A) The NF-ĸB family contains five 
subunits: RelA (p65), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2). NF-κB1 and NF-κB2 
are processed and become fully-activated p50 and p52, respectively. All members of NF-κB family 
possess a N-terminal RHD (Rel-homology) domain, which is responsible for dimerization, nuclear 
localization and DNA binding. The Rel subunits are characterized with C-terminal transcriptional 
activation domains (TADs). (B) The IκB family is composed of IκBα, IκBβ, IκBε and BCL-3. The IκB 
subunits contain ankyrin-repeat motifs (ANK). (c) The IKK family contains 3 members: IKKα, IKKβ and 
IKKγ, which later one also known as NF-κB essential modifier (NEMO). These three IKK subunits 
together form the IKK complex. LZ, RelB-transactivation-domain containing a putative leucine-zipper-
like motif; PEST, domain rich in proline (P), glutamate (E), serine (S) and threonine (T); ZF, zinc-finger 
domain; HLH, helix–loop–helix; NBD, NEMO-binding domain. Figure is adapted and modified from 
(Perkins, 2007). 
All members of the NF-κB family contain a Rel-homology domain (RHD) at the 
N-terminus, which is involved in dimerization and DNA binding. The Rel subfamily 
members are also characterized by the presence of one or two C-terminal 
transcriptional activation domains (TADs) (Figure 9). Apart from the similar structure 
and the DNA binding capability, NF-κB members are reported to have different 
functions (Gerondakis et al., 1999; Hoffmann et al., 2003).  
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In unstimulated healthy mammalian cells, members of Rel family are mainly 
restricted in the cytoplasm together with the IκB proteins (Hayden and Ghosh, 2004). 
The IκBs are known to sequester NF-κB subunits and prevent their translocation into 
the nucleus by masking the nuclear localization signal (NLS) in the RHD. Due to the 
partial masking effect of IκBα, NF-κB/IκBα complexes are able to translocate into 
nucleus without any stimulation. Owning to the nuclear export sequence (NES) on 
IκBα, the complexes are soon exported back to cytoplasm (Hayden and Ghosh, 2004; 
Perkins, 2007). 
Ankyrin-repeat motifs are characteristic for the NF-κB subunits p105 and p100, 
and can be found in IκB proteins as well (Figure 9). The function of p100 and p105 is 
similar to IκB proteins because they help the cytoplasmic sequestration of NF-κB-
subunit dimers (Hayden and Ghosh, 2004; Perkins, 2007). There are several 
mechanisms to process of p100 and p105, which are necessary for the activation of 
p50 and p52. The homodimers of p50 and p52 are able to interact with BCL-3 in the 
nucleus. In contrast to IκBs, BCL-3 is working as a transcriptional coactivator 
(Hayden and Ghosh, 2004; Perkins, 2007). Due to the ability to avoid IκBs regulation, 
p50 and p52 homodimers stay consititutively in the nucleus. When members of Rel 
subfamily form heterodimers with p50 or p52, they are no longer able to escape the 
regulation of IκBs (Hayden and Ghosh, 2004; Perkins, 2007). The p52–RelB complex 
is the only exception that evades the regulation due to its low affinity for IκBα 
(Dobrzanski et al., 1994). 
1.9.1. The NF-κB  signaling pathways 
There are three NF-κB activation pathways. The most common one is the 
canonical, classical pathway (Figure 10), which is triggered by a range of 
inflammatory stimuli such as interleukin-1 (IL-1), tumour necrosis factor-α (TNFα), 
engagement of the T-cell receptor (TCR) and lipopolysaccharide (LPS) (Hayden and 
Ghosh, 2004). The activation of canonical pathway is characterized by the serine 
phosphorylation of IκBα at the amino acid positions 32 and 36, followed with its 
proteosomal degradation (Hayden and Ghosh, 2004; Perkins, 2007). In various types 
of cell, IκBβ and IκBε are phosphorylated and degraded slower than IκBα (Hayden 
and Ghosh, 2004; Perkins, 2006; Perkins, 2007). 
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In the NF-κB canonical pathway, phosphorylation of IκB is the consequence of 
IKK-complex activation (Hayden and Ghosh, 2004). There are three components in 
the IKK complex, IKKα (IKK1), IKKβ (IKK2) and NF-κB essential modifier (NEMO, 
also known as IKKγ) (Hayden and Ghosh, 2004). IKKβ has been proved as the major 
IκB kinase in NF-κB canonical pathway (Bonizzi and Karin, 2004; Pasparakis et al., 
2006). 
The non-canonical or alterative pathway can be induced by stimuli such as 
LPS, CD40, B-cell-activating factor of the TNF family, and the latent membrane 
protein-1 (LMP1) of Epstein–Barr virus (Bonizzi and Karin, 2004; Perkins, 2003). The 
activation of IKK complex, which lack Nemo, by the NF-κB-inducing kinase (NIK) 
processes p100 into p52 (Bonizzi and Karin, 2004; Perkins, 2006). Afterwards, the 
p52 complex shuttles into the nucleus for gene regulation. p52-RelB dimers have 
higher affinity for a subset of κB elements and regulate certain NF-κB target genes 
(Figure 10). The non-canonical pathway has been suggested to be regulated by IKKα 
homodimers instead of the larger IKK complex (Bonizzi and Karin, 2004; Perkins, 
2006).  
Certain stimuli such as hypoxia, reoxygenation and hydrogen peroxide cause 
Tyr42 phosphorylation of IκBα, which is subsequentially degraded or dissociated 
from the NF-κB complex (Perkins, 2006; Perkins and Gilmore, 2006). Exposure to 
ultraviolet (UV) light or constitutively activation of HER2 in breast cancer cells also 
triggers PEST domain phosphorylation of IκBα by casein kinase-II (CK2) (Perkins, 
2006). Both phenonmenons are IKK-independent and lead to NF-κB activation which 
is classified as atypical NF-κB pathway.  
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Figure 15: Activation of NF-κB pathways. The canonical pathway is depended on IKKβ activation 
and induced by many stimuli (e.g. IL-1 and TNFα). The IKK complex is activated by Ser32 and Ser36 
phosphorylation of IκBα, which is subsequently degraded. Later, p50/RelA dimer is released and 
translocated into the nucleus. In certain situation such as genotoxic stress, NF-κB essential modifier 
(NEMO) is processed by ataxia telangiectasia mutated (ATM) checkpoint kinase in nucleus and enters 
the cytoplasm for the activation of IKK complex afterwards. Tyrosine kinases and casein kinase-II 
(CK2) are known to mediate the activation of atypical NF-κB signaling. The non-canonical NF-κB 
pathway is regulated by NF-κB-inducing kinase (NIK), which activates IKKα and the following 
modification of p100. The active p52/RelB dimer (non-canonical) regulates distinct genes comparing to 
canonical/atypical NF-κB signaling. Figure is adapted and modified from (Perkins, 2007). 
1.9.2. Activation of the IKK complex 
The NF-κB canonical pathway activation can be induced by numbers of 
external stimuli, which usually trigger membrane receptors and/or inner signaling 
pathways (Chen, 2005; Hayden and Ghosh, 2004; Kawai and Akira, 2006; 
Krappmann and Scheidereit, 2005; Perkins, 2006). The regulatory subunit NEMO is 
elementary for IKK complex activation. NF-κB activating stimuli cause Lys63-linked 
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ubiquitylation of NEMO (Burns and Martinon, 2004; Chen, 2005; Krappmann and 
Scheidereit, 2005; Perkins, 2006). The Lys63-linked ubiquitylation is known to 
promote interactions between proteins with ubiquitin-binding domains (Burns and 
Martinon, 2004; Chen, 2005; Krappmann and Scheidereit, 2005; Perkins, 2006). 
Transforming growth factor-beta (TGFβ)-activated kinase-1 (TAK1) is recruited after 
ubiquitylation of NEMO and phosphorylates IKKβ at Ser177 and Ser181 (Burns and 
Martinon, 2004; Chen, 2005; Krappmann and Scheidereit, 2005; Perkins, 2006). 
Among NF-κB activating stimuli, genotoxic stimuli are also known to initiate 
NEMO-dependent IKKβ activation in NF-κB canonical pathway (Figure 10) (Janssens 
and Tschopp, 2006). Under certain	 circumstances, NEMO interacts with ataxia 
telangiectasia mutated (ATM) and translocates into nucleus for following sumoylation 
and phosphorylation (Wu et al., 2006). The mono-ubiquitylation is then substituted for 
the sumoylation of NEMO-ATM complex, which is exported back to cytoplasm and 
activates the IKK complex. 
1.9.3. NF-ĸB pathway in skeletal development and arthritis  
Previous studies using genetic-engineered mice have gained us valuable 
information of NF-ĸB pathway during skeletal development. p50/p52 double knockout 
mice displayed an arrest of osteoclast maturation, which results in imbalance of bone 
production/resorption and sequentially causes osteopetrosis. The mutant phenotype 
is cured by bone marrow transplantation, which indicates the components of 
hematopoietic system are also affected (Iotsova et al., 1997). The IKK1 knockout 
mice die shortly after birth and show impaired skeletal development and epidermal 
differentiation (Li et al., 1999a). Overexpressing wild type IKK1 in epidermal cells of 
IKK1-null mice rescues the skin as well as the skeletal phenotype. The appropriated 
morphogenesis of skeletal components originated from mesoderm likely requires 
epidermal-mesenchymal interactions (Sil et al., 2004). Owning to the normal 
development of cartilage and bone in rescued mice, IKK1 seems to be replaceable in 
skeletal development. The p65-null, NEMO-null and IKK2-null mice die in early- or 
mid-embryonic stage due to liver degeneration and massive hepatic apoptosis (Beg 
et al., 1995; Li et al., 1999b; Rudolph et al., 2000). The heterozygous NEMO-
deficient (+/-) female mice display skin lesions similar to the human genetic disorder 
incontinentia pigmenti (Schmidt-Supprian et al., 2000).  
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Studies of human cell culture, tissue explant cultures and patient samples 
have indicated the involvement of NF-ĸB activation in rheumatatic disorders such as 
RA, OA, juvenile RA, psoriatic and septic arthritis (Roman-Blas and Jimenez, 2006). 
IKKs, p65 and p50 are involved in synovitis and are abundant in OA and RA. IKK2 
activation has been suggested to be a critical step in NF-ĸB-mediated cytokine and 
collagenase upregulation in synoviocytes in response to TNF-α and IL-1β stimulation 
(Aupperle et al., 2001). In the inflammatory arthritis animal models such as collagen 
type II or rat adjuvant induced arthritis, activation of NF-ĸB is one of the earliest 
events in disease progression and associated with the level of MMP-13 and MMP-3 
(Makarov, 2001; Mor et al., 2005). The intra-articular injection of adenoviral construct 
carrying IKK2 gene results in severe arthritis coupling with synovial swelling, 
indicating the essential role of IKK2 in synovial inflammation (Tak et al., 2001). In RA 
rat model, inhibition of IKK2 has proved to ease damage to cartilage and bone 
(Schopf et al., 2006). Similar to synoviocytes, NF-ĸB appears to be pivotal in 
mediating inflammatory and catabolic processes in articular chondrocytes: 1) NF-ĸB 
is activated in articular cartilage chondrocytes upon stimulation with TNF-α and IL-1β; 
2) it regulates the expression of MMP-1, -3 and -13 in response to proinflammatory 
cytokines (Roman-Blas and Jimenez, 2006); 3) chemical inhibition of IKK in IL-1-
treated cartilage explants blocked collagen II and aggrecan degradation by 
suppressing the expression of collagenases and ADAMTS-5 (Pattoli et al., 2005); 4) 
NF-ĸB is rapidly activated by physical trauma induced by articular cartilage 
explantation and cutting (Gruber et al., 2004); 5) proteolytic cleavage fragments of 
collagen II and fibronectin (Fn) have NF-ĸB-dependent cartilage destructive activities 
(Ding et al., 2009); 6) elimination of IKK1 and IKK2 by shRNAs in osteoarthritic 
chondrocytes has showed the protective potential to increase cartilage ECM 
production (Olivotto et al., 2008). These scientific evidences imply that blockade of 
the NF-ĸB pathway through pharmacological or gene therapeutic inhibition is a 
potential strategy against OA and RA. However, since NF-ĸB is believed to exert 
positive physiological functions such as its anti-apoptotic effect on CD95-induced 
apoptosis (Kuhn et al., 2000), further in vivo studies are needed to clarify the natural 
roles of NF-ĸB signaling in the skeletal system in order to develop effective therapy 
for joint diseases. This is especially relevant in cartilage, as chondrocyte apoptosis is 
considered to be an important early event in induction of disease. 
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1.10. Model to study NF-κB canonical pathway in cartilage 
development 
Although numerous animal species are used for studying the development and 
function of skeletal tissues, mouse (Mus musculus) is one of the most common 
genetic model organisms owing to its easily-manipulated genome. Mouse strains with 
engineered gene mutations have been increasingly used to understand the complex 
interaction between ECM, cytokines, receptors, signaling molecules  and 
transcription factors during OA (Aszodi et al., 2006; Raducanu and Aszodi, 2008). 
Because the skeletal development and the genome are very similar between human 
and mouse, genetically-modified mice have shown precious insights of the 
differentiation and function of the mammalian cartilaginous skeleton. 
Transgenic and gene knock-out experiments have significantly contributed to 
the clarification of the physiological functions of NF-ĸB signaling pathways 
(Pasparakis et al., 2006). Inhibition of the canonical NF-ĸB pathway by ablating the 
genes coding for p65/RelA, NEMO or IKK2 by conventional knockout (constitutive 
null mutation) results in early to mid-embryonic lethality owing to hepatic apoptosis 
and liver degeneration (Beg et al., 1995; Li et al., 1999a; Rudolph et al., 2000). 
Owing to the early lethal phenotype of mice with constitutive deletion of genes, 
conditional gene targeting strategies utilizing the Cre/LoxP recombination system 
(Rajewsky et al., 1996) have been developed to dissect the function of NF-ĸB 
pathways in an inducible and/or tissue-specific manner. Inhibition or forced activation 
of NF-ĸB in these mice as well as the classical transgenic mice overexpressing 
constitutively active or dominant-negative proteins have revealed the critical role of 
NF-ĸB/Rel proteins in various cells and tissues including lymphocytes, myeloid and 
epithelial cells, neurons and skeletal muscle (Pasparakis et al., 2006). By utilizing the 
NEMO conditional knockout mice, we are able to analyze the role of canonical NF-
ĸB-mediated processes in the regulation of normal and pathological cartilage 
functions. 
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2. Aim and milestones of the thesis 
The NF-κB transcription factors are believed to be important for articular 
cartilage destruction during osteoarthritis and rheumatoid arthritis through their 
capacity to mediate protease induction by pro-inflammatory cytokines such as IL-1 
and TNFα, cartilage injury directly, or articular cartilage degradation products such as 
fibronectin fragments. Consequently, numerous studies have been devoted to 
develop therapeutic strategies aiming to treat these debilitating rheumatoid 
conditions by inhibition the canonical NF-κB signaling pathway. However, the exact 
role of NF-κB in cartilage physiology is unclear, hampering the discovery of effective 
strategies that consider both the beneficial and deleterious effects of NF-κB activation 
on cartilage pathology.  
The hypothesis of this study is that a suitable mouse model with inhibited 
canonical NF-κB signaling in chondrocytes could significantly contribute to our 
knowledge about the function of NF-κB in cartilaginous tissues. The main objective of 
the proposed research is the analyses of the NEMO-Col2a1cre conditional knockout 
mice, in which the canonical NF-κB pathway is inhibited genetically in chondrocytes, 
to promote our understanding of NF-κB-mediated processes on the regulation of 
normal and pathological cartilage functions. 
 
The following milestones are defined: 
 
1. Understand the impact of NEMO-deficiency on endochondral bone formation. 
 
2. Clarifying the role of canonical NF-κB pathway in cartilage metabolism using 
hip explant culture. 
 
3. Investigate the role of canonical NF-κB pathway in cartilage responses upon 
ex vivo-induced hip injury. 
 
4. The involvement of canonical NF-κB pathway in the development of 
spontaneous osteoarthritis with aging. 
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3. Materials and Methods 
3.1. Animal 
3.1.1. Mouse housing and breeding 
The floxed NEMOfl/fl female mice were generated from C57BL/6J background 
(Schmidt-Supprian et al., 2000, generously provided by Dr. Marc Schmidt-Supprian, 
Max Planck Institute for Biochemistry, Martinsried, Germany). Due to NEMO gene is 
located on X-chromosome, intercrosses between NEMOfl/fl females and wild-type 
C57BL/6J male resulted in a ratio of 50% heterozygous NEMOfl/+ females and 50% 
NEMOfl/Y males. Next, homozygous NEMOfl/fl females and NEMOfl/Y males were 
obtained from inbreeding of homozygous NEMOfl/fl females with NEMOfl/Y males.  
NEMOfl/YCOL2a1Cre males were generated from intercrosses of NEMOfl/fl female 
with Col2a1Cre male (Sakai et al., 2001). In this study, we used NEMOfl/Y male as 
control group to compare difference with NEMOfl/YCol2a1Cre male.  
All mice were housed under standard laboratory conditions with controlled 
temperature and ventilation, under a 12:12 h light/dark cycle and fed ad libitum. Mice 
were sacrificed vial cervical dislocation and tissues dissection was done post mortem. 
3.1.2. Mouse genotyping 
Genomic DNA (gDNA) was isolated from 2-3 mm length mouse tail were lysed 
overnight (O/N) at 55°C in 0.2 ml lysis buffer. The digestion was neutralized at 95°C 
for 10 minutes. After centrifugation to spin down non-digested tissue, the solution 
was placed on ice and used directly for PCR reaction. The PCR products were 
visualized by agarose gel electrophoresis in 1x TAE solution with 0.05 µl/ml ethidium 
bromide on the UV imager. Instruments, chemicals, buffers and PCR condition were 
listed in table 1 and 2. 
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3.2. Primary chondrocyte isolation 
Primary mouse chondrocytes were isolated from rib cage. Pups were sacrificed 
soon after birth and briefly disinfected with 70% ethanol. From this point on, all the 
procedures were carried out in sterile conditions in a primary cell culture laminar flow 
hood (Heraeus Instruments, Jena, Germany). Isolated rib cages were placed in 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 Ham 1:1 (DMEM/F12) 
(Thermo Fisher Scientific, USA) media, adherent tissues were removed with sterile 
surgical forceps. The pre-cleaned ribs were put into DMEM/F12 media containing 2 
mg/ml type II collagenase (Worthington, USA) at 37°C for 30 minutes. The partially 
digested perichondrium around ribs was again carefully removed with dissecting 
forceps and scissors (DUMONT, Switzerland). Afterwards, cleaned ribs were 
replaced to fresh DMEM/F12 media containing type II collagenase in a humidified 
atmosphere (5% CO2, 95% air and 37°C) for 3 h. After enzymatic digestion, the cell 
suspension was centrifuged at 500g for 5 minutes. The supernatant was discarded 
and pelleted cells were resuspended in fresh DMEM/F12 media supplemented with 
10% fetal bovine serum (FBS) (Thermo Fisher Scientific, USA) and 1% 
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penicillin/streptomycin (Pen/Strep) mixture (Biochrom, UK). Primary chondrocytes 
were counted and plated as passage 0.  
3.3. Cell culture 
3.3.1. Primary cells and culture media 
Primary chondrocytes were isolated from the rib cages of NEMO knockout 
mice and their wild-type littermate as described above. Since primary cells were 
rapidly loss of characteristics in vitro, all experiments were performed at low passage 
number (no more than passage 4). Primary chondrocytes were cultured in complete 
DMEM/F12 enriched with 10% FBS, and 1% Pen/Strep mixture.  
3.3.2. Passaging and counting cells 
Chondrocyte monolayer was washed with 1x PBS (Biochrom, UK) and then 
detached by covering with 1x Trypsin/EDTA (Biochrom, UK) for 5 min at 37°C. A 
double volume of complete DMEM/F12 media was added to neutralize the effect of 
trypsin. Cells were pelleted by centrifugation at 500g for 5 minutes. The supernatant 
was removed and cells were resuspended thoroughly with complete DMEM/F12. 100 
µl cell suspension was transferred and mixed with equal amount of Trypane blue 
(Thermo Fisher Scientific, USA), an aliquote of 10 µl mixture was injected into a 
Neubauer chamber (Brand, Grafrath, Germany) for counting. Cells were counted in 
the four quadrants and the total number of cells per ml was determined. Cells were 
then plated into new culture flasks (Thermo Fisher Scientific, USA) and incubated in 
Water Jacketed CO2 Incubator TC 230 (Thermo Scientific, USA) under constant 
conditions of 37°C and 5% CO2. Cells were maintained at a maximum of 80% 
confluence and media-renewed every third day. 
3.3.3. Cryopreservation and thawing of cells 
	 To cryopreserve the primary murine chondrocytes, freezing medium consisting 
of 70% of DMEM/F12 media, 20% of FBS and 10% of dimethylsulfoxide (DMSO) 
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(Sigma-Aldrich, USA) was used. After trypsinization, cells were pelleted by 
centrifugation at 500g for 5 min. The supernatant was removed and cells were 
resuspended in pre-cooled freezing media and aliquoted into cryovials (Thermo 
Scientific, USA), which were then placed in freezing container (Sigma-Aldrich, USA) 
stored at -80°C freezer or liquid nitrogen tank (Thermo Scientific, USA). To thaw cells, 
cryovials were placed in a water bath at 37°C until suspension melted. Afterwards, 
cells were mixed with fresh media into a 15 ml Falcon tube and spinned down for 5 
min at 500g. Next, the supernatant was aspirated and the cells were resuspended in 
fresh and pre-warmed complete DMEM/F12 media and finally transferred into culture 
flask T-75 (Thermo Fisher Scientific, USA). Complete DMEM/F12 media was 
changed after 24h in order to remove non-attached/dead cells.  
3.4. Tissue culture techniques 
3.4.1. Femoral head explant culture 
Femoral heads were harvested from euthanized 4-week-old control and 
NEMOfl/YCol2a1Cre mice. The experimental procedures were briefly describes as 
followed: (1) the euthanized mouse was placed in dorsal recumbency and sprayed 
with 70% ethanol; (2) the dissecting scissors were used to cut skin open at the mid-
abdomen of mouse; (3) grasp the skin with hands and gently pull toward the feet to 
expose the underlying hind limb; (4) the little dissecting scissors were used to cut 
muscle around hip joint; (5) tissue forceps were used to grasp the mid of femur and 
carefully disarticulate the hip joint (Figure 16)	 (Stanton et al., 2011). The femoral 
head was then exposed and collected from cutting the femoral neck and cultured in 
300 µl of serum-free DMEM/F12 media supplemented with streptomycin-penicillin in 
a 48-well cell culture plate (Thermo Fisher Scientific, USA) for 4 days. The femoral 
heads were treated with 100 ng/ml TNF-α (R&D, USA) or 10 ng/ml IL-1 (R&D, USA) 
from the first and third day of the culture. At the end of the experiment, femoral heads 
were fixed in 4% paraformaldehyde (PFA) (Merck, Germany)/PBS solution. 
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3.4.2. Mechanically-induced hip injury 
Articular cartilage of femoral head was harvested from euthanized 4-week-old 
control and NEMOfl/YCol2a1Cre mice. The isolation procedures are mostly the same 
as described in 3.4.1. To mimic mechanical injury, the articular cartilage of femoral 
head was carefully pilled off by tissue forceps (Figure 16) and frozen in isopropanol 
chamber in liquid nitrogen. Half of harvested femoral head articular cartilage was 
frozen immediately. To observe the genes responding to mechanical injury, the other 
half of the articular cartilage of femoral head was cultured at 37°C for 4 hours in 
DMEM/F12 media and frozen down afterwards. Frozen samples were then subjected 
to Taqmen Low-Density Array (TLDA) experiment that carried out in Tonia Vincent’s 
lab (Kennedy Institute of Rheumatology, UK) 
 
Figure 16: Isolation of articular cartilage of femoral head. a: the underlying leg was exposed after 
pulling skin toward the mouse feet. b: the femoral head was disarticulated by tissue forceps and visible. 
c: tissue forceps pinched the neck of femoral head. d:  applied pressure to tissue forceps caused 
breakage at femoral physis and the articular cartilage of femoral head was released (Stanton et al., 
2011). 
3.4.3. Metatarsal explant culture  
Embryos were harvested from pregnant female mice of wild-type or 
NEMOfl/YCol2a1Cre at E15.5 postcoitum. Tissue forceps were used to remove 
surrounding tissue and release metartarsals (Figure 17). The 2nd, 3rd and 4th 
metatarsals were selected for explant culture and incubated in 48-well cell culture 
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plates. Metatarsal explants were cultured in BGjb media (Thermo Scientific, USA) 
supplemented 1% streptomycin/penicillin with or without 100 ng/ml BMP-2 (R&D, 
USA), 100 ng/ml FGF-2 (R&D, USA), 100 ng/ml TGFβ-1 (R&D, USA) or 10 ng/ml 
IGF-1 (R&D, USA) for 5 days. The metatarsals were fixed in 4% PFA/PBS solution, 
paraffin-embedded and sectioned as 7 µm thick. 
 
Figure 17: Dissection procedure of metatarsal isolation. The euthanized E15.5 mouse embryo 
was surface-sterilized with 70% ethanol. By holding tibia with one pair of tissue forceps, used the other 
pair of forceps carefully remove the surrounding tissue underneath metatarsals. Metatarsals were 
pulled away with tarsal and separated each other with tweezers (Song et al., 2015). 
3.5. mRNA analysis 
3.5.1. Total RNA isolation 
Isolation of total RNA from primary chondrocytes was performed with the 
Qiagen RNeasy Mini kit (Qiagen, Netherlands) according to the manufacturer’s 
instruction. Briefly, Cells were lysed in Buffer RLT supplemented with 1% β-
mercaptoethanol and homogenized by passing through a QIAshredder spin column 
(Qiagen, Netherlands). 1 ml of 70% ethanol was add to the homogenized lysatem 
and mixed by pipetting. Afterwards, samples were loaded into RNeasy Mini Spin 
Column and subjected to an on-column genomic DNA digestion with 10 U of DNase 
(Qiagen, Netherlands). Column was washed twice with Buffer RPE and dried by 
centrifugation at maximum speed. Finally total RNA was eluted in RNase-free water 
and measured with NanoDrop 1000 (Thermo Scientific, USA) at A260 and at 
A260/A280, respectively for the evaluation of the RNA concentration and purity. 
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3.5.2. Complementary DNA (cDNA) synthesis 
 cDNA synthesis was performed with the Transcriptor First-Strand cDNA 
Synthesis Kit (Roche, Switzerland). Briefly, 1 µg of total RNA, hexamer-random 
primers (50 ng/µl) and 10mM dNTPs were heated for 5 min at 65°C. The denaturated 
RNA was then added to a mixture of PCR buffer, 40U of RNase inhibitor, 0.1M 
dithiothreitol (DTT) and 15U of reverse transcriptase for 1 hour at 50°C. The newly 
synthesized cDNA was tested for the expression of a housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to evaluate the synthesis 
quality and to normalize the input of different samples. 
3.5.3. Polymerase chain reaction (PCR) 
Semi-quantitative RT-PCR for the genes of interest were performed adding a 
normalized amount (determined by the expression of GAPDH) of cDNA to a master 
mix containing PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.25 pmol gene-specific 
primers and 1 U Taq DNA polymerase (Roche, Switzerland) in the PCR thermal 
cycler. Instruments and chemicals were the same as used in mouse genotyping 
(Table 1). Sequence of primers, PCR condition and size of PCR products were 
showed in table 3. 
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3.6. Western blotting 
3.6.1. Protein extraction from monolayer culture 
Cells were washed 2 times in PBS and lysed with radioimmunoprecipitation 
assay buffer (RIPA) containing protease inhibitor cocktail (PIC). Chemicals and buffer 
were showed in table 4. Cell scrapers (Sigma-Aldrich, USA) were used to collect cell 
lysates. After centrifugation at 14000 rpm, 4°C for 30 minutes, the supernatants were 
transferred to new eppendorf and stored at -20°C. 
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3.6.2. Protein quantification 
The total protein concentration was measured using the bicinchoninic acid 
(BCA) protein assay kit (Thermo Fisher Scientific, USA). Briefly, the protein 
concentration was determined based on a chemical reaction where BCA interact with 
the cuprous cations that are reduced by the proteins in an alkaline media. As a result 
an intense purple-colored reaction is observed and the intensity of the color 
correlates with the protein concentration. The protein amount was calculated using a 
standard curve that is built by serial bovine serum albumin (BSA) (Thermo Fisher, 
Scientific USA) dilutions. The optical density measurements were performed at 450 
nm on a FC Microplate Reader (Fisher Scientific, USA). 
3.6.3. SDS-Polyacrylamide gel electrophoresis (PAGE) 
Protein extracts (ca. 20 µg) were mixed with 4x Laemmli buffer and boiled for 
5 min at 99°C. The protein mixtures were spinned down and loaded on 12% 
acrylamide gels. The electrophoresis was performed in 1x running buffer composed 
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of 0.25 M Tris-base pH 8.3, 1% SDS and 1.92 M glycine. As molecular weight 
standard, PageRuler Plus prestained protein ladder (Thermo Scientific, USA) was 
used. The electrophoresis was run at constant 60 mA in an electrophoresis tank (Bio-
Rad, USA). Information of instruments, chemicals and buffers were listed in table 5. 
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3.6.4. Protein transfer 
The protein transfer was performed by applying the vertical wet transfer 
method. Briefly, the gel loaded with proteins was equilibrated for 15 min in 1x blotting 
buffer. Meanwhile, the polyvinylidene fluoride (PVDF) membrane was activated by 
soaking into methanol for few seconds, rinsed in water and placed in 1x blotting 
buffer. The western blot “sandwich” was then assembled and the protein transfer was 
performed in a trans-blot system (Bio-Rad), O/N at 4°C with a constant voltage of 30 
V. Afterwards, membranes were proceed for immunodetection or stored in a 0.1% 
PBS/Tween-20 (PBST) washing solution at 4°C until use. The instruments, chemicals 
and buffers were listed in table 6. 
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3.6.5. Protein immunodetection 
For immunodetection, PVDF membranes were blocked with 5% skimmed milk 
(Merck, Germany) in 0.1% PBST buffer for 1 hour at room temperature (RT) under 
gently shaking. Afterwards, PVDF membranes were incubated O/N with appropriate 
dilutions of primary antibody in blocking buffer at 4°C. The membrane was washed 
10 min for 3 times with 0.1% PBST solution and incubated with diluted, 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibody in the 
blocking solution at RT for 1 hour. Finally, the membrane was washed 10 min for 3 
times with 0.1% PBST buffer. Proteins on PDVF membrane were visualized by using 
chemi-luminescent Amersham ECL plus solution and the luminiscent image analyser 
Image Quant LAS 4000 mini (GE Healthcare, USA). Antibodies used in western 
blotting were listed in table 7. 
 
3.6.6. Gelatin/collagen Zymography 
Cultured media from femoral head explant (see 3.4.1) were centrifuged at 
maximum speed at 4°C to remove cell debris and subjected to Gelatin Novex 
Zymogram Gels (Thermo Fisher Scientific, USA) and collagen I SDS-polyacrylamine 
gel. The electrophoresis was performed in 1x running buffer and coupled with 
PageRuler Plus prestained protein ladder (see table 5). The electrophoresis was run 
at constant 60 mA in an electrophoresis tank (see table 5). After electrophoresis, the 
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gels were incubated in 1x Novex Zymogram Renaturing Buffer (Thermo Fisher 
Scientific, USA) for 30 min at room temperature with gentle agitation. The gels were 
incubated in 1x Novex Zymogram Developing Buffer (Thermo Fisher Scientific, USA) 
for 30 min with gentle agitation and fresh 1x Novex Zymogram Developing Buffer at 
37°C O/N. Afterwards, the gels were stained with coomassie staining solution, 
destained with destain solution and dried by using DryEase Mini-Gel Drying System 
(Thermo Fisher Scientific, USA). Instruments, chemicals and buffers for zymography 
are listed in table 8. 
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3.7. NF-κB reporter assay 
3.7.1. Transfection 
Cignal NF-κB reporter assay kit (Qiagen, Netherlands) was utilized to monitor 
NF-κB activity in NEMOfl/YCol2a1cre chondrocytes. Experimental procedure was 
followed the handbook of the kit. 1x104 Primary wild-type/NEMOfl/YCol2a1cre 
chondrocytes were trypsinized and resuspended in reduced serum medium 
modification of minimal essential media (Opti-MEM) (Thermo Scientific, USA). 
Transient transfection of Cignal reporter was carried out in 4D-Nucleofector Core Unit 
(Lonza, Switzerland). 1x103 transfected cells were then seeded into 96-well cell 
culture plate and incubated for 24 hours. After 24 hours incubation, media were 
replaced with complete DMEM/F12 media. 
3.7.2. Dual-Luciferase assay 
The luciferase assay was performed by using a dual-luciferase reporter assay 
system (Promega, USA) according to manufacturer’s instructions. The cells were 
washed with PBS twice and mixed with 20 µl passive lysis buffer after 10 ng/ml IL-1 
treatment for one hour. After gently shaking at room temperature for 15 minutes, the 
lysate was transferred to new 96-well cell culture plate with 100 µl luciferase assay 
reagent. SAFIRE2 Microplate Reader (Thermo Fisher Scientific, USA) was used to 
measure firefly luciferase activity. 100 µl Stop&Glo® Reagent was add into each well 
to measure Renilla luciferase activity that normalized for cell death caused by the 
treatment. 
3.8. Time-lapse migration and adhesion assay 
2x104 primary chondrocytes were seeded sparsely in 6-well cell culture plate. 
The cell culture plate was then put into environment control chamber with heating 
unit, CO2 controller (Pecon, Germany). The system included a stage top 
environmental control chamber (Pecon, Germany) and an automated XY stage 
controller (Proscan, Canada). AxioCam MRc (Carl Zeiss, Germany) and Axiovision 
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Rel. 4.8 (Carl Zeiss, Germany) were used for automated image acquisition. Images 
were acquired with a 10X UPLANFL Ph1/0.30 objective in bright field mode and 
using a defined time interval. The observation of cell adhesion, spreading and 
migration was lasted for 48 hours and analyzed by ImageJ. 
 
3.9. Cell attachment assay 
96-well cell culture plate was pre-coated with 10 µg/ml fibronectin (R&D, USA), 
10 µg/ml vitronectin (R&D, USA), 10 µg/ml laminin (R&D, USA), 10µg/ml collagen 
type I (R&D, USA), 10 µg/ml collagen type II (R&D, USA), 10% FBS and 1% BSA for 
1 hour at 37°C. Pre-coating solution was replaced with 1% BSA to block non-specific 
binding sites for 1 hour at 37°C. After washing with PBS, 1x105 wild-type and 
NEMOfl/YCol2a1cre chondrocytes were seeded into the plate and incubated for 1 
hour. Afterwards, cells were wished with PBS, fixed with 96% ethanol for 10 minutes, 
stained with 0.1% crystal violet/H2O for 30 minutes at room temperature and lysed 
with 0.1% Triton X-100/H2O. The optical measurement was performed at 595 nm on 
a microtiter-plate reader (Thermo Scientific, USA). 
3.10. Immunofluorescence staining 
Primary chondrocytes 
Primary wild-type and NEMOfl/YCol2a1Cre chondrocytes (1x104 cells/cm2) 
were grown in presence of complete DMEM/F12 media on chamber slides (Thermo 
Scientific, USA) for at least two or three days under normal culture conditions. 
Afterwards, cells were rinsed in PBS and fixed with 4% PFA for 20 min at room 
temperature (RT).  
For immunodetection, fixed cells were rehydrated in PBS (3x5 min at RT) and 
permeabilized with 0.2% Triton X-100/PBS for 15 min. Image-iT FX Signal Enhancer 
(Invitrogen, USA), a solution which reduces the unspecific binding of secondary 
antibodies, was applied for 30 min. Slides were placed in 2% BSA/PBS solution for 
one hours at RT and then incubated with primary antibodies (Table 9) O/N at 4°C. 
After PBS washing (5 minutes for 3 times), corresponding secondary antibodies 
conjugated with fluorescence were applied to slides for 1 hour at RT. Finally, slides 
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were washed with PBS (3 times for 5 minutes at RT) and a nuclear counterstaining 
was performed with 4', 6-diamidino-2-phenylindole (DAPI) for 5 min. After PBS 
washing (3 times for 5 minutes), slides were mounted with Fluoromont Anti-Fading 
Mounting Media (Sigma- Aldrich, USA). Negative controls for antibody were carried 
out on the same slide by omitting the primary antibody. Primary, secondary 
antibodies and dyes were listed in table 10. Photomicrographs were taken with 
Axiocam MRm camera mounted on Axio Observer Z1 Microscope (Carl Zeiss, 
Germany). 
Knee sections 
 Knee sections of 2-week-old mice were dewaxed, rehydrated, peroxidase-
blocked, hyaluronidase-treated and incubated in 1% BSA/PBS solution. Sections 
were then incubated with anti-NEMO antibody (1:1000, Table 9) O/N at 4°C. After 
washing with PBS for 3 times, sections were incubated with Alexa Fluor 488-
conjugated Phalloidin and Alexa Fluor 546 Dye for 1 hour at room temperature. 
Finally, sections were PBS-washed, counterstained with DAPI for 5 min and mounted 
with Fluoromont Anti-Fading Mounting Media. Photomicrographs were taken with 
Axiocam MRm camera mounted on Axio Observer Z1 Microscope. 
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3.11. Whole-mount skeletal staining 
The gross morphology of the whole skeleton was analyzed by Alician 
blue/Alizarin red staining of E13.5 – E16.5 and newborn. Euthanized embryo and 
newborn specimens were deskinned and eviscerated, fixed in 95% ethanol for 3 days 
and then transferred into acetone for 1 day. Staining was performed in the alizarin 
red/alcian blue solution for 3 days at 37°C. Samples were rinsed in water and cleared 
for 3 days in 1% potassium hydroxide (Merck, Germany) followed by clearing in 
KOH/glycerol (0.8% and 20%, respectively) solution for 1 week. Samples were then 
transferred into 0.5%/50%, 0.3%/80% KOH/glycerol solution and finally 100% 
glycerol for long-term storage. The humerus, femur, and tibia were dissected from ten 
control and ten double NEMOfl/YCol2a1Cre mice and measured longitudinally using a 
fine calibrated ruler. Chemicals and buffers used were listed in table 10. 
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3.12. Histology 
3.12.1. Fixation 
Hind limbs of euthanized mouse were de-skinned, the muscles around knee 
joints removed and rinsed in PBS. Knee joints were fixed in pre-cooled 4% PFA O/N, 
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fixed samples were washed 15 min in PBS for 3 times with slow shaking at room 
temperature. 
3.12.2. Decalcification 
Decalcification of bony tissues was achieved by incubating PFA-fixed samples 
in a 20% EDTA/PBS solution (pH 8) for approximately 4 weeks. Chelating agents 
such as EDTA captured the calcium ions and soften bones. 20% EDTA/PBS solution 
was renewed twice per week. 
3.12.3. Embedding 
Decalcified samples were ready either for cryo or paraffin embedding. For 
frozen sectioning, specimens were firstly rinsed 15 min in PBS for 3 times and were 
then placed in an ascending solution of sucrose/PBS: 10 and 15% for 2 hour each 
and 20% O/N at 4°C. The next day, specimens were embedded in FSC 22 Frozen 
Media (Leica, Germany) in plastic base mould disposable cassettes (Leica, Germany) 
placed on a copper plate on dry ice. Samples were stored wrapped in parafilm 
(Sigma-Aldrich, USA) at 20°C until use. 
For paraffin sectioning, specimens (placed in embedding cassettes 
(Proscitech, Australia)) were firstly rinsed 15 min in PBS for 3 times and then passed 
through ascending row of ethanol solution (50, 70, 80, 90 and 2x100 %, one hour for 
each step), xylol (5 min for 2 times) and melted Paraplast Paraffin Tissue Embedding 
Media (60°C, 1 hour for 3 times) (Leica, Germany). Afterwards, specimens were 
embedded in paraffin tissue embedding media in stainless steel base embedding 
cassettes (Leica, Germany) on Tissue Embedding Center (IMEB, USA). 
3.12.4. Sectioning 
Cryosectioning was performed with a Cryotome Microm HM500 (Thermo 
Scientific, USA) and slices of 10 µm thickness were collected on SuperFrost glass 
slides (Thermo Scientific, USA) and stored at -20°C. 
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Paraffin blockes specimens were cut with a Rotary Microtome HM360 (Thermo 
Scientific, USA) and slices of 8 µm were collected on SuperFrost glass slides. Slides 
were kept O/N at 37°C and then stored at room temperature. 
3.12.5. Hematoxillin and eosin (H&E) staining 
For a first screening of the general tissue morphology H&E staining was 
performed. Paraffin sections of 8 µm thickness were rehydrated through a 
descendent ethanol row (100, 90, 80 and 70% for 5 min each) and a final step in 
dH2O. 0.1% Mayer’s Hematoxillin Solution (Merck, Germany) was applied for 5 min, 
followed by intense washing with tap water. Next, slides were rinsed in dH2O and 
incubated in 0.1% eosin (Sigma-Aldrich, USA) solution for 5 min. After rinsing in 
dH2O, slides were dehydrated in an ascending ethanol row (70, 80, 90, 100 and 
100% for 5 min each) and cleared by two steps in xylol for 5 min each. Finally, slides 
were mounted with DPX mounting media (Sigma-Aldrich, USA). Pictures were taken 
on an Axiovert 100 microscope using AxioCam ICc3 colour camera (Carl Zeiss). 
3.12.6. Safranin orange staining 
After dewaxing in xylene and stepwise rehydration in ethanol (100, 90, 80 and 
70% for 5 min each), and distilled water (dH2O), the sections were stained with 0.1% 
Safranin-O (Sigma-Aldrich, USA) for 3 min. Afterwards, sections quickly went through 
95%, 100% ethanol, xylene and mounted with DPX mounting media. 
3.12.7. Von Kossa staining 
Sections of E16.5 embryo were dewaxed, rehydrated and exposed to bright 
light with Silver nitrate (Merck, Germany) for 30 min. Sections were washed with 
distilled water and incubated with 2.5% sodium thiosulphate (Merck, Germany) for 5 
min. After washing with dH2O, sections were counterstained with safranin orange for 
3 min and quickly went through 95%, 100% ethanol, xylene and mounted with DPX 
mounting media.  
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3.12.8. Toluidin blue staining 
Sections were rehydrated (described above) and stained with 0.1% Toliudine 
blue in toluidine buffer pH 2.5 (0.1M K2HPO4 and 0.1M HCl (Merck, Germany)) for 10 
mins, followed by staining with 2% K3Fe (CN6) for 3 min, excessive staining reagents 
were removed by WATTMAN paper (Sigma-Aldrich, USA). Sections were finally air-
dried, mounted with DPX mounting media. 
3.12.9. Tartrate-resistant acid phosphatase staining (TRAP) 
Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich, USA) was used to 
perform the TRAP staining on E15.5 sections. According to manufacturer’s 
instruction, paraffin-fixed sections were rehydrated and incubated in pre-warmed  
staining solution (37°C) containing 0.5 ml Fast Garnet GBC Base solution (Sigma-
Aldrich, USA), 0.5 ml Sodium Nitrite Solution (Sigma-Aldrich, USA), 0.5 ml Naphthol 
AS-BI Phosphate Solution (Sigma-Aldrich, USA), 2 ml Acetate Solution (Sigma-
Aldrich, USA), 1 ml Tartrate Solution (Sigma-Aldrich, USA) and 45ml Deionized water 
(Thermo Scientific, USA) at 37°C for 1 hour. Afterwards, sections were rinsed in 
deionized water and counterstained in Hematoxylin solution, Gill No 3 (Sigma-Aldrich, 
USA) for 2 min followed by tap water washing for 5 min. Sections were then air-dried 
and mounted with DPX mounting media. 
3.12.10. Immunohistochemistry staining (IHC) 
After dewaxing and rehydration, specimens were placed in 0.01% hydrogen 
peroxide (H2O2) (Merck, Germany)/methanol (Merck, Germany) solution for 20 min at 
room temperature to block endogenous peroxidase activity. After washing with PBS, 
antigen retrieval was achieved by incubating specimens with 0.2% Bovine Testicular 
Hyaluronidase (Sigma-Aldrich, USA)/PBS solution for 30 min at 37°C. Specimens 
were then washed with PBS and blocked with 1% BSA/PBS solution for 1 hour and 
incubated with primary antibody/blocking solution O/N at 4°C. Primary antibodies 
used in IHC staining were listed in table 11. Afterwards, the specimens were washed 
by PBS and incubated with Biotinylated Anti-mouse IgG Reagent from Mouse on 
Mouse (M.O.M. Kit) (Vector Laboratories, USA) for 1 hour. The specimens were then 
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wash by PBS and incubated with Vectastain ABC solution from Vectastain Elite ABC 
Kit (Vector Laboratories, USA) for 30 min at room temperature. For color detection, 
specimens were placed in 3,3′-diaminobenzidine (DAB) solution (pH7.2) containing 
0.05% DAB (Sigma-Aldrich, USA) and 0.015% H2O2 in PBS for 7 min in dark. After 
color detection, specimens were washed in dH2O, counterstained in Mayer’s 
Hematoxylin Solution, dehydrated and mounted with DPX mounting media.  
 
3.12.11. Measurement of growth plate 
H&E stained knee sections of 2-week-old and 4-week-old mice were pictured 
and analyzed in Adobe Photoshop CS2 (Adobe, USA). All measurements were 
performed in the central two-thirds of growth plate sections. The area of total growth 
plate (TGP) was defined from the top of resting zone (RZ) through proliferating zone 
(PZ) to the bottom of hypertrophic zone (HZ). The height of TGP, RZ+PZ and HZ 
were presented as mean ± standard deviation (SD). 
3.12.12. Analysis of proliferating columns in growth plate 
All measurements were performed in the central two-thirds of growth plate 
sections. Using Photoshop CS2, the axis of proliferating columns in growth plate and 
the horizontal angle were measured. The shape of columns was determined by ratio 
of horizontal axis / vertical axis. It was generally accepted that proliferating column 
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were supposed to be oval shape and ratio below 0.7. Columns with ratio over 0.7 
were more round-liked in shape. The horizontal angle of vertical axis were also 
measured (Figure 18), most of the columns were perpendicular to the growth plate 
under normal development. 
 
Figure 18: Schematic representation of methods to analyze shape and angle of columns. Shape 
was determined by the ratio defined as horizontal axis of column / vertical axis of column (e.g. 0.1 
represented slit-shaped columns, 1 represent round-liked column). Horizontal angle (angle between 
vertical axis and horizontal line) of proliferating columns was measured. 
3.13. Non-radioactive in situ hybridization 
Plasmid linearization and generation of RNA probes 
DNA templates were linearized with restriction enzymes for RNA in vitro 
transcription (Table 12). 10 µg of plasmid DNA were linearized with restriction 
endonucleases and buffers according to manufacturer’s instruction (restriction 
endonucleases and buffers were all from New England BioLab, USA). Linearized 
DNA were purified through Nucleospin column (Macherey-Nagel, Germany) and in 
vitro transcripted with T3 RNA polymerase in 10x transcription buffer with digoxigenin 
(DIG) labeled ribonucleotides (Roche, Switzerland) for 2 hour at 37°C. Afterwards, 
transcription was examined by electrophoresis in 2% agarose gel. The transcripted 
RNA was purified after DNA digrestion with G-50 spin columns (GE Healthcare Life 
Science, USA), suspended in RNase-free water and restored in -80°C. 
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Unfixed, cryo-embedded sections of newborn limb were fixed in 4% 
PFA/Diethyl pyrocarbonate (DEPC)-PBS (pH 9.5) solution for 1 hour and rinsed in 
DEPC-PBS (pH 9.5). The sections were placed in 1% Triton X-100/DEPC-PBS (pH 
9.5) solution for 20 min, then 5x saline-sodium citrate (SSC)/50% formamid solution 
for 15 min and pre-heat (80°C) hybridization solution with 2 µl RNA probe 
(approximately 200 ng) at 95°C for 2 min. Afterwards, the sections were covered with 
parafilm and placed in humid chamber soaked with 2x SSC/50% formamid at 55°C 
O/N followed by washing with pre-heat washing solution I and II at 55°C for 30 min. 
After washing with 0.2x SSC for 5 min and PBS (pH 7.4) for 3 times at room 
temperature, the sections were then incubated with an alkaline phosphatase-coupled 
antibody against DIG (Roche, Switzerland) diluted (1:500) in PBS (pH 7.4) containing 
10% FBS for 1 hour at room temperature. The sections were then rinsed in PBS (pH 
7.4) 5 min for 3 times, incubated with DIG III solution for 10 min and placed in 
staining solution for color development. After sufficient color reaction, sections were 
mounted with Aqua mounting media (Sigma-Aldrich, USA). Chemicals and buffers for 
in situ hybridization were described in table 13. 
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3.14. Sulpated glycosaminoglycan (sGAG) assay 
The sGAG in conditioned DMEM/F12 media of hip explant was examined by 
sGAG assay kit (Biocolor, UK). The assay was performed as manufacturer’s 
instruction. Briefly, Conditioned DMEM/F12 media were centrifuged at 10000g for 10 
minutes to remove cell debris and assay the supernatant. 10µl conditioned media 
from each group were added into 1ml 1x Blyscan Dye Reagent (Biocolor, UK) and 
incubated for 30 minutes. After centrifuging 10000g for 10 minutes and removing 
supernatant, insoluble sGAG-dye complex was seen at the bottom of the tube. 500 µl 
Dissociation Reagent (Biocolor) was added to resolve the GAG-dye complex. 
Transfer 200 µl well-mixed samples into 96-well plate and measure absorbance in 
microtiter-plate reader (Thermo Scientific, USA) at 656 nm. The data was exported to 
Office Excel 2003 (Microsoft, USA) for statistical analysis. 
3.15. Pathological Scoring System of Articular Cartilage 
The NEMOfl/YCol2a1Cre and wild-type mice were euthanized and knees were 
harvested at various time points. The samples were fixed in 4% PFA/PBS solution, 
decalcified in 20% EDTA/PBS and processed to paraffin embedding. Approximately 
250 serial, 7-µm-thick sections were collected from 1 specimen. Every 10th slide was 
chosen to stain with hematoxilin-eosin for general H&E or SO to view proteoglycans 
(PGs) depletion. About 8-10 serial sections representing the entire knee were 
evaluated from every mouse of age and genotype. Based on previous study of our 
laboratory, to assess pathological changes of the articular cartilage (Raducanu et. al., 
2009), we used a scoring system as follows: I, cartilage erosion (0–5; 0, smooth 
cartilage surface; 1, surface irregularities; 2, cleft to transition zone; 3, cleft to radial 
zone; 4, cleft to calcified zone; 5, exposure of subchondral bone bone; II, cellularity 
(0–3; 0, normal;1, hypercellularity; 2, clustering; 3, hypocellularity); III, tidemark 
integrity (0–1; 0, normal; 1, loss of tidemark); IV, GAG content in the pericellular 
matrix (PM) (0–2; 0, normal SO staining intensity; 1, focally increased intensity; 2, 
increased intensity throughout the cartilage); V, GAG content in the interterritorial 
matrix (ITM) (0–3; 0, normal SO staining intensity; 1, reduced staining; 2, focal patchy 
loss of staining; 3, 50% of cartilage without staining; VI, osteophyte formation (0–2; 0, 
none; 1, formation of cartilage; 2, formation of bone). Total scale (0–16) and OA 
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severity were as follows: 0–1, normal; 2–5, mild OA; 6–11, moderate OA; 12–16, 
severe OA (Raducanu et al., 2009).   
X-ray imaging 
1-year and 1.5-year-old NEMOfl/YCOL2a1Cre and control mice were euthanized 
and radiographs were taken with a sealed x-ray cabinet 43855A (Faxitron, USA) at 
35 kV, 2 mA and 2 sec of exposure time. 
3.16. Proliferation and Apoptosis Assays 
Proliferation of chondrocytes in vivo was monitored by incorporation of 
bromodeoxyuridine (BrdU) (Sigma-Aldrich, USA) into 2- and 4-week-old wild-type 
and NEMOfl/YCOL2a1Cre mice. 5 mg/ml BrdU/PBS solution was injected 
intraperitoneally and the injected amount was approximately 50 µg/g per body weight. 
Mice were euthanized 2 hours after injection, isolated knee joints were fixed, paraffin 
embedded, sectioned (7µm), stained with primary BrdU antibody (Table 11) and 
counterstained with hematoxylin. The number of labeled cells and total cell number 
were scored and analyzed by Photoshop CS2 and Office Excel 2003.  
To investigate primary chondrocyte proliferation in vitro, a Cell Proliferation 
Enzyme-Linked Immunosorbent (ELISA) Assay Kit (colorimetric) (Roche, Switzerland) 
was utilized to analyze the incorporation of BrdU during DNA synthesis following the 
manufacturer’s protocols. Briefly, 1x104 cells were seeded in 96 well culture plate and 
incubated with DEME/F12 media containing BrdU labeling Solution (working 
concentration of BrdU: 10 µM) (Roche, Switzerland) for 2 hours. Labeled cells were 
air-dried for 15 min and incubated with FixDenat Solution (Sigma-Aldrich, USA) for 30 
min at room temperature. After removing the FixDenat Solution, 100 µl anti-BrdU-
POD solution (Sigma-Aldrich, USA) was added to each well and incubated for 90 min 
at room temperature followed by washing 3 times with Washing Solution (Sigma-
Aldrich, USA). 100 µl Substrate Solution (Sigma-Aldrich, USA) was then added to 
each well and incubated for 20 min at room temperature. The absorbance of the 
samples was measured in microtiter-plate reader (Thermo Scientific, USA) at 370 nm. 
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 To detect apoptotic and necrotic cells in vitro, an Apoptotic/Necrotic/healthy 
Cells Detection Kit (PromoKine, Germany) was used. Primary chondrocytes of wild-
type or NEMOfl/YCol2a1Cre were treated with or without 100 ng/ml TNF-α for 24 
hours and proceeded as manufacturer’s instruction. The cells were washed twice 
with 1x Binding Buffer (PromoKine, Germany) and stained with solution containing 5 
µl fluorescein isothiocyanate (FITC)-AnnexinV (PromoKine, Germany), 5 µl ethidium 
homodimer III (PromoKine, Germany) and 5 µl Hoechst 33342 (PromoKine, Germany) 
for 15 min at room temperature in dark. Stained cells were washed twice and 
mounted with Binding Solution. Afterwards, sections were pictured using AxioCam 
MRm camera (Carl Zeiss, Germany) mounted on Axio Observer Z1 Microscope (Carl 
Zeiss, Germany) with 10x objective.  
3.17. Atomic force microscopy (AFM) 
All AFM measurements were carried out using a NanoWizard AFM instrument 
(JPK Instruments, Berlin, Germany) mounted on a modified microscope stage of an 
inverted optical microscope (Axiovert 200, Zeiss). The optical microscope with a 40x 
magnification was used to ensure the right positioning of the cantilever tip on the 
proliferating zone of growth plate. The AFM had a maximum horizontal scanning 
range of 100 x 100 µm2 and a vertical range of 15 µm. Prior to each measurement, 
the force constants of all cantilevers were determined individually using the thermal 
noise method (Butt, 1995). Calibrations were performed in PBS. In order to obtain an 
accurate calibration, three independent measurements were performed and the 
mean value was used for the experiment. All analyses were processed with the JPK 
Data processing software 4.0.23 (JPK instruments). The AFM observation was 
performed in collaboration with Carina Preis, under supervision of Prof. Hauke 
Clausen-Schaumann (Hochschule Munich, Germany). 
3.18. Taqman Low-Density Array (TLDA) microfluidic cards 
 Prof. Tonia L. Vincent (Kennedy Institute of Rheumatology, UK) and her group 
carried out this experiment and the following data analysis as described (Burleigh et 
al., 2012). Briefly, complementary DNA (cDNA) was generated from articular 
cartilage RNA using a Promega Reverse Transcription system. TLDA microfluidic 
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cards were custom designed for a set of 47 pre-determined genes that known to be 
strongly regulated following injury.  All thermo cycles were carried out on a 7900HT 
system (Thermo Scientific, USA). The 47 pre-determined genes were list in table 14. 
 
 
MATERIALS AND METHODS 
	 69	
 
3.19. Microscopy 
The microscopes and cameras used in this thesis were purchased from Carl 
Zeiss MicroImaging (Germany). Phase-contrast picturess of tissue histology staining 
were imaged using the AxioCam ICc3 colour camera (Carl Zeiss, Germany) mounted 
on AxioVert S100 Inverted Microscope (Carl Zeiss, Germany) with 10x objective.  
MATERIALS AND METHODS 
	 70	
3.20. Computer software and statistical analysis 
In this doctoral thesis a number of programs for processing and analyzing data 
were used. Primers sequences were designed using Clone Manager 9 (Sci-Ed 
software, USA). Photomicrographs were processed with AxioVision LE software (Carl 
Zeiss, Germany). Quantitative data, various graphs and charts were evaluated and 
created by using Microsoft Office Excel 2003 and GraphPad Prism 5 (GraphPad, 
USA). The student t-test was performed to compare two normal distributed sets of 
samples. Non-parametric Mann-Whitney U test was applied to compare sets of non-
normal distributed data. All data was presented as the mean ± SD. p value less than 
or equal to 0.05 was considered as statistically significance and symbolized as 1 star 
(*). p value less than or equal to 0.01 or 0.001 was symbolized as 2 (**) or 3 stars 
(***), respectively. Analysis of stained cells, cell number, bone length and metaphysis 
measurement were performed with Adobe Photoshop CS2. Morphometric analysis 
was peformed with ImageJ 1.41o. Bibliography of this thesis was managed with 
EndNote X7.5.3 (Thomson Reuters, USA). 
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4. Results 
4.1. Characterization of NEMOfl/YCol2a1Cre mice 
To study the function of the canonical NF-ĸB pathway in endochondral bone 
formation and articular cartilage, we have used the floxed (fl) NEMO mice (Schmidt-
Supprian et al., 2000, generously provided by Dr. Marc Schmidt-Supprian, Max 
Planck Institute for Biochemistry, Martinsried, Germany) and the Col2a1-Cre 
transgenic mouse line generated in the Aszodi lab (Sakai et al., 2001). The murine 
gene encoding NEMO is X chromosome localized, whereas in Col2a1-Cre mice cre 
is driven by the type II collagen regulatory regions, and efficiently deletes floxed 
genes in differentiated chondrocytes. To obtain mice lacking NEMO in cartilage, 
NEMOfl/fl females were crossed with Col2a1-Cre males. From such a cross, 
NEMOfl/Y-Col2a1Cre males were generated that lack NEMO expression in 
chondrocytes (Figure 19). 
 
Figure 19: Schematic representation of the generation of NEMOfl/YCol2a1Cre mice. The X 
chromosome-localized NEMO gene was floxed (fl) using the LoxP sites. The chromosome 
recombinase (Cre) was controlled by Col2a1 promoter, which was specifically active in differentiating 
chondrocytes. To achieve chondrocyte-specific deletion, floxed NEMO females were then crossed 
with males carrying the Col2a1cre transgene males.  
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4.1.1. RNA and protein expression of NEMO in NEMOfl/YCol2a1Cre 
chondrocytes were completely inhibited 
The offspring carrying floxed NEMO gene and Col2a1Cre transgene 
expressed abnormal NEMO mRNA with disrupted exon 2. Deletion of exon 2 of 
NEMO was examined by PCR primers designed for fragment from exon 1 to exon 3 
of NEMO gene (Figure 20A). The exon 1 to exon 3 in wild-type chondrocytes from 
PCR amplification gave 489 base pairs (bps) products. Due to the disruption of exon 
2 of NEMO gene in mutant chondrocytes, the size of PCR product was 301 bps. The 
exon 2 of NEMO gene was completely deleted in mutant chondrocytes, and, 
incomplete NEMO mRNA was suggested to translate abnormal NEMO protein. The 
NEMO protein was not detected in primary mutant chondrocytes (Figure 20B). 
Misfolded NEMO protein in mutant chondrocytes was likely degraded by 26S 
proteasome or existed as inclusion bodies within the cell.  
 
 
 
Figure 20: RT-PCR and WB results of wild-type (WT) and mutant (MT) chondrocytes. (A) 
Fragment from exon 1 to 3 of NEMO gene was amplified by RT-PCR. In wild-type chondrocytes, a 489 
bps product was observed that represented the length of exon 1 to 3. Owing to the deletion of exon 2 
of NEMO gene, a shorter PCR product (301 bps) was showed. (B) NEMO protein expression was 
clarified by western blotting (WB). No signal of NEMO protein was detected in mutant chondrocytes. 
The lack of full-length NEMO mRNA might lead to misfolding of protein structure or formation of 
aggregates known as inclusion bodies. 
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4.1.2. Activation of NF-κB canonical pathway was diminished in 
NEMOfl/YCol2a1Cre chondrocytes  
To examine the activation of NF-κB was diminished in NEMO-deficient 
chondrocytes, NF-κB reporter assay was applied to monitor the activity of NFκB-
regulated signal transduction pathways. The pro-inflammatory cytokines interleukin-1 
(IL-1β) was known to elevate chondrocyte catabolism and block chondrocyte 
anabolism partially via through the canonical NF-κB signaling.  IL-1β was applied to 
induce NF-κB activation in wild-type and mutant chondrocytes (Figure 21). In 
response to IL-1β, wild-type chondrocytes showed a significantly increase of NF-κB 
activation comparing to mutant chondrocytes. Due to the critical role that NEMO 
played in regulation of NF-κB canonical activation, we suggested that the canonical 
signaling of NF-κB in mutant chondrocytes was successfully blocked. A light NF-κB 
activation was detected in mutant chondrocytes toward IL-1β. It was possibly caused 
by contamination of normal NEMO-expressed cell types in the population of mutant 
chondrocytes. 
 
Figure 21: NF-κB reporter assay of wild-type and mutant chondrocytes. Primary chondrocytes 
were transiently transfected with NF-κB-responsive firefly luciferase construct and constitutively 
expressing Renilla luciferase construct (served as internal control for transfection efficiency). 24 hours 
after transfection, chondrocytes were incubated with complete DMEM/F12 (with 10% FBS and 1% 
pen/strep mix) or DMEM/F12 with 10ng/ml IL-1β for 24 hours. Dual Luciferase assay was performed 
48 hours after the transfection. By measuring the absorbance using an ELISA reader, promoter 
activity values are expressed as arbitrary units using a Renilla reporter for internal normalization. In 
response to IL-1β, activation of NF-κB arose to 140 folds of RLU compared to non-stimulate states. 
Owning to the lack of NEMO protein, NF-κB activation was largely reduced in mutant chondrocytes. As 
the essential role of NEMO in regulating NF-κB canonical signaling, we suggested that NF-κB 
canonical activation was shot down in mutant chondrocytes. The minor activation of NF-κB in mutant 
group was possibly from normally-NEMO-expressing cells in the population. Values were presented as 
mean±SD, ***: p<0.001. 
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4.1.3. IκBα sequestered p65 dimers in cytoplasm of NEMOfl/YCol2a1Cre 
chondrocytes  
IκBα was functioned to inhibit the NF-κB transcription factor. By masking the 
nuclear localization signals (NLS) of NF-κB proteins, IκBα kept NF-κB homo- or 
heterodimers sequestered in an inactive state in the cytoplasm (Jacobs and Harrison, 
1998). Among NF-κB activation, IκBα was phosphorylated and degraded through an 
ubiquitin-dependent process. Thus, degradation of IκBα was generally regarded as a 
marker of NF-κB canonical pathway activation. To test the phosphorylation of p65 
and degradation of IκBα followed by canonical NF-κB activation, primary wild-type 
and mutant chondrocytes were treated with IL-1 and incubated for different time 
periods (0, 5, 10, 15 and 20 minutes). A rapid phosphorylation of p65 and IκBα 
degradation were observed in wild-type chondrocytes upon 5 minutes IL-1 treatment. 
As we expected, neither phosphorylation of p65 nor degradation of IκBα was 
detected in mutant chondrocytes toward IL-1β stimulation (Figure 22). 
 
Figure 22: WB of wild-type and mutant chondrocytes in response to IL-1β induction from 
different time points. Primary chondrocytes were treated with 10 ng/ml IL-1β for several time periods 
(0, 5, 10, 15 and 20 minutes). Degradation of IκBα was considered as a marker of NF-κB canonical 
activation. IκBα degradation and p65 phosphorylation, which represented activation of NF-κB 
canonical pathway, were showed at 5 minutes of IL-1 treatment in wild-type chondrocytes. However, 
IκBα degradation and p65 phosphorylation was mostly suppressed in mutant chondrocytes.  
4.1.4. p65 in NEMOfl/YCol2a1Cre chondrocyte failed to relocate into nucleus  
In the activation of NF-κB canonical pathway, the NF-κB/Rel complexes were 
further activated by post-translational modifications (phosphorylation, acetylation, 
glycosylation) and translocate to the nucleus. Primary wild-type and mutant 
chondrocytes were treated with or without proinflammatory cytokines TNF-α and IL-1 
to induce NF-κB activation and the following nuclear relocation. The p65 dimers were 
relocated by its N-terminal nuclear localization signal (NLS) sequence due to the 
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proinflammatory stimuli (Figure 23, upper). On the contrary to wild-type chondrocytes, 
p65 in mutant chondrocytes were failed to translocate into nuclei. NF-κB conponent 
p65 was kept inactive, NLS-masked and sequestered in cytoplasm of mutant 
chondrocytes due to NEMO-deficiency (Figure 23, lower). 
 
Figure 23: Immunofluorescence staining of p65 in primary chondrocytes. Chondrocytes were 
pre-treated with TNF-α (20 ng/ml, 10 minutes) or IL-1 (10 ng/ml, 10 minutes) or complete media only. 
With treatment of TNF-α and IL-1β shortly before staining, p65 home- or heterodimer complexes were 
translocated into nucleus of wild-type chondrocytes. The lack of p65 nuclear translocation in mutant 
chondrocytes was found. The NLS sequence was still remain masked in mutant chondrocytes. 
4.1.5. Expression of NEMO was specifically prohibited in cartilage tissue of 
NEMOfl/YCol2a1Cre mice 
To clarify NEMO expression in vivo, immunofluorescence staining was applied 
to sections of hindlimb of newborn. Sections of knee joints were processed and 
stained with NEMO antibody. In wild-type mouse, NEMO expressed widely in 
muscles and cartilage (Figure 24, upper). No signal of NEMO was observed in 
sections of mutant knee, whereas other tissue in mutant mouse such as the muscle 
still expressed NEMO independently of the genotype (Figure 24, lower). Taken 
together, the NEMO conditional knockout mouse model was therefore successfully 
established, which characterized by specific prohibition of NF-κB canonical pathway 
activation in chondrocytes. 
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Figure 24: Immunohistochemistry using a NEMO-specific antibody on newborn limb section. 
NEMO was silenced in cartilage tissue of NEMOfl/YCol2a1Cre mice. Conditional knockout strategy 
worked successfully in NEMOfl/YCol2a1Cre mice. 
4.2. The influence of NEMO-deficiency on the skeleton development 
of the embryonic stage 
4.2.1. NEMOfl/YCol2a1Cre mice displayed similar skeleton development at 
embryonic stage 
Cartilaginous tissue development of mouse began approximately from 
embryonic day 13.5. To determine the role of NF-κB canonical pathway in 
development of cartilaginous skeleton, embryos at days 13.5-16.5 and newborns 
were selected for skeletal staining. All skeletal elements formed normally in 
NEMOfl/YCol2a1Cre embryos and no obvious difference in the lengths of long bones 
was found compared with wild-type at these stages (Figure 25, data of E13.5 and 
E14.5 not shown). Despite of the individual difference between every embryo during 
embryonic stage, the average size and skeleton were no statistically different. 
Interestingly, a trend of decreased size showed in neonatal mutants. Although the 
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difference was not statistically significant, it might provide hints for the following 
surveys. 
 
Figure 25: Total skeleton staining of different embryonic stages and newborn mice. Staining 
with alcian blue and alizarin red showed that the NEMOfl/YCol2a1Cre skeletons at E15.5, E16.5 and at 
the newborn stage apparently did not differ from that of wild-type mice. The skeletal staining of E13.5 
and E14.5 were also comparable between wild-type and mutant group (data not shown). Development 
of skeleton in mutant embryos was normal and similar to that of wild-type. 
4.2.2. Length and ossification of NEMO-deficient long bone were similar to 
wild-type 
To compare growth of long bones from wild-type and NEMOfl/YCol2a1Cre mice, 
the length of long bones from embryonic stages until newborn was quantified (Figure 
26, upper). From E13.5 to newborn, length of long bones in NEMOfl/YCol2a1Cre mice 
was almost identical (data of E13.5, E14.5 and E16.5 not shown). Interestingly, long 
bone length of newborn mutants was shorter as observed above (Figure 25). 
Although the difference was not significant, it displayed a possible trend that 
NEMOfl/YCol2a1Cre mice might likely be smaller after birth. Approximately at E15.5, 
endochondral ossification started from the middle of diaphysis of long bones. To 
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explore the influence of NEMO ablation in embryonic skeleton development, 
ossification region of forelimbs and hindlimbs was carefully measured (Figure 24, 
lower). Similar to length of long bones, ossified region of long bones in newborn 
NEMOfl/YCol2a1Cre mice presented the same pattern, even though there was no 
difference of ossification region at embryonic stage.  
 
Figure 26: Quantification of length and ossified region of long bones. The length and ossified 
region from humerus, femur and tibia from E15.5 and neonatal mice were measured. During 
embryonic development, length of long bones and ossified region from mutants were consistent with 
wild-type (data of E14.5 and E16.5 not shown). Note the reduced pattern of length and ossified region 
at newborn stage, length and ossification region of long bones from mutant were slightly shorter 
compared to wild-type. However, the difference was not significant. Values were presented as 
mean±SD, 
4.2.3. Skeleton differentiation in NEMOfl/YCol2a1Cre mice during embryo stage 
were fairly the same as wild-type 
Due to the important role of NF-κB pathway in chondrogenic differentiation, 
markers for osteogenic and chondrogenic differentiation were examined via in situ 
hybridization. Since the phenotype of NEMO-deficiency was likely showed after birth, 
the riboprobes that specific for cartilaginous markers such as Collagen II (cartilage 
marker) and X (hypertrophic cartilage marker), for skeletal development markers 
such as collagen type I (bone marker) were applied to the hindlimb sections of 
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newborns (Figure 27). Cartilage and bone differentiation markers expressed and 
distributed correctly in mutant epiphysis of tibia. The expression patterns in both wild-
type and mutant was the same. Col I was regarded as a bone differentiation marker 
that predominately expressed in bone tissue. The expression of Col I in mutant 
epiphysis was consistently distributed in bone tissue as wild-type (Figure 27, upper). 
Col II and Col X were markers for proliferating and hypertrophic chondrocytes, 
respectively. The expression and distribution of Col II and Col X were comparable to 
wild-type as well (Figure 27, lower). 
 
Figure 27: in situ hybridization on paraformaldehyde (PFA)-fixed sections of tibia epiphyseal 
cartilage from new born mice using DIG-labelled riboprobes specific for CoI I, Col II and Col X. 
Col I, Col II and Col X were expressed comparably in wild-type and NEMOfl/YCol2a1Cre mice. 
4.2.4. No difference was noticed in long bone morphology and proliferation 
To check the morphology of developed long bones, hematoxylin-eosin staining 
was performed to hindlimb sections of E15.5 and newborn mice (Figure 28). In gross 
observation of H&E stained sections, NEMOfl/YCol2a1Cre mice displayed normal 
structure of tibia epiphysis as wild-type. Due to the delayed growth of long bones and 
endochondral ossification we previously revealed, a BrdU incorporation experiment 
was performed to clarify the underlying reason that lead to the delay growth and 
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endochondral ossification (Figure 29). To our expectation, numbers of proliferating 
cells in tibia epiphysis were comparable during embryonic stage, whereas slightly 
less proliferation was detected in mutant epiphysis. Nevertheless, proliferation in 
mutant epiphysis was not significantly reduced as well. 
 
Figure 28: Hematoxylin-Eosin (H&E) staining of tibia epiphysis from E15.5 and newborn mice. 
Sections of E15.5 and newborn epiphyseal cartilage were processed and stained with H&E. 
Development and structure of mutant epiphysis at neonatal stage were more or less normal as wild-
type. 
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Figure 29: BrdU incorporation assay in tibia epiphysis from E15.5 and newborn stage. Sections 
of E15.5 and newborn epiphyseal cartilage incorporated with BrdU and stained with anti-BrdU 
antibody. Proliferating chondrocytes was presented as BrdU-positive cells (brown). The numbers of 
BrdU-positive cells were comparable to wild-type during embryonic stage. However, reduced 
proliferating activity was observed in mutant at newborn stage as reduced bone length and ossification 
we previous found. 
4.2.5. Vascular invasion and intramembranous ossification of NEMO-deficient 
skeleton were comparable to wild-type  
At day 14 of embryo development, chondrocytes in the center of the cartilage 
model mature to hypertrophy. One day later, the hypertrophic cartilage begins to be 
invaded by sprouting blood vessels, osteoclastic cells, and hematopoietic precursors; 
in the perichondrium, a bone collar is forming. To examine the impact of NF-κB 
canonical pathway in vascular invasion and bone formation, the invading vasculature 
was examined by histochemical staining for tartrate resistant acid phosphate (TRAP) 
activity (Figure 30, left). Ossification level was identified by SO-von Kassa staining 
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(Figure 30, right). The level of vascular invasion and ossification were fairly the same 
in wild-type and NEMOfl/YCol2a1Cre mice.  
 
Figure 30: TRAP and SO-von Kassa stained tibia of wild-type and mutant. TRAP staining and 
SO-von Kassa were performed to PFA-fixed E15.5 and E16.5 sections, respectively. Vascular 
invasion was showed as purple dots, and ossified matrix was stained as deep purple. The level of 
vascular invasion and ossified bone in embryonic development were mostly similar between wild-type 
and mutant. 
4.2.6. In cytokine-induced growth, NEMO-deficient metatarsals demonstrated 
comparable growth pattern as wild-type 
To test the response of cytokine-induced growth, the metatarsal culture 
experiment was performed with cytokines such as BMP-2 and IGF-1 that were known 
to be partially regulated by NF-κB canonical pathway and play important role in 
skeleton development (Wu et al., 2008; Wu et al., 2011). The metatarsals were 
cultured for 5 days with BMP-2 or IGF-1 or BGjb media only (Figure 31A). The growth 
of metatarsal rudiments was not altered in NEMOfl/YCol2a1Cre mice upon BMP-2 or 
IGF-1 stimulation. Quantified charts confirmed again that there was no significant 
change of metatarsal growth between wild-type and mutant (Figure 31B). 
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Figure 31: Cytokines induced metatarsal growth. (A) Metatarsals isolated from E15.5 embryo were 
incubated with BGjb or BMP-2 or IGF-1 for 5 days. The second, third and fourth metatarsal bone 
rudiments were selected for this experiments. The growth of mutant metatarsal rudiments in BMP-2 
and IGF-1 groups was comparable to wild-type. (B) Quantification of metatarsal length confirmed 
again that cytokine-induced metatarsal growth was comparable between wild-type and mutant. 
	
The impact of NF-κB canonical pathway to embryonic skeleton development 
we had studied in various ways such as morphology, length, ossification, vascular 
invasion, proliferation and cytokine-induced growth. The results indicated that 
NEMO-deficient mutants were with normal skeleton development during embryonic 
stage. We suggested that NF-κB canonical pathway was likely optional for skeletal 
development in embryo stage.  
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4.3. The impact of NEMO-deficiency to skeleton development at 
postnatal stage 
4.3.1. Post-natal skeletal phenotype of NEMOfl/YCol2a1Cre mice 
	 To investigate the phenotype of NEMO-deficiency after birth, 2-, 4-week-old 
and 1-year-old NEMOfl/YCol2a1Cre mice were collected and compared morphological 
and skeletal differences. A moderate postnatal dwarfism was showed in 
NEMOfl/YCol2a1Cre mice that appeared to be a lifelong defect (Figure 32 left). To 
understand the impact of NEMO-deficiency in NEMOfl/YCol2a1Cre mice at post-natal 
stage, totally skeletons were took as X-ray pictures. Proportionally smaller of skeleton 
was found in NEMOfl/YCol2a1Cre mice, whereas all skeleton elements were 
apparently normal as wild-type (Figure 32, right). 
 
Figure 32: Gross analysis of 2-week-, 4-week- and 1-year-old mice. NEMOfl/YCol2a1Cre mice 
displayed dwarfism from age of 2 weeks, 4 weeks and 1 year (left). We suggested that the phenotype 
of NEMO-deficiency was lifelong that did not catch up. The x-ray picture at age of 1 year showed the 
proportional reduction of skeleton in mutant mice (right).  
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4.3.2. Length of NEMO-deficient long bones was significantly shorten 
As we found in fig. 30 that proportional smaller skeleton in NEMOfl/YCol2a1Cre 
mice, length of long bones was then measured. Neonatal, 2-, 4-week-old and 1-year-
old mice were selected to measure body weight, length of humerus, femur and tibia 
(Figure 33). Due to NEMOfl/YCol2a1Cre mice with integrally smaller skeleton, the 
average body weight of mutant was smaller as expected (Figure 33, left upper). The 
long bones of NEMOfl/YCol2a1Cre mice such as humerus, femur and tibia were 
averagely 2-3 mm shorter than wild-type (Figure 33A, B and C).  Consistent with the 
previous results, it was confirmed that ablation of NEMO specifically in chondrocytes 
resulted in the delayed growth of long bone after birth. We suggested that delay 
growth of long bones in mutant might be due to impaired secondary endochondral 
ossification that began at perinatal stage, which was responsible for the following 
skeleton growth. 
 
Figure 33: Measurement of body weight and long bone length of wild-type and 
NEMOfl/YCol2a1Cre mice. (A) The body weight of mutant was significantly smaller that was not 
surprised since NEMOfl/YCol2a1Cre mice were bearing proportional smaller skeleton. The 
measurement of long bones such as humerus (B), femur (C) and tibia (D) from NEMOfl/YCol2a1Cre 
mice was further confirmed that defect of NEMO ablation showed after birth. Averagely, length of 
humerus, tibia and femur were 2-3 mm shorter compared to wild-type. Values were presented as 
mean±SD, **: p<0.01, ***: p<0.001. 
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4.3.3. Metaphysis of NEMO-deficient long bone was characterized with shorten 
growth plate 
The secondary endochondral ossification was essential for skeleton growth 
during the postnatal and adolescent years. In long bones, the secondary ossification 
appeared in the epiphysis. The epiphyseal plates (known as growth plate) 
continuously generated more chondrocytes through mitosis and increase the length 
of long bones.  To know the impact of NEMO deficiency in growth plate, growth plate 
morphometric analysis was performed at 2 and 4 weeks of age. Total growth plate 
(TGP) was divided into resting zone (RZ), proliferating zone (PZ) and hypertrophic 
zone (HZ). Hematoxylin and eosin (HE)-stained sections through the tibiae revealed 
significantly shortened TGP, RZ+PZ and HZ in mutant growth plates at age of 2 
weeks (Figure 34A). At age of 4 weeks, we observed no statistically significant 
differences in zone lengths between wild-type and NEMOfl/YCol2a1Cre mice. Results 
were further confirmed with quantified measurements of TGP, RZ+PZ and HZ (Figure 
34B). At age of 2 weeks, the average length of wild-type total growth plates was 
approximately 600µm (resting+proliferating zone and hypertrophic zone were 350 
and 250µm, respectively). Length of total Growth plate of NEMOfl/YCol2a1Cre was 
400µm (RZ+PZ and HZ were about 250 and 150µm, respectively). The shorten PZ 
and HZ in mutant growth plate implied that proliferation of chondrocytes was likely 
affected. However, no statistically significant differences in zone lengths between 
wild-type and mutants at 4 weeks of age were found.  However, phenomenon of 
shorten growth plate at age of 2 weeks provided a hint that likely the proliferation of 
mutant chondrocytes was altered due to ablation of NF-κB canonical pathway. 
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Figure 34: Growth plate morphometric analysis of 2- and 4-week-old mice. (A) Analysis of 
cartilage development on H&E-stained sections through the tibia in 2 weeks and 4 weeks old mice. 
The TGP was consisted of RZ+PZ and HZ. (B) Quantified chart showed that the structure and the 
length of growth plate zones were significantly shorten in NEMOfl/YCol2a1Cre mice (TGP, total growth 
plate; RZ, resting zone; PZ, proliferative zone; HZ, hypertrophic zone). Values were presented as 
mean ± SD, *: p<0.05, **: p<0.01. 
4.3.4. NEMO-deficient chondrocytes displayed reduced proliferation activity 
As previous showed NEMOfl/YCol2a1Cre mice were characterized with 
proportional smaller skeleton. We suggested that proliferation of chondrocytes were 
likely altered. To test this hypothesis, BrdU incorporation assay was applied to 
identify chondrocytes in the S phase of the cell cycle in 2 and 4-week-old growth 
plate sections. Interestingly, at age of 2 and 4weeks, proliferation activity of mutant 
chondrocytes was decreased compare to wild-type chondrocytes (Figure 35A). In 
proliferating zone of growth plate, approximately 25% and 22% of wild-type 
chondrocytes were actively proliferating at age of 2 and 4 weeks, respectively. 
Whereas, there were 18% and 7% of NEMO-deficient chondrocytes were BrdU 
positive at age of 2 and 4 weeks, respectively (Figure 35B). To further confirm the 
decrease of proliferation, a BrdU ELISA assay was performed in primary 
chondrocytes (Figure 35C). As expected, proliferation of primary mutant 
chondrocytes was significantly reduced compared to wild-type. Thereby, impaired 
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proliferation in mutant chondrocytes was confirmed both in vivo and in vitro. Our 
preliminary PCR results showed that blockade of NF-κB canonical pathway might 
result in up-regulation of p16 mRNA, cyclin-dependent kinase inhibitor 2A, which 
prohibited cells entering S phase (Figure 33D). 
 
Figure 35: BrdU incorporation assay of PFA-fixed sections from mice knee joint. (A) Under 
microscope, there were less BrdU-positive cells in growth plate of NEMOfl/YCol2a1Cre mice at age of 2 
and 4 weeks. (B) Quantified results from A. (C) BrdU ELISA assay was performed to primary 
chondrocytes. Reduced proliferation of NEMO-deficient chondrocytes was confirmed both in vivo and 
in vitro. Values were presented as mean±SD, *: p<0.05, **: p<0.01, ***: p<0.001. (D) RT-PCR showed 
the increased level of p16 mRNA in NEMOfl/Y-Col2a1cre chondrocytes. 
4.3.5. Apoptotic cells were found in NEMO-deficient growth plate 
As previously mentioned that p65- or NEMO-null mice displayed early 
embryonic lethality coupling with liver degeneration and enhanced apoptosis. 
Blockade of NF-κB canonical pathway might lead to apoptosis of chondrocyte as well. 
To examine this, TUNEL assay was performed to sections of tibia at age 2- and 4-
week-old. Apoptotic cells were found in sections of the growth plate from 
NEMOfl/YCol2a1Cre mice at age of 2 and 4 weeks (Figure 36, arrows). Instead of 
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massive apoptosis, apoptotic cells in mutant growth plate were showed sporadically. 
It implied that mutant chondrocytes were more sensitive to apoptosis compared to 
wild-type. There was no apoptotic cell found in growth plate of wild-type mice.  
 
Figure 36: Apoptosis assay in tibia sections of wild-type and mutant. TUNEL assay was 
performed to sections of 2- and 4-week-old tibia. Notice that apoptotic cell (white arrow) appeared in 
growth plate of NEMOfl/YCol2a1Cre mice. 
4.3.6. In proinflammatory cytokine induced apoptosis, primary NEMO-deficient 
chondrocytes were more sensitive to TNF-α-induced apoptosis 
To further confirm this finding, primary chondrocytes were isolated and treated 
with TNF-α as reported that proinflammatory cytokines could effectively trigger cell 
apoptosis. Massive apoptosis was showed in wild-type chondrocytes as we expected 
(Figure 37, left lower). Abundant annexinV and ethidium homodimer signals 
represented late stage of apoptosis. Signal of ethidium homodimers was 
predominantly showed in mutant chondrocytes treated with TNF-α, whereas very few 
annexinV was detected. It seemed that apoptosis was triggered in most of NEMO-
deficient chondrocytes in response to TNF- α prior to wild-type chondrocytes (Figure 
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37, right lower). It was also possible that NEMO-deficient chondrocytes underwent 
necrosis. 
 
Figure 37: Health/apoptotic/necrotic cells assay in primary chondrocytes with or without pro-
inflammatory cytokine stimulation. In response to TNF-α, wild-type chondrocytes displayed 
massive apoptosis. Further stage of apoptosis was mutant chondrocytes, which implied that apoptosis 
occurred prior than wild-type. 10 ng/ml TNF-α was 24 hours pre-treated before assay, cells with 
annexinV (green) and ethidium homodimer (pink) were in late stage of apoptosis. Cells with only 
ethidium homodimer were likely at the end stage of apoptosis or necrosis.  
4.3.7. Disoriented columns in proliferating zone of NEMOfl/YCol2a1Cre mice 
	 In low magnification, fat, oval-shaped columns were found in the mutant 
growth plate as fig. 32 showed. To study this interesting phenomenon, high 
magnification pictures were took for further analysis. It seemed that the PZ of mutant 
GP was composed of round-shaped proliferating columns whereas linear-shaped 
column distributed in wild-type GP, in age of 2 and 4 weeks (Figure 38A). When 
chondrocytes in growth plate proliferated, divided daughter cells were then soon 
formed a linear-shaped column by compression of surrounding ECM and its own 
migration ability. The disoriented columns indicated a possibility that migration ability 
of chondrocyte or ECM stiffness was altered in NEMOfl/YCol2a1Cre mice. To 
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understand whether cell number within column affected shape of columns, analysis 
to cell number within each column was performed. Interestingly, mutant at age of 2 
weeks, a 20% increase in 16-20 cells subset was found that represent 20% of total 
columns were consisted of 16-20 chondrocytes (Figure 38B). The formation of 
disoriented columns in mutant was likely because of over-averaged chondrocytes in 
a mutant column. At age of 4 weeks, mutant columns were bearing comparable cells 
within and displayed twisted shape coupling with column-column fusion.  
 
Figure 38: Hematoxylin and eosin (HE) staining of sections of 2- and 4-weeks old growth plate. 
(A) At high magnification, proliferating columns of mutant were disoriented and formed a fat-oval 
shape. Under normal circumstance, chondrocytes divided into 2 daughter cells and formed a linear 
column due to its own migration ability and the compressive stress from surrounded cartilage ECM. 
The disoriented proliferating columns implied that migration of mutant chondrocytes or stiffness of 
ECM might be altered. (B) Quantification of cell number in columns. Note an 20% increase of 16-20 
subset in mutant columns at age of 2 weeks, which might cause round-shape column formation with 
16 to 20 chondrocytes within (upper). Comparable composition of cells in columns was observed in 
both wild-type and mutant. However, fused and twisted columns were found in mutant growth plate. 
Abnormal proliferating columns might result in malformation of bone. 
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4.3.8. Fat-oval-shaped proliferating columns were pronounced in NEMO-
deficient growth plate 
To further investigate twisted columns in NEMOfl/YCol2a1Cre mice, we 
analyzed shape of and horizontal angle of columns. In survey of column shape 
difference, mutant columns displayed a shifting proportion of horizontal-vertical ratio 
toward 1 (Figure 39A, upper). In another word, there were more roundish-shaped 
proliferating columns in mutant growth plate at age of 2 weeks. Similar results were 
showed in mutant at age of 4 weeks as well (Figure 39A, lower). These disoriented, 
round-shaped proliferating columns in mutant growth plate might increase the 
incidence of bone malformation; however, bone malformation was likely 
imperceptible (no obvious malformation was noticed) and the implication was still 
remained unclear. As for analysis of horizontal angle of columns, results from wild-
type and mutant were fairly comparable (Figure 39B). Most of columns from both 
groups were more or less perpendicular to the growth plate. These preliminary 
results indicated NEMOfl/YCol2a1Cre mice were with more round-shaped columns 
and more chondrocytes within; however, no bone malformation was observed. More 
efforts are required to conclude this interesting finding. 
 
Figure 39: Analysis of proliferating columns in growth plate at age of 2- and 4-week-old mice. 
(A) Ratio of short-long axis analysis of proliferating columns. At age of 2 weeks, a proportional ratio 
shift from linear-shaped to round-shaped was observed. Similarly, results of 4-week-old showed the 
same shifted pattern that indicated mutants were with more round-like columns. (B) Analysis of 
horizontal angle showed a fairly the same distribution in both wild-type and mutant. 
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4.3.9. NEMO-deficient chondrocytes displayed a reduced migration activity 
At metaphyseal side, cartilage cells become aligned into well-defined columns 
due to compression of matrix and mobility of chondrocytes, known as zone of cellular 
proliferation (proliferating zone). Failure of these chondrocytes to thrive resulted in 
abnormal growth of bones. The disoriented columns that we previously discovered 
indicated a possibility that migration ability of chondrocyte or ECM stiffness was 
altered in NEMOfl/YCol2a1Cre mice. To examine our hypothesis of migration 
alteration in mutant chondrocytes, migration ability of chondrocytes was tested. A 24-
hours random migration assay was performed to check mobility of wild-type and 
mutant chondrocytes. Wild-type chondrocytes were able to explore averagely 100-
200 µm range from origin, whereas the exploring area of mutant chondrocytes was 
narrowed down to below 100µm (Figure 40A, left). Quantification of velocity shown 
mutant chondrocytes were with slower mobility compare to wild-type chondrocytes 
(Figure 40B, right). Further quantification showed that the average velocity of mutant 
chondrocytes was 0.2µm/min, which was half speed of wild-type chondrocytes. 
Consistent with our hypothesis, migration ability of mutant chondrocytes was 
impaired. 
 
Figure 40: Migration assay of primary chondrocytes. (A) 24-hours random migration assay of 
chondrocytes. Primary NEMOfl/Y and NEMOfl/YCol2a1Cre chondrocytes from frame by frame analysis 
of time-lapse was recording during a 20-mins observing period.  (B) The migration velocities of the 
respective cells are indicated (mean±SD, **: p<0.01, migration data of over 30 cells). Quantification of 
cell migration velocity indicated NEMOfl/YCol2a1Cre chondrocytes with reduced migration. 
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4.3.10. NEMO-deficient chondrocytes possess higher adhesion to 
cartilage ECM 
Generally, adhesion strength and dynamic could determine migration ability of 
cells. To clarify whether attachment of mutant chondrocytes to ECM ligands was 
altered, an adhesion assay was performed. Usual and abundant ECM components 
such as fibronectin, vitronectin, laminin, collagen I and collagen II were tested. 
Interestingly, NEMO-deficient chondrocytes exhibited higher binding affinity to both 
cartilaginous (collagen I, fibronectin, laminin) and non-cartilaginous (vitronectin, 
collagen I) ECM components (Figure 41A). The generally enhanced adhesion of 
mutant cells to ECM could affect migration ability of mutant chondrocytes, which may 
involve integrin-associated signaling pathways. In order to test if downstream 
signaling of integrins was effected by the lack of NEMO, primary chondrocytes were 
analyzed for IL-1-induced activation of mitogen activated protein (MAP) kinases, focal 
adhesion kinase (FAK) and AKT (or protein kinase B) by western blotting (Figure 
41B). Surprisingly, we could not detect any obvious difference in the timely 
phosphorylation status of FAK, AKT, ERK and p38 between the genotypes implying 
that integrin-associated signaling cascades are likely not affected in the absence of 
NEMO/canonical NF-κB pathway in chondrocytes.  
 
Figure 41: Increased adhesion to ECM ligands is not associated with obvious changes in 
integrin signaling pathways.  (A) Stronger adhesion of Nemo-deficient chondrocytes to ECM 
substrates. Components of ECMs (fibronectin, vitronectin, laminin, collagen I and collagen II) were 
pre-coated on plastic surface, than wild type and mutant chondrocytes were added and allowed to 
adhere for one hour. Mutant chondrocytes showed stronger binding affinity than wild type 
chondrocytes as verified by the increased absorbance at 540 nm after cresyl violet staining. (B) 
Western blotting of cultured primary chondrocytes with or without IL-1 stimulation shows no significant 
differences in activation of integrin-linked signaling molecules. 
RESULTS 
	 95	
4.3.11. The stiffness of cartilage ECM from NEMOfl/YCol2a1Cre mice was 
fairly the same as wild-type 
To verified the last suggestion of possible reasons that resulted in disoriented 
columns in NEMOfl/YCol2a1Cre mice growth plate. The stiffness of ECM in 
disoriented columns in NEMOfl/YCol2a1Cre mice was tested by atomic force 
microscope (AFM). The vDflection of wild-type and mutant, which represented the 
topography of cartilage ECM, were comparable (Figure 42A). The composition of 
cartilage ECM in NEMOfl/YCol2a1Cre mice was fairly comparable to wild-type. The 
matrix elasticity analysis showed the same cartilage matrix stiffness between wild-
type and NEMOfl/YCol2a1Cre mice (Figure 42B). The elastic modulus (E) of wild-type 
and NEMOfl/YCol2a1Cre were 49±0.7kPa and 55.5±1.1kPa, respectively. The elastic 
moduli from both were in the range of normal elasticity modulus.  Even though the 
stiffness of mutant cartilage was approximately 5kPa more than of wild-type, no 
statistical significance was found. 
 
Figure 42: Atomic force microscope (AFM) observed comparable ECM orientation and elasticity. 
(A) Topology of cartilage ECM surface was presented as height and vDeflection. It showed 
comparable cartilage ECM surface between wild-type and mutant cartilage. (B) Elastic modulus from 
both groups was calculated. Similar ECM stiffness was concluded as were 49±0.7 kPa in wild-type 
and 55.5±1.1 kPa in mutant, respectively.  E=elastic modulus (calculation formula not shown).  
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4.3.12. NEMO-deficient chondrocytes displayed larger spreading area in 
vitro 
During experiment of migration assay, we found that mutant chondrocytes 
were with larger spreading area (data not show). To confirm this observation, cell-
spreading assay was performed. With time after chondrocytes seeding to petri-dish, 
NEMO-deficient chondrocytes were observed with larger spreading area compared to 
wild-type chondrocytes (Figure 43A). The average cell spreading area of mutant 
chondrocytes could reach 6500 µm2; however, the spreading area of wild-type 
chondrocytes was half of mutant chondrocytes (Figure 43B). The average spreading 
time was approximately 6.5 hours post seeding, which was comparable between 
wild-type and NEMO-deficient chondrocytes (Figure 43C). Enlarged cell spreading 
area might be related to remodeling of actin cytoskeleton or alteration of adhesion 
molecules. To further investigate the spreading phenotype, we have seeded wild-
type and NEMO-deficient chondrocytes on fibronectin-coated glass slides and 
stained with paxillin to visualize focal adhesion sites, and with phalloidin to detect 
actin cytoskeletal structures. After 24 hours, we could not observe obvious 
differences in the appearance and number of focal complexes, and the organization 
of cytoskeletal elements including actin stress fibers, microfilaments and lamelopodia.  
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Figure 43: Abnormal spreading behavior of NEMOfl/YCol2a1cre chondrocytes. (A) Representative 
images of time laps recording showing cell spreading through the indicated time points on the plastic 
surface in the presence of serum. Note that NEMO-deficient chondrocytes spread into larger area than 
wild-type cells. (B) Quantification of cell spreading area. (C) Quantification of cell spreading time of 
wild-type and NEMOfl/YCol2a1Cre chondrocytes. Average spreading time was comparable between 
the genotypes. (D) On fibronectin coated glass slide, Nemo-deficient chondrocytes show comparable 
distribution of focal complexes (demonstrated by paxillin staining) and normal formation of cytoskeletal 
structures (actin stress fibers, micro-spikes, lamellopodia) compared with wild-type after 24 hours of 
seeding.  
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4.4. The role of NF-κB canonical pathway in cartilage metabolism 
using hip explant culture 
Degradation of proteoglycans and glycosaminoglycans breakdown were 
partially eased in hip cap of NEMOfl/YCol2a1Cre mice 
The proinflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor 
α (TNF-α) were known to elevate chondrocyte catabolism and block chondrocyte 
anabolism partially via through the canonical NF-ĸB signaling. To address to role of 
NF-ĸB in cartilage metabolism pathologically, in vitro experiments were performed 
with femoral head cartilage explants isolated from wild type and NEMOfl/YCol2a1Cre 
mice as described in a previous publication from the Aszodi lab (Raducanu et al., 
2009). After 4-days treatment of TNF-α and IL-1β, the loss of proteoglycans in 
articular cartilage was observed in wild type femoral head. However, the 
proteoglycan breakdown in articular cartilage from NEMO-deficient group was largely 
reduced (Figure 44A and 44B). Signals of aggrecan neoepitope G1-TEGE and 
VIDIPEN were pronounced at the surface and growth plate of wild-type articular 
cartilage that indicated where the massive cartilage ECM breakage occurred. As 
expected, the signals of G1-TEGE and VIDIPEN were much milder in articular 
cartilage of NEMOfl/YCol2a1Cre mice (Figure 44C and D). Blocking NF-κB signaling 
had been merged as very attractive and potential strategy against OA. Our results 
supported this view as well. However, the experiment time was relatively short 
compared to spontaneous progression of cartilage ECM breakdown. The protection 
from blocking NF-κB canonical signaling might only decelerate progression of ECM 
breakdown at early stage. More efforts were need to verify the effect of blocking NF-
κB canonical pathway in mid and later stage of cartilage ECM loss. 
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Figure 44: Reduced aggrecanolysis in NEMO-deficient hip explants upon cytokines treatment. 
Femoral heads were harvested from 4-week-old control and NEMOfl/YCol2a1Cre mice and cultured in 
serum-free DMEM with or without treatment with TNF-α (100 ng/ml) and IL-1 (10 ng/ml). (A) Safranin 
orange staining indicated only moderate loss of sulfated GAGs in mutant explants. (B) Immunostaining 
demonstrates that aggrecan retains in the mutant cartilage matrix after cytokine treatments. (C) 
Increased protrution of the ADAMTS4/5-induced aggrecan degradation neoepitope TEGE was 
observed in control but not in NEMOfl/YCol2a1cre explants. (D) Cytokines treatments increase the 
exposure of the MMP-induced aggrecan degradation neoepitope VIDIPEN in control but not in of 
NEMOfl/YCol2a1cre explants. 
	
To determine the glycosaminoglycans (GAG) concentration in media of wild-
type and NEMO-deficient groups, sulfate GAG (sGAG) assay was performed. In 
response to TNF-α and IL-1 stimuli, sGAG in media from cartilage of NEMO-deficient 
groups was much less than amount of GAG released into media largely increased in 
wild-type group (Figure 45). To our expectation, the loss of cartilage ECM triggered 
by inflammatory cytokines, could be effectively eased by blocking NF-ĸB canonical 
pathway during early stage of inflammation. 
 
Figure 45: Less soluble GAGs were detected in condition medium of NEMOfl/YCol2a1cre against 
cytokine-induced proteoglycan degradation. The blockade of NF-κB canonical pathway could 
effectively reduce proteoglycan breakdown during early stage of inflammation. 
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Next, we have investigated the expression and activity of selected matrix 
metalloproteinases (MMP) using immunohistochemistry and gel zymograpy. Using 
antibodies against gelatinases (MMP2 and MMP9, Figure 46A and 46B) and 
collagenases (MMP13, Figure 46C), we could not detect any genotype-specific 
difference in the expression of these MMPs upon immunostaining. Collagen and 
gelatin gel zymography further demonstrated normal activation of collagenases and 
gelatinases in mutant explants treated with the cytokines (Figure 46E). However, we 
did observe reduced expression of the aggrecan-degrading MMP3 in IL-1β and TNFα 
stimulated mutant explants compared with wild type (Figure 46D).  These results 
indicated that IL-1β and TNFα stimulation of aggrecanases and MMP3 was partially 
regulated by NF-κB and blocking NEMO may be an important approach for the 
development of intervention strategies for OA. 
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Figure 46: Cytokines-induced expression of MMP3 was decreased in mutant explants. No 
difference in the expression of MMP2 (A), MMP9 (B) and MMP13 (C) was observed between control 
and mutant explants after TNF-α (100 ng/ml) and IL-1 (10 ng/ml) treatment. (D) IL-1β and TNFα 
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elevate MMP3 expression in control but not in NEMOfl/YCol2a1cre explants. (E) Collagen and gelatin 
zymography demonstrate no obvious difference in the activity of collagenases and gelatinases in 
control and mutant explants. 
4.5. Regulation of NF-κB in cartilage responses upon ex vivo 
induced hip injury 
Against mechanical stress, ARG-1, HAS-2, IL-18 and MMP-3 were significantly 
regulated in hip cap of NEMOfl/YCol2a1Cre mice compare to wild-type 
	 Joint injury significantly increased the risk of OA, therefore dissecting the 
pathways that were induced after trauma was important for understanding cartilage 
degeneration. It had been previously shown that physical damage of the articular 
cartilage rapidly activates the three major MAP kinases (ERK1/2, Jnk, p38) as well as 
NF-ĸB, which in turn triggered intracellular inflammatory signaling pathways (Gruber 
et al., 2004). To clarify the role of NF-κB in this process, we applied a mechanical 
injury model developed by Tonia L. Vincent (Kennedy Institute of Rheumatology 
Division, Imperial College School of Medicine, London, UK). Briefly, intact femora 
were isolated from 4-week-old wild-type and NEMOfl/YCol2a1Cre mice, and the injury 
was induced by forcing the hip cartilage from the underlying femoral head. The 
cartilaginous femoral heads were either immediately frozen in liquid nitrogen 
(negative control) or cultured in serum-free DMEM for 4 hours before snap freezing. 
RNA was extracted from the pulverized samples and RT-PCR was performed for a 
set of 47 pre-determined genes, which were known to be strongly regulated following 
injury using microfluidic Taqman low-density arrays. 
According to the microarray data, there were only few genes significantly 
regulated in NEMO-deficient group compared to wild-type. The only suppressed 
gene in NEMOfl/YCol2a1Cre hip upon injury was arginase I (ARG-1). Hyaluronan 
synthase-2 (HAS-2), interlukin-18 (IL-18) and matrix metalloprotease-3 (MMP-3) 
were up-regulated genes in NEMO-deficient group compared to wild-type (Figure 47). 
Arginase1 encoded arginase, which was an enzyme participating in urea cycle, a 
series of reactions that occurs in liver cells. Basically, ARG-1 was characterized by its 
role in metabolism. However, the role ARG-1 among mechanical stress in articular 
cartilage was still largely unknown. HAS-2 encoded hyaluronan synthase that was 
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responsible for production of hyaluronan, which was a component of cartilage ECM. 
Enhanced- regulation of HAS-2 gene in articular cartilage of NEMOfl/YCol2a1Cre 
mice was suggested a repair mechanism against the mechanical stress. 
Consequently, HAS-2 might continuously produce hyaluronan to replenish the loss of 
cartilage ECM resulted from mechanical stress. 
MMP-3 was known to play important role in degradation of cartilage ECM 
among injury. Enhanced MMP-3 expression in mutant articular cartilage implied an 
acceleration of cartilage ECM breakdown among mechanical stress. IL-18, a 
structure homolog of IL-1, was up-regulated as well. By sharing structure similarity 
with IL-1, IL-18 might be able to trigger the same signaling as IL-1 induced during 
injury. However, the role of IL-18 in injury-induced cartilage ECM degradation was 
remained unclear. 
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Figure 47: RT-PCR of 47 pre-determined, osteoarthritis-related genes using TaqMan 
microfluidic cards. It demonstrated that ARG-1 was the only down-regulated gene in 
NEMOfl/YCol2a1cre group compared to control; HAS-2, IL-18 and MMP-3 were the up-regulated genes 
response to mechanical damage in NEMOfl/YCol2a1cre group. 
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4.6. The role of NF-κB canonical pathway in spontaneous OA model 
NEMO-deficiency has no impact on age-associated, spontaneous osteoarthritis 
in mice  
Idiopathic OA is normally slow progressing; increased mechanical loading 
upon traumatic lesions could accelerate the disease. To assess the role of 
NEMO/canonical NF-κB in spontaneous osteoarthritis, H&E and toluidine blue 
stained sections of NEMOfl/Y and NEMOfl/YCol2a1Cre knee joints were examined for 
histological evidence of articular cartilage (AC) degeneration at age of 1 and 1.5 year. 
The knee joint overview of NEMOfl/Y and NEMOfl/YCol2a1Cre mice were similar with 
no significant difference (Figure 48). The collateral ligament and synovial tissue from 
both groups were still health, even at age of 1.5 year. The H&E and toluidine blue 
stained sections showed that all of the mice including 1- and 1.5-year-old displayed 
surface irregularity or rift to the transition zone and almost the same proteoglycans 
level of articular cartilage (Figure 49A and 50A). Hypercellularity was noticed in both 
1- and 1.5- year old models. According to the scoring system previously described in 
materials and methods, cartilage erosion and total OA score of 1-year-old and 1.5-
year-old articular cartilage were evaluated. Grade 2 erosions, represented as cleft to 
the transition zone, were observed in NEMOfl/Y and NEMOfl/YCol2a1Cre mice at age 
of 1 and 1.5 year (Figure 49B and 50B). Both groups of 1-year-old and 1.5 year-old 
were with total OA score 6-7, which indicating mild OA progression (Figure 49C and 
50C). Analysis of AC thickness (Figure 49D and 50D) and uncalcified/calcified region 
(Figure 49E and 50E) showed no difference as well. Results of AC thickness and 
uncalcified/calcified region measurement were almost the same between NEMOfl/Y 
and NEMOfl/YCol2a1Cre mice at age of 1 and 1.5 year. To summarize, no statistically 
difference of cartilage erosion, total OA score, AC thickness and unclacified/calcified 
region of AC was found between NEMOfl/Y and NEMOfl/YCol2a1Cre mice. 
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Figure 48: Knee overview of 1- and 1.5-year-old mice. NEMO-deficiency did not influence 
spontaneous knee osteoarthritis in mice. Representative H&E stained knee sections from (A) 1- and 
(B) 1.5-year-old mice of NEMOfl/Y and NEMOfl/YCol2a1Cre mice were comparable. No significant 
difference was observed in collateral ligament, synovial tissue (at higher magnification) and articular 
cartilage. 
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Figure 49: Evaluation of cartilage erosion, OA progression and AC composition at age of 1 year. 
(A) H&E and toluidine blue stained knee sections showed comparable cartilage damage in both 
groups. (B) According to erosion assessment, the level of cartilage damage was into transition zone. 
(C) Total OA score revealed that NEMOfl/Y and NEMOfl/YCol2a1Cre mice were with mild OA. (D) The 
AC thickness of wild type and NEMO-deficiency mice were almost the same. (E) The ratio of 
uncalcified and calcified region in AC was comparable as well. 
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Figure 50: Evaluation of cartilage erosion, OA progression and AC composition at age of 1.5 
year.  (A) H&E and toluidine blue stained knee sections showed comparable cartilage damage in both 
groups. (B) According to erosion assessment, the level of cartilage damage was into transition zone. 
(C) Total OA score revealed that NEMOfl/Y and NEMOfl/YCol2a1Cre mice were with mild OA. (D) The 
AC thickness of wild type and NEMO-deficiency mice were almost the same. (E) The ratio of 
uncalcified and calcified region in AC was comparable as well. 
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To examine the cartilage ECM breakage, IHC staining of aggrecan neoepitope 
such as G1-TEGE and VIDIPEN were performed. At age of 1- and 1-5-year-old wild 
type and NEMOfl/YCol2a1Cre mice, TEGE-stained signals were evenly distributed in 
articular cartilage (Figure 51A). VIDIPEN was sporadically detected in 1-year-old AC 
and largely increased in 1.5-year-old AC (Figure 51B). 
 The following immunostaining for aggrecanases MMP-2, -9 and -13 did not 
reveal significant differences between NEMOfl/Y and NEMOfl/YCol2a1Cre mice (Figure 
52). To conclude, these results have suggested that NEMO is likely a dispensable 
factor in spontaneous knee osteoarthritis. 
 
Figure 51: IHC staining of aggrecan neoepitopes. (A) In 1- and 1.5-year-old models, the signals of 
G1-TEGE were evenly distributed near the surface of articular cartilage. (B) Signals of VIDIPEN were 
sporadically found in 1-year-old cartilage and heavily increased in 1.5-year-old cartilage. Both groups 
at age of 1 and 1.5 year showed comparable G1-TEGE and VIDIPEN signals. 
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Figure 52: IHC staining of aggrecanases. (A) The signals of MMP2 were similar to G1-TEGE, which 
were distributed near the surface. (B) The signals of MMP-9 were pronounced in 1-year-old cartilage 
and slightly reduced in 1.5-year-old group. (C) MMP-13 was predominantly detected in subchondral 
bone. Comparison of NEMOfl/Y and NEMOfl/YCol2a1Cre at age of 1 and 1.5 year, expression of MMP-2, 
-9 and -13 were similar and no significant difference. 
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5. Discussion 
Nuclear factor–kappaB proteins control the expression of numerous genes in 
respond to stress conditions such as inflammation, infection or injury. In the recent 
years, pharmacological blockade of NF-κB canonical pathway has been suggested 
as a potential therapeutic treatment against bone degenerative disorders such as 
rheumatoid arthritis and osteoarthritis.  In spite of the suggested beneficial role of 
diminished NF-κB activation in amelioration of cartilage degradation, the role of the 
canonical NF-κB pathway in normal skeletal development still remains unclear, 
mainly because of the shortage of appropriate model animal. Using a Col2a1Cre 
transgenic mouse line, in this study we have successfully deleted the floxed Nemo 
gene in cartilage, which allowing us to clarify the role of canonical NF-κB signaling in 
skeletal physiology. 
5.1. The NEMO-mediated, canonical NF-κB pathway regulates 
postnatal growth of endochondral bones via the control of 
growth plate functions 
Previous studies have been revealed that conventional knock-outs of RelA (p65) 
and NEMO in mice result in diminished activation of the canonical NF-κB pathway 
and cause embryonic lethality between gestation days 12 and 16 (Beg et al., 1995; 
Rudolph et al., 2000). The embryonic lethality in both mutant strains was found due 
to apoptosis of hepatocytes and severe liver degeneration. Interestingly, no other 
abnormalities, including any skeletal defects, were reported in the p65-null and 
NEMO-null mice. In our study, conditional inactivation of NEMO in chondrocytes led 
to normal embryogenesis without signs of any skeletal malformations. Investigation of  
the skeleton of NEMOfl/YCol2a1Cre embryos and newborn animals using various 
techniques including whole-mount skeletal staining, morphometry, histological 
analysis, and proliferation assays showed that the skeletal appearance and skeletal 
growth of the mutants comparable to that of the wild-type mice. This observation 
indicates that NEMO/canonical NF-κB is dispensable for fetal skeletogenesis.   
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In contrast to the embryonic stages, NEMOfl/YCol2a1Cre mice exhibited 
progressive growth retardation which begun at around 1 week of age and persisted 
throughout the whole life. Besides the skeletal phenotype, NEMO-deficient animals 
were fertile, had normal life span and showed no abnormal organ functions. On 
histological level, the observed postnatal dwarfism was characterized with shortened 
growth plate and reduced lengths of both the proliferating and hypertrophic zones. 
The growth plate shortening was accompanied with reduced BrdU incorporation rate 
in the proliferative zone, indicating that the canonical NF-κB pathway modulates the 
mitotic activity of proliferative chondrocytes. We have also found that p16 (also called 
cyclin-dependent kinase inhibitor 2A) mRNA is up-regulated in NEMO-deficient 
chondrocytes strongly implying a role of canonical NF-κB signaling in the control of 
cyclin dependent kinases. It has been shown in various cellular systems that p16 
plays critical regulatory function in cell cycle by suppressing G1/S transition (Hara et 
al., 1996; Rayess et al., 2012). A previous study has showed that expression of p16 
and NF-κB p65 is inversely correlated in melanocytes during melanoma progression 
(Ghiorzo et al., 2004). The fact that p16 was up-regulated in the cartilage of 
NEMOfl/YCol2a1Cre mice, further demonstrate that NEMO/ canonical NF-κB is a 
generalized signaling mechanisms which modulates cell cycle progression in different 
cell types, including chondrocytes. Mechanistically, several studies have indicated 
that p16 up-regulation keeps retinoblastoma proteins (pRB) un-phosphorylated, 
which results in decelerated progression from G1 to S phase. Whether or not the 
same mechanisms acting in the NEMO-deficient chondrocytes remains unresolved 
and needs to be elucidated in the future. 
BMP-2, a member of the TGFβ superfamily of growth factors, is known to play 
an important role in regulating embryonic and postnatal bone growth. A recent report 
has showed that BMP-2 expression is regulated by NF-κB signaling in growth plate 
chondrocytes both in vitro and in vivo (Feng et al., 2003). The NF-κB subunits p50 
and p65 bind to regulatory elements of the BMP-2 gene, and possibly regulating 
BMP-2 expression.  Importantly, p50/p52 double knockout mice with insufficient NF-
κB activation display reduced BrdU incorporation rate in proliferative growth plate 
chondrocytes accompanied by decreased BMP-2 expression.  In our study, we have 
not investigated BMP-2 expression in postnatal NEMOfl/YCol2a1Cre chondrocytes. 
However, we did not find a difference in chondrocyte proliferation upon BMP-2 
treatment between NEMO-deficient and control metatarsal explants suggesting that 
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the ablation of the canonical p50/p65 pathway may not be crucial for BMP-2 induced 
growth.  Nevertheless, the relation between BMP-2 expression and canonical NF-κB 
signaling in postnatal NEMOfl/YCol2a1Cre growth plate chondrocytes should be 
investigated with more details in the future. 
5.2. NEMO/canonical NF-κB signaling modulates chondrocyte survival in 
postnatal growth plate 
Under normal circumstances, terminally differentiated hypertrophic 
chondrocytes at the chondro-osseous either die by apoptosis or transdifferentiate into 
osteoblast (Zhou et al., 2014). Chondrocyte death is not typical in upper growth plate 
zones, and the appearance of apoptotic cells in the proliferative zone is usually 
associated with growth plate dysfunction. In the growth plate of NEMOfl/YCol2a1Cre 
mice, we have detected apoptotic chondrocytes scattered through the proliferative 
and upper hypertrophic zones by TUNEL assay. Although the rate of apoptosis was 
low in the mutant growth plate, we hypothesize that a constant cell death in the 
proximal growth plate zones could also contribute, besides the proliferation defect, to 
the dwarf phenotype of NEMOfl/YCol2a1Cre mice. Several studies have indicated the 
participation of NF-κB subunits in the control of apoptosis (Beg and Baltimore, 1996; 
Van Antwerp et al., 1996; Wang et al., 1996). Recently, it has been shown that p65 is 
constitutively activated by the NK homo-protein Nkx3.2 to support chondrocyte 
survival in proliferative chondrocytes (Park et al., 2007). The expression of Nkx3.2 is 
reduced in mature chondrocytes (Church et al., 2005; Provot et al., 2006). Moreover, 
chondrocyte apoptosis and NF-κB activation are inversely related during cartilage 
maturation. Interestingly, the constitutive activation of NF-κB mediated by Nkx3.2 in 
chondrocytes also requires IKK-β and NEMO (Yong et al., 2011). Apart from Nkx3.2-
mediated survival effect, it has known that several distinct elements are also involved 
in regulation of viability including β1-integrin and HIF-1α (Hirsch et al., 1997; Schipani 
et al., 2001). In our NEMO-deficient chondrocytes, Nkx3.2-mediated survival 
pathways might be blocked as well as canonical NF-κB signaling and could account 
for the increased apoptotic rate in the proliferative and upper hypertrophic zones of 
NEMOfl/YCol2a1Cre growth plate owning to the lack of NEMO expression and 
canonical NF-κB activation (Figure 53). However, further investigation is required to 
confirm this assumption. 
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Figure 53: NEMO is involved in Nkx3.2-mediated constitutive activation of NF-κB signaling. 
Nkx3.2, specifically expresses in proliferative chondrocytes in association with the NEMO-IKKβ 
complex, and constitutively activates RelA and maintains chondrocyte viability. However, the NEMO-
deficient chondrocytes are more vulnerable to apoptosis due to the destruction of NF-κB-Nkx3.2-
NEMO-IKKβ complex, which is likely responsible for the increased apoptotic rate in the proliferative 
zone of NEMO-deficient growth plate. Figure is adapted and modified from (Park et al., 2007). 
5.3. Primary NEMOfl/YCol2a1Cre chondrocytes exhibit severe death 
phenotype upon exposure to TNF-α 
Inflammation enhances cartilage degradation in the processes of osteoarthritis 
and rheumatoid arthritis, therefore blocking inflammatory cytokines such as tumor 
necrosis factor (TNF, TNFα) or interleukin-1 (IL-1) is a potential therapeutic approach 
for the prevention of the progression of these diseases. TNF signaling proceeds 
through NEMO/ NF-κB dependent and independent pathways, which are not only 
regulates the expression of pro-inflammatory proteins but are also involved in the 
control of death-survival decision of the cells. 
In most cell types, upon TNF engagement by TNF receptor-1 (TNRF-1), NF-κB 
activation is initiated by the binding of TNFR-1 associated death domain protein 
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(TRADD) to the cytoplasmic part of TNFR-1, which subsequently recruits receptor-
interacting serine-threonine protein kinase 1 (RIPK-1), TNFR-associated factor 2 
(TRAF-2) and the E3 type ubiquitin ligase clAP1 or clAP2 (Devin et al., 2000; Hsu et 
al., 1996; Kelliher et al., 1998; Ting et al., 1996). After RIPK-1 undergoing poly-
ubiquitination (Bertrand et al., 2008; Lee et al., 2004b; Wang et al., 2008; Wertz et al., 
2004), it interacts with the ubiquitin-binding domains of NEMO (Laplantine et al., 
2009). The binding of NEMO to RIPK-1 is a critical step to recruit the whole IKK 
complex and activation of the canonical NF-κB pathway (Ea et al., 2006; Li et al., 
2006). RIPK-1/NEMO-induced NF-κB activation leads to the expression of several 
anti-apoptotic genes (e.g. IAPs, Bcl-2 family subunits, cFLIP) and thus promotes cell 
survival (Micheau et al., 2001; Wang et al., 1998). TNF-induced NF-κB activation was 
considered as a late-stage pro-survival checkpoint in T lymphocytes (O'Donnell et al., 
2007). Apart from participating in NF-κB-regulated pro-survival function, NEMO was 
reported to possess a relatively early pro-survival activity that is independent from the 
canonical NF-κB pathway (Legarda-Addison et al., 2009). RIPK-1 is able to bind 
caspase-8 initiating a classical apoptosis pathway. NEMO, before TNF-induced NF-
κB activation, masks caspase-8 binding sites on RIPK-1, therefore it suppress 
apoptotic activity. The pro-apoptotic activity of RIPK-1 is appears when NEMO is 
absent (Legarda-Addison et al., 2009) or ubiquitination is not present (Bertrand et al., 
2008; O'Donnell et al., 2007; Wang et al., 2008). Consequently, a novel role of 
NEMO in pro-survival pathway has been suggested. According to above evidences, 
TNF signal transduction likely has two checkpoints. (1) Binding with of NEMO and 
attachment of non-degradative ubiquitin chains in RIPK-1 (early checkpoint). 
Afterwards, IKK complex is recruited by NEMO-RIPK-1 which in turn leads to (2) up-
regulation of NF-κB-mediated pro-survival genes (late checkpoint). Different from the 
temporary pro-survival effect provided by the primary checkpoint, the secondary 
checkpoint offers sustained expression of pro-survival genes. Hence, TNF-stimulated 
apoptosis could occur if one of the pro-survival checkpoints is abolished. Furthermore, 
a recent study using T lymphoma cells demonstrated that NEMO-deficiency results in 
hypersensitivity to necroptosis (or regulated necrosis) in the absence of caspase 
(apoptosis) inhibitors, which, again, does not depend on the activation of the 
canonical NF-κB pathway (O'Donnell et al., 2012). In summarizing the literature data, 
NEMO and NEMO/NF-κB signaling cascades fine-tunes the TNF-dependent outcome 
of cell survival or death (apoptosis or necroptosis). In our study, we have investigated 
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the respond of primary NEMO-deficient chondrocytes to TNF-α exposure in 
monolayer culture. As the lack of NEMO interferes with both the pro-survival function 
of TNF/NF-κB signaling and the anti-apoptotic/anti-necrotic function of RIPK-1, it is 
not surprising that the mutant cells showed massive cell death after TNF-α treatment 
(Figure 54). However, the used methodology to stain live, apoptotic, and necrotic 
cells do not allow to clearly discriminating among the potential cell death pathways in 
the absence of NEMO. The predominant staining of ethidium homodimer and the 
lack of significant annexin V-positive cell membrane could be interpreted as very late 
stage apoptosis with already prominent cell membrane degradation or late stage 
necroptosis. Clearly, further investigation is required to devote into this interesting 
issue. Importantly, blockage of the canonical NF-κB pathway in arthritic disorders by 
inhibiting NEMO function may induce chondrocyte death in the articular cartilage and 
countervail its beneficial effect on suppressing the expression of catabolic proteins in 
an inflammatory environment (see later).  
 
Figure 54: NEMO plays a key role in pro-survival activities against TNF-α stimuli. (A) In response 
to TNF-α induction, the poly-ubiquitylation of RIPK-1 and its binding with NEMO are regarded as the 
primary or early pro-survival checkpoint. The NF-κB-regulated pro-survival activities are served as the 
secondary or late pro-survival checkpoint. The lack of either checkpoint (or excessive TNF-α stimuli) 
results in apoptosis or necroptosis. (B) In NEMO-deficient chondrocytes, the canonical and intrinsic 
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activations of NF-κB are both abolished, which eliminate both survival checkpoints and lead to 
massive apoptosis/necroptosis. Figure is adapted and modified from (Brenner et al., 2015).  
5.4. NEMO modulates growth plate architecture  
The proper geometry, size, number and orientation of growth plate 
chondrocytes are important factors which ensure longitudinal growth (Ascenzi et al., 
2011; Ivkovic et al., 2003). As a result of spatially coordinated proliferation and 
remodeling at the proximal and distal growth plate, respectively, the length of 
endochondral bones is gradually increasing during embryonic and early postnatal 
development. The normal epiphyseal growth plate consists of 3 major layers, namely 
the resting zone, the proliferating zone, and the hypertrophic zone along the proximo-
distal axis of the bone (Karsenty et al., 2009; Kronenberg, 2003). In the proliferative 
zone, chondrocytes undergo oriented cell division followed by rotational movements, 
and form linear columns with coin-like arrangements as seen on Figure 8. In 2 to 4 
weeks old NEMOfl/YCol2a1Cre mice we have observed a slight disorganization of 
proliferative chondrocytes characterized by a tendency for the formation of less 
elongated columns. Instead of organized into linear stacks, mutant chondrocytes 
arranged into more oval clusters indicating failure in cell migration. The mild 
disarrangement of NEMO-deficient chondrocytes in the proliferative zone might be 
caused by changes in cell-matrix interactions, in ECM stiffness, or both (Aro et al., 
2015; Prein et al., 2016; Raducanu et al., 2009). Using indentation-type atomic force 
microscopy, we did not find a significant difference in the elasticity of the cartilaginous 
matrix of the growth plate between mutant and control animals. This may indicate 
that the hypothetic migration deficit of NEMO-deficient growth plate chondrocytes 
could be caused by abnormal cell-matrix interactions and/or anchorage-dependent 
dysfunction of cytoskeletal proteins.  Consistent with this hypothesis, we have shown 
that NEMO deficient chondrocytes display increased binding to ECM ligands such as 
collagens, fibronectin and laminin in vitro. Furthermore, monitoring chondrocyte 
migration by life cell imaging on plastic surface in the presence of serum, we have 
found reduced spontaneous movements of NEMO-null chondrocytes compared to 
wild type. 
Chondrocyte shape and migration are ultimately determined by integrin-
mediated cell-matrix interactions. Integrins are heterodimeric transmembrane 
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receptors composed of alpha and beta subunits with the ability to bind various 
extracellular matrix ligands.  Multiple integrin heterodimers are present in 
chondrocytes including collagen binding (α1β1, α2β1, α10β1), fibronectin binding 
(α5β1, αvβ3 αvβ5) and laminin binding integrins. Integrins connect the cartilage ECM 
to the intracellular cytoskeletal system, and transmit chemical and biomechanical 
signals from the pericellular environment into the cell interior via focal adhesion 
complexes and various intracellular signaling pathways. This signaling network, 
called outside-in signaling, controls diverse cellular functions such as proliferation, 
survival, polarity and movement. Perturbed or diminished integrin signaling has 
severe influence on cytoskeletal dynamics controlled by the Rho family of small 
GTPases, or on calcium inflow important for proper cell behavior. The signaling 
process occurs via phosphorylation of kinases such as focal adhesion kinase (FAK) 
or mitogen-activated protein kinases (MAPKs) and could modulate the expression of 
transcription factors (e.g. NF-κB family subunits). Previous studies in genetically 
modified mice have identified that the lack of β1 integrins, the largest integrin 
subfamily, on chondrocytes severely impairs chondrocyte function in the growth plate 
and in the articular cartilage. Conditional-knockout of the β1 subunit in chondrocytes 
(β1fl/flCol2a1Cre mice) (Aszodi et al., 2003) or in limb bud mesenchymal precursor 
cells (β1fl/flPrx1Cre mice) (Raducanu et al., 2009) resulted in chondrocyte 
proliferation, survival, adhesion and migration defects.  Importantly, in both mouse 
model the orientation and columnar organization of growth plate chondrocytes were 
abnormal, which in some respect, resemble to the phenotype observed in the NEMO-
deficient growth plate.  Furthermore, accumulating evidence has pointed out the 
significance of integrins in determination of cell polarity in various tissues (Streuli, 
2009) such as keratinocytes (Lechler and Fuchs, 2005), mammary gland cells 
(Taddei et al., 2008) or Drosophila follicular epithelial cells (Fernandez-Minan et al., 
2007) through regulating the orientation of the mitotic spindle apparatus (Toyoshima 
and Nishida, 2007). In our NEMOfl/YCol2a1Cre mice we found much milder growth 
plate phenotype compared to the phenotypes reported in mice with chondrocyte-
specific deletion of β1 integrins. Indeed, the distribution of the integrin-associated 
focal adhesion protein paxillin in cultured chondrocytes (Figure 43D) and the 
activation of integrin signaling molecules such as MAPKs, AKT and FAK were 
apparently normal in NEMOfl/YCol2a1Cre mice (Figure 41B), suggesting that an 
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abnormal integrin function is probably not causative for the observed growth plate 
anomalies.  
Cdc42 and Rac1, two members of Rho GTPases, controls cytoskeletal 
organization important for cell shape determination and cell movements. Mice lacking 
either Cdc42 or Rac1 also exhibit growth plate defects with misoriented chondrocyte 
columns (Nagahama et al., 2016; Wang et al., 2007), implying that cytoskelatal 
dynamics is important for normal morphogenesis of the growth plate. The abnormal 
migration and spreading behavior of Nemo-null chondrocytes in vitro may indicate 
impaired function of Rho GTPases and the cytoskeletal system (Figure 43A,B). In 
this study we have not determined the activation status of Rho GTPases, but 
immunofluorescence staining of the actin cytoskeletal system by phalloidin in Nemo-
deficient chondrocytes did not indicate any obvious abnormalities of stress fiber, 
micro-spike and lamellopodia formation, controlled by RhoA, Cdc42 and Rac1, 
respectively (Figure 43D). Nevertheless, additional studies should be performed in 
order to investigate any possible connection between canonical NF-κB signaling and 
Rho GTPases-mediated, cytoskeleton-dependent migration behavior of chondrocytes. 
5.5. Efficient ablation of NEMO in chondrocytes alleviate 
proteoglycan loss upon pro-inflammatory cytokine treatment in 
hip explant culture 
Pro-inflammatory cytokines IL-1β and TNF-α enhance the catabolic activities 
of cartilage and are known as critical players in cartilage degradation during arthritis 
with inflammatory component. Previous studies have shown the involvement of 
canonical NF-κB signaling in cartilage breakdown in response to stimulations with IL-
1β or TNF-α. In experiments of human OA chondrocytes, synovial and 
chondrosarcoma cells, NF-κB was reported to modulate the expression of matrix 
metalloproteinases including MMP-1, -2, -3, -9 and -13 (Amos et al., 2006; Liacini et 
al., 2003; Vincenti and Brinckerhoff, 2002). Furthermore, it has been shown that NF-
κB signaling also participates in the activation of ADAMTS-4 and -5, two critical 
members of the “a disintegrin and metalloprotease with thrombospondin motifs” 
family, which mediate aggrecan degradation during OA (Verma and Dalal, 2011; 
Yaykasli et al., 2015). Numerous publications have suggested the therapeutic 
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potential of blocking NF-κB signaling in the treatment of rheumatic diseases. To 
confirm this hypothesis, hip explant model with pro-inflammatory cytokines induction 
was used in our study to examine the early onset of cartilage degradation. 
Treatments of the hip explants with IL-1β and TNF-α ex vivo resulted in massive 
proteoglycan breakdown in the wild type group characterized by high amount of 
GAGs in the culture medium (Figure 45); reduced Safranin Orange staining and 
strong exposure of aggrecan degradation neo-epitopes including VIDIPEN and 
TEGE (Figure 44). NEMO-deficient cartilage displayed significantly reduced GAGs 
release into the medium, and showed less intensive immunostaining for the VIDIPEN 
and TGEG neo-epitopes in response to the stimulation of IL-1β and TNF-α (Figures 
44 and 45). The neo-epitopes VIDIPEN and TEGE are generated by the action of 
MMP-3 and ADAMTS-4/-5, respectively (Nagase and Kashiwagi, 2003; Westling et 
al., 2002). Our immunohistochemical staining demonstrated that the expression of 
MMP-3 induced by IL-1β and TNF-α was greatly reduced by blocking canonical NF-
κB signaling (Figure 46). In contrast, the deposition of MMP-2, -9 and -13 in were 
comparable between wild type and Nemo mutant explants. The expression of 
ADAMTS-4/5 was not assessed in our study due to the lack of antibodies working on 
section immunohistochemical staining. In summary, however, our results are 
consistent with previous studies (Marcu et al., 2010; Roman-Blas and Jimenez, 2006), 
and clearly demonstrate that the blockade of canonical NF-κB signaling can 
effectively protect the cartilage from pro-inflammatory cytokines induced proteoglycan 
loss by reducing expression of critical degradation enzymes such as MMP3 and 
probably ADAMTS-4/5. It should also mention that the protection against IL1β- and 
TNFα-induced proteoglycan breakdown was only partial, implying that we cannot fully 
prevent IL1β- and TNFα- triggered cartilage degradation by suppressing the NF-κB 
canonical pathway. Nevertheless, our findings strongly suggest that elimination of the 
canonical NF-κB signaling in articular cartilage chondrocytes has the therapeutic 
potential to ameliorate IL1β- and TNFα-induced cartilage degradation during OA 
progression. 
The blockade of NF-κB canonical signaling in rheumatoid diseases of the joint 
is still controversial owning to the unselective elimination of its various advantages 
(e.g. on chondrocyte survival), and issues of practical applications such as targeted 
delivery of the blocking agent(s) (Roman-Blas and Jimenez, 2006). Thus, subsequent 
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investigations are required to gain more detailed insights into the utility of NF-κB 
blockade for the development of effective therapeutic strategies against OA and RA. 
5.6. An ex vivo hip avulsion model does not indicate a particular 
importance of NF-κB canonical signaling in injury induced 
activation of inflammatory gene expression. 
Joint damage due to injury significantly elevates the risk of osteoarthritis; 
therefore analyzing the pathways that are induced upon trauma has unquestionable 
importance for better understanding cartilage degeneration. A previously study has 
showed that physical damage of the articular cartilage rapidly activates the three 
major MAP kinases (Erk, Jnk, p38) as well as NF-κB, which in turn triggers 
intracellular inflammatory signaling pathways (Gruber et al., 2004). Taking into 
account the advantage of using mice with ablated Nemo/canonical NF-κB pathway, 
we have performed an avulsion injury model to assess the contribution of NF-κB to 
injury-induced gene expression profile. We have performed expression analysis on a 
pre-determined, injury-induced panel of genes and, surprisingly, we found that very 
few genes showed differential expression in NEMO-deficient explants compared with 
control explants. The only gene suppressed in NEMOfl/YCol2a1Cre hips upon 
explantation of the cartilaginous cap of the hip was Arginase 1. In wild-type, ARG-1 
was the most upregulated gene upon injury. ARG-1 is known to participate in hepatic 
urea cycle, immune system and inflammation responses (Munder, 2009). The 
function of ARG-1 protein in cartilage so far is still unclear. Curiously, it seems to be 
regulated in a similar fashion to ADAMTS5, although ADAMTS5 was not significantly 
suppressed in our experiment. We suggest that the up-regulation of ARG-1 in wild-
type group is possibly due to the inflammation followed by mechanical-induced 
cartilage damage. Less-regulated ARG-1 in NEMOfl/YCol2a1Cre hip cap might 
represent lower catabolic metabolism compared to the wild-type group.  
We have observed the up-regulation of Hyaluronan synthase 2 (HAS-2) in 
NEMOfl/YCol2a1Cre hip caps suggesting the activation of a mechanism which aims to 
compensate mechanical stress-induced cartilage damage. HAS-2 protein is 
responsible for hyaluronan (HA) production, which possess multiple functions such 
as ECM cue for cell migration, space cram and joint lubrication (Spicer and Nguyen, 
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1999; Watanabe and Yamaguchi, 1996). HA is constitutively generated in the period 
of injuries to build a scaffold for the growth of fibroblasts and angiogenesis. Elevation 
of HA concentration in the blood is related to OA and RA. The up-regulation of HAS-2 
in NEMOfl/YCol2a1Cre articular cartilage may enrich cartilage ECM and provides a 
protective mechanism against mechanical stress. Thus, apparently the canonical NF-
κB pathway has a negative influence on hyaluronan-mediated anabolic processes 
induced upon injury.  
MMP-3 and IL-18 were also up-regulated in NEMOfl/YCol2a1Cre hip caps 
compared to wild-type. Degradation of aggrecan in degenerative articular cartilage 
was mainly due to the actions of MMPs and ADAMTSs (Struglics et al., 2006). MMPs 
are also known to cut collagen II into smaller parts, which could be cleaved by 
gelatinases (Tchetverikov et al., 2005). In injured or post-compressed human 
cartilage, the expression of MMP-3 is up-regulated, which is similar to MMP-3 
enhancement in the synovial fluid of traumatized-knee (Chubinskaya et al., 1999). 
The up-regulation of MMP-3 mRNA in NEMOfl/YCol2a1Cre hips upon injury may 
promote cartilage ECM breakdown. Interestingly, Nemo deficiency results in 
decreased deposition of MMP-3 in hips exposed to inflammatory cytokines (see 
before); and in elevated MMP-3 gene expression in hip caps exposed to mechanical 
stress. This discrepancy may indicate a differential role of the canonical NF-κB 
signaling in the control of MMP-3 expression, depending on the nature of external 
stimuli (inflammatory versus mechanical).  
IL-1β is initially produced as a non-active molecule which needs to be further 
processed to become fully functional. (Black et al., 1988; Hazuda et al., 1989; Mosley 
et al., 1987). Such processing is carried out by the IL-1β converting enzyme (ICE or 
caspase-1) (Black et al., 1989; Miller et al., 1993). Aside from IL-1, IL-18 (interferon 
gamma inducer) was also found as the substrate of ICE (Dinarello, 1998; Fantuzzi 
and Dinarello, 1999). IL-1 and IL-18 are structurally-similar, and both initially 
generated as non-active precursors (Ghayur et al., 1997; Gu et al., 1997). ICE is 
produced both in the cartilage and the synovial membrane; and the expression of 
ICE is significantly increased in OA-affected joints. ICE is proposed to be essential 
for maturation of IL-1β and IL-18 in OA-affected joints (Saha et al., 1999).	Moreover, 
the expression of IL-1β, IL-18 and ICE was remarkably increased in OA-affected 
cartilage. (Saha et al., 1999).  Although these observations indicate that IL-18 may 
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play a role in OA progression, its exact function in OA is still unclear. The fact that 
upon injury IL-18 is up-regulated in NEMO-null hips compared to wild-type implicates 
that NF-κB signaling negatively regulates the expression of this cytokine in a 
mechanically challenged environment.  
Taken together, our ex vivo hip injury model demonstrated the upregulation of 
one “good” gene and two “bad” genes in the absence of NEMO. As for ARG-1, it is 
speculative whether these changes in gene expression are stood for beneficial or 
harmful response against mechanical stress in the cartilaginous NEMOfl/YCol2a1Cre 
hip cap. HAS-2 up-regulation can be recognized as a beneficial factor against the up-
regulation of the harmful MMP-3 and IL-18. Interestingly, although Gruber et al., 
(2014) previously showed that the activation of the NF-κB signaling pathway among 
the immediate response to mechanical injury of the articular cartilage, our expression 
analysis indicates that NEMO/canonical NF-κB has little influence on the expression 
of typical genes activated upon mechanical stress.   
5.7. NEMO/canonical NF-κB-deficiency has no apparent 
consequence on spontaneous, age-associated OA progression 
in mice 
Human osteoarthritis is a slowly progressing degenerative disorder of the 
articular cartilage in association with, but not caused by aging. Age-related changes 
in the cartilage ECM, chondrocyte senescence, genetic and epigenetic factors are all 
contribute for the onset and progression of the diseases (Loeser, 2013). Recent 
studies have indicated that age-related, or spontaneous, osteoarthritis may be 
promoted by low level of inflammation of the joint (Greene and Loeser, 2015). This 
age-associated inflammation is called “inflamm-aging” and NF-κB signaling could be 
involved in its regulation. In order to assess the role of Nemo/ NF-κB in spontaneous 
osteoarthritis, we have monitored osteoarthritis-like changes of the knee in aging 
wild-type and NEMOfl/YCol2a1Cre mice. Evaluating distinct levels of cartilage 
damage, tidemark integrity, chondrocyte cellularity, GAG content and osteophyte 
formation, these parameters give an overall estimation of OA progression. For our 
surprise, the assessment of OA progression indicated that NEMOfl/YCol2a1Cre mice 
displayed comparable cartilage erosion, chondrocyte cellularity and proteoglycan 
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loss as wild-type mice. No osteophyte formation is found in control and mutant mice. 
Importantly, careful analysis of the synovial tissue of the joint, we have found no 
evidence for inflammation or synovial changes in the genotypes. These results 
demonstrate that NEMO may have a dispensable role in naturally occurring primary 
osteoarthritis, at least in out rodent model. 
However, the impact of canonical NF-κB signaling in the development of 
secondary OA is still unclear. To further address this topic and investigate the effect 
of blocking canonical NF-κB pathway in post-traumatic OA, we will induce OA by 
surgical procedures in wild-type and NEMO-deficient mice. Transection of the 
anterior cruciate ligament transection (ACLT) in mouse results in severe OA 
development post-surgery, thus the ACLT mouse model creates a time-pressing 
window for studying the early symptoms of OA. Compared to ACLT model, 
destabilization of the medial meniscus (DMM) surgical instability model offers slower 
progression of OA and excellent reproducibility. Moreover, the OA symptoms and 
slow progression of mice receiving DMM surgery are similar to the mice from 
spontaneous OA models, which make the DMM model more suitable for assessing 
the early features of secondary OA than ACLT model. Therefore, the DMM model of 
osteoarthritis (Glasson et al., 2007) will be used in future experiments to confirm the 
potential of blocking NF-κB canonical signaling. 
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6. Conclusion 
1. The normal appearance of the pre-natal skeleton in NEMOfl/YCol2a1Cre mice 
implies that the canonical NF-κB signaling is dispensable embryonic 
development of endochondral bones.  
2. The dwarf phenotype of NEMOfl/YCol2a1Cre mice after birth demonstrates that 
Nemo/	NF-κB controls potnatal growth of the endochondral skeleton. 
3. The canonical NF-κB signaling modulates proliferation of postnatal growth plate 
chondrocytes through the control of p16 expression. 
4. In the absence of Nemo/canonical NF-κB signaling, cell survival of growth plate 
chondrocytes is compromised. 
5. In TNF-α induced cell death, NEMOfl/YCol2a1Cre chondrocytes were more 
sensitive to apoptosis. 
6. Nemo/NF-κB is important for postnatal growth plate morphogenesis by 
modulating the formation of longitudinal chondrocytes columns. 
7. Canonical NF-κB signaling/Nemo play roles for chondrocyte adhesion and 
spreading. 
8. Nemo-deficiency does not alter the biomechanical properties of the postnatal 
growth plate ECM. 
9. Ablation of NEMO in chondrocytes results in partial protection against pro-
inflammatory cytokine-induced proteoglycan lost in hip explants, suggesting that 
suppressing the canonical NF-κB cascade by blocking NEMO is a potential 
therapeutic intervention strategy to ameliorate inflammation-driven arthritis. 
10. Nemo/NF-κB has minor role for injury-induced inflammatory gene expression in 
a murine articular cartilage avulsion model. 
11. In rodent, canonical NF-κB signaling is dispensable for age-related spontaneous 
osteoarthritis. 
In summary, here we have reported that NEMO-deficient mice display a 
moderate postnatal dwarfism phenotype due to impaired proliferation and apoptosis 
of growth plate chondrocytes. Reduced migration and enhanced ECM ligand binding 
affinity of chondrocytes are likely responsible for the slightly disorganized columns in 
the growth plate of NEMO-deficient mice. Thus, the phenotype of NEMOfl/YCol2a1Cre 
mice demonstrates a moderate role of NF-κB canonical pathway in development of 
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the postnatal endochondral skeleton. We have proved by mouse genetics that 
NEMO/NF-κB is indispensable for mediating pro-inflammatory cytokines-triggered 
catabolism of the articular cartilage, but it have little of any effect in trauma-induced 
gene expression and age-associated, spontaneous osteoarthritis. 
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7. Summary 
NF–κB proteins are known to mediate expression of numerous genes 
responding to stress conditions such as inflammation, infection or injury. Studies of 
bone degenerative diseases have indicated the blockade of NF-κB canonical 
signaling as a potential strategy against arthritis. Owning to the absence of suitable 
animal models, the role of NF–κB signaling in normal skeletal physiology is still not 
completely understood. In this study, the X chromosome-localized gene encoding 
NF-κB essential modulator (NEMO), a key regulator of the canonical NF-κB pathway, 
was conditionally knocked-out using a chondrocyte-specific Col2a1cre transgene in 
mice. NEMOfl/YCol2a1cre mice showed the absence of the canonical NF–κB 
activation in chondrocytes; and exhibited moderate dwarfism postnatally 
characterized by shortened growth plate, mild disorganization of columnar 
chondrocytes and increased apoptosis/necrosis. Primary chondrocytes isolated from 
costal cartilage displayed reduced migration and proliferation. Pro-inflammatory 
cytokines induced proteoglycan depletion, monitored by the exposure of the 
aggrecan degradation neoepitopes and glycosaminoglycan release, was significantly 
less in NEMO-deficient hip explants compared with controls. Using an ex vivo hip 
avulsion model, microarray analysis demonstrated only a few changes in the 
expression of injury-induced genes compared to wild type. Assessing age-associated, 
spontaneous osteoarthritis of the knee joint, NEMOfl/YCol2a1cre mice displayed 
comparable articular cartilage destruction with controls. Taken together, the NEMO-
deficient conditional mouse model demonstrated that: 1) the canonical NF-κB 
signaling plays an important role in postnatal skeletal growth; 2) the catabolic effects 
of pro-inflammatory cytokines in cartilage can be partially eased by blocking the 
canonical NF-κB pathway; 3) Nemo-dependent NF-κB activation has moderate role 
for gene induction upon injury; and 4) NEMO/canonical NF-κB signaling is 
dispensable for spontaneous knee arthritis. The NEMOfl/YCol2a1cre mice, thus, 
provide a valuable model system for better understanding the role of canonical NF-
κB for the development and function of the cartilaginous skeleton. 
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8. Zusammenfassung 
Proteine der NF–κB-Familie beeinflussen die Expression einer Vielzahl von 
Genen, die auf zelluläre Stresssituationen wir Inflammation, Infektion oder 
Verletzungen reagieren. Studien von degenerativen Knochenerkrankungen haben 
die Bedeutung der Blockade des kanonischen NF–κB Signalwegs als potentielles 
Ziel zur Behandlungen von Osteoarthrose und rheumatoide Arthritis verdeutlicht. 
Durch den Mangel an geeigneten Tiermodellen ist die Rolle des NF-κB Signalwegs in 
der normalen Skelettphysiologie noch immer nicht vollkommen verstanden. In der 
vorliegenden Studie wurde das X-chromosomalliegende Gen NEMO (NF-κB 
essential modulator), ein Schlüsselregulierer im kanonischen NF-κB Signalweg, 
konditional, durch die Verwendung einer knorpelspezifischen Col2a1cre transgenen 
Mauslinie, gelöscht. NEMOfl/YCol2a1cre Mäuse zeigten ein Ausbleiben der 
kanonischen NF–κB Aktivierung in Chondrozyten und entwickelten postnatal einen 
mäßigen Kleinwuchs, der durch eine verkürzte Wachstumsfuge, eine leichte 
Unordnung der säulenförmigen Chondrozyten und eine erhöhte Nekrose/Apoptose 
verursacht wurde. Primäre Chondrozyten, die aus Rippenknorpel isoliert wurden, 
zeigten eine reduzierte Migration sowie Proliferation. Pro-inflammatorische Zytokine 
induzierten Proteoglykanverminderung, dass durch die Freisetzung von Aggrecan-
Neoepitopen und Glykosminoglykanen nachgewiesen wurde, war signifikant weniger 
in NEMO-deifizieren Hüftkopfexplantaten im Vergleich zu den Kontrollen. Durch die 
Verwendung eines Hüftkopfdistorsionmodells konnte eine Mikroarrayanalyse einige 
kleine Veränderungen in der Expression von verletzungsbedingten Genen im 
Vergleich zu Wildtypen aufgezeigt werden. Des Weiteren konnte durch die 
Beurteilung von altersbedingter, spontaner Osteoarthrose der Kniegelenke eine 
vergleichbare Zerstörung des artikulären Knorpels in NEMOfl/YCol2a1cre Mäusen 
und Kontrolltieren festgestellt werden. Zusammenfassend zeigte das NEMO-
defizitäre konditionale Mausmodell, dass 1) der kanonische NF-κB Signalweg eine 
wichtige Rolle für das postnatale Skelettwachstum spielt; 2) der katabolische Effekt 
von pro-inflammatorische Zytokinen im Knorpel durch die Blockierung des NF-κB 
Signalwegs verringert werden kann; 3) die Aktivierung von NF-κB durch NEMO einen 
moderate Rolle in der Geninduktion nach Verletzungen hat; und 4) NEMO-vermittelte 
kanonische NF-κB Signaltransduktion entbehrlich für spontane Kniearthrose ist. 
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NEMOfl/YCol2a1cre Mäuse stellen somit ein nützliches Modellsystem dar, um die 
Rolle von kanonischem NF-κB in der Entwicklung und Funktion des Knorpelskeletts 
zu verstehen.  
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10. List of abbreviations 
AC    Articular cartilage 
ACL    Anterior cruciate ligament 
ACLT Anterior cruciate ligament transection 
ADAMTS-5 A disintegrin and metalloproteinase with thrombospondin 
motifs 5 
AFM    Atomic force microscopy 
AKT    Protein kinase B (PKB) 
ARG-1   Arginase-1 
ATM    Ataxia telangiectasia mutated 
BCL    B-cell lymphoma 
BMP-2   Bone morphogenetic protein 2 
BrdU    5-bromo-2'-deoxyuridine 
BSA    Bovine serum albumin 
CD95    Cluster of differentiation 95 
cFLIP Cellular FLICE (FADD-like IL-1β-converting enzyme)-
inhibitory protein 
Col    Collagen 
CK-2    Casein kinase-II 
CRE    Chromosome recombinase 
COMP   Cartilage oligo matrix protein 
COX-2   Cyclooxygenase 2 
DDR-2   Discoidin domain-containing receptor 2 
DAPI    4,6-diamidino-2-phenylindole 
DMEM   Dulbeco's minimal essential medium 
DNA    Deoxyribonucleic acid 
dNTP    Deoxyribonucleotide triphosphate 
dKO    Double knockout 
DMM    Destabilization of the medial meniscus 
DMSO   Dimethyl sulfoxide 
DTT    Dithiothreitol 
dsRNA   Double strand RNA 
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ECM    Extracellular matrix 
EDTA    Ethylenediaminetetraacetic acid 
e.g.    Exempli gratia (for example) 
ELISA    Enzyme-linked immunosorbent assay 
ERK    Extracellular signal-regulated kinases 
FAK    Focal adhesion kinase 
FBS    Fetal bovine serum 
FGF    Fibroblast growth factor 
FGFR    Fibroblast growth factor receptor 
FITC    Fluorescein isothiocyanate 
Fn    Fibronectin 
GADPH   Glyceraldehyde 3-phosphate dehydrogenase 
GAG    Glycosaminoglycan 
gDNA    Genomic DNA 
gp-39    Glycoprotein 39 
GTP    Guanosine triphosphate 
HA    hyaluronan 
HAS-2   Hyaluronan synthase 2 
HER-2   Human epidermal growth factor receptor 2 
HLH    Helix-loop-helix 
HZ    Hypertrophic zone 
H&E    Hematoxyl & eosin 
ICE    IL-1β converting enzyme 
IGF    Insulin-like growth factor 
IL    Interleukin 
IĸB Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor 
IKK    IκB kinases 
iNOS    Inducible nitric oxide synthase 
ITM    Interterritorial matrix 
Jnk    c-Jun N-terminal kinase 
KO    Knockout 
LMP    Latent membrane protein 
LNA    Lock nucleic acid-antisense 
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LPS    Lipopolysaccharide 
LZ    RelB-transactivation domain 
MAPK    Mitogen-activated protein kinase 
MEF    Mouse embryonic fibroblasts 
MGP    Matrix gla protein 
ML    Mediolateral 
MMP    Matrix metalloproteinase 
mRNA   Messenger RNA 
MSC    Mesenchymal stem cell 
NBD    NEMO binding domain 
Nemo    NF-kappa-B essential modulator, also known as IKK-γ 
NF-ĸB Nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NIK-1    NF-ĸB-inducing kinase 1 
NKx3.2   NK3 homeobox 2, also called Bapx-1 
NLS    Nuclear localization signal 
NO    Nitrogen oxide 
NSAID   Non-steroidal anti-inflammatory drug 
OA    Osteoarthritis 
OD    Osteochondritis dissecans 
ODN    Oligodeoxynucleotides 
OPN    Osteopontin 
p16    Cyclin-dependent kinase inhibitor 2A 
PBS    Phosphate-buffered saline 
PCM    Pericellular matrix 
PD    Proximaldistal 
PEST Domain rich in proline (P), glutamate (E), serine (S) and 
threonine (T). 
PFA    Paraformaldehyde 
PGE    Prostaglandin E 
PGs    Proteoglycans 
PI3K    Phosphoinositide 3-kinase 
PM    Periterritorial matrix 
PRb    Retinoblastoma protein 
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	 157	
PTHrP   Parathyroid hormone-related peptide 
PVDF    Polyvinylidene fluoride 
PZ    Proliferating zone of growth plate 
RA    Rheumatoid arthritis 
RHD    Rel-homology domain 
RIPK-1   Receptor-interacting protein kinase 1 
RNA    Ribonucleic acid 
RNAi    RNA interference 
RT    Room temperature 
RT-PCR   Reverse transcriptase polymerase chain reaction 
RZ    Resting zone of growth plate 
SDS    Sodium dodecyl sulfate 
siRNA    Small interfering RNA 
SCW    Streptococcal cell wall 
SOX    Sex determining region Y box 9 
SUMO   Small ubiquitin-like modifier protein 
TAD    Transcriptional activation domain 
TCR    T-cell receptor 
TGP    Total growth plate 
TIMP    Tissue inhibitors of metalloproteinases 
TLDA 
TNF-α    Tumor necrosis factor alpha 
TNFR    Tumor necrosis factor receptor 
TRAP    Tartrate resistant acid phosphatase 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
ZF    Zinc-finger domain 
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